<SEC-DOCUMENT>0001213900-18-012289.txt : 20180907
<SEC-HEADER>0001213900-18-012289.hdr.sgml : 20180907
<ACCEPTANCE-DATETIME>20180907172310
ACCESSION NUMBER:		0001213900-18-012289
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20180907
DATE AS OF CHANGE:		20180907

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-227243
		FILM NUMBER:		181060882

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>fs12018_aytubioscience.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>As filed with the Securities and Exchange Commission on September 7, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AYTU BIOSCIENCE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>47-0883144</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard Industrial</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Classification Code Number)</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>373 Inverness Parkway</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 206</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Englewood, Colorado 80112</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(720) 437-6580</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code and telephone
number, including area code, of registrant&rsquo;s principal executive offices) &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Joshua R. Disbrow </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>373 Inverness Parkway, Suite 206</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Englewood, Colorado 80112</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (720) 437-6580</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code and telephone
number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Copies to: </I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nolan S. Taylor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Anthony Epps</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Michael R. Newton</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dorsey &amp; Whitney LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">111 South Main St., Suite 2100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Salt Lake City, Utah 84111</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(801) 933-7360</P></TD>
    <TD STYLE="width: 10%; padding-right: -0.5in; padding-left: 5.4pt; font-size: 10pt"></TD>
    <TD STYLE="width: 47%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Michael Nertney</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Charlies Phillips</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ellenoff Grossman &amp; Schole LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1345 Avenue of the Americas, 11<SUP>th</SUP>
        Floor</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, NY 10105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(212) 370-1300</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18.35pt"><FONT STYLE="font-size: 8pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Approximate date of
commencement of proposed sale to the public: As soon as practicable after the effective date of the registration statement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the securities
being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), check the following box. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this form is a
post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; &ldquo;smaller
reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated
    filer&nbsp;&nbsp;&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-accelerated
        filer&nbsp;&nbsp;&#9744;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&nbsp;&nbsp;&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<I>Do not check if a smaller reporting
    company)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&nbsp;&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Title of Each Class of Securities to be Registered</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Proposed
</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Maximum</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Aggregate </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Offering</B></FONT></P>
                                                                                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Price<SUP>(1)</SUP></B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Amount of</B></FONT><BR> <FONT STYLE="font-size: 10pt"><B>Registration Fee<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Class A Units consisting of:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-size: 10pt">(i) Common Stock, par value $0.0001 per share<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 10pt">(ii) Warrants to purchase Common Stock<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Class B Units consisting of</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">(i) Series C Preferred Stock, par value $0.0001 per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 10pt">(ii) Common Stock issuable upon conversion of the Series C Preferred Stock<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9.25pt"><FONT STYLE="font-size: 10pt">(iii) Warrants to purchase Common Stock<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Common Stock issuable upon exercise of warrants<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Representative&rsquo;s warrant to purchase shares of Common Stock(3)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Common Stock issuable upon exercise of representative&rsquo;s warrant to purchase common stock(4)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,000,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">996.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) of the Securities Act of 1933, as amended. Includes the price of additional shares of common stock and/or warrants to purchase shares of common stock that the underwriters have the option to purchase to cover over-allotments, if any. See &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No fee pursuant to Rule 457(i) under the Securities Act of 1933,
        as amended.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents warrants to purchase a number of shares of common stock equal to 3% of the number of shares of Common Stock (including the shares of Common Stock issuable upon conversion of the Series C Preferred Stock) being offered at an exercise price equal to 125% of the public offering price per Class A Unit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of
the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: red"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
relating to these securities filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to
sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt; color: red"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: red"><B>SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: red"><B>DATED &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aytu BioScience, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class&nbsp;A Units consisting of common
stock and warrants and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Class&nbsp;B Units consisting of shares
of Series C Preferred Stock and warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(and &nbsp; shares of common stock underlying
shares of Series C Preferred Stock and warrants)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are offering
Class&nbsp;A Units, with each Class&nbsp;A Unit consisting of one share of common stock, par value $0.0001 per share (the &ldquo;common
stock&rdquo;) and a warrant to purchase one half of one share of our common stock (together with the shares of common stock underlying
such warrants, the &ldquo;Class&nbsp;A Units&rdquo;) at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Class&nbsp;A Unit. Each warrant included in the Class&nbsp;A Units entitles its holder to purchase one half of one share of
common stock at an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are also offering
to those purchasers whose purchase of Class&nbsp;A Units in this offering would result in the purchaser, together with its affiliates
and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding
common stock following the consummation of this offering, the opportunity to purchase, if they so choose, in lieu of the number
of Class&nbsp;A Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%), Class&nbsp;B
Units. Each Class&nbsp;B Unit consists of one share of Series C Preferred Stock, par value $0.0001 per share (the &ldquo;Series
C Preferred Stock&rdquo;), convertible into one share of common stock and a warrant to purchase one half of one share of common
stock (together with the shares of common stock underlying such shares of Series C Preferred Stock and such warrants, the &ldquo;Class&nbsp;B
Units&rdquo; and, together with the Class&nbsp;A Units, the &ldquo;units&rdquo;) at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Class&nbsp;B Unit. Each warrant included in the Class&nbsp;B Units entitles its holder to purchase one half of one share of
common stock at an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Class&nbsp;A
Units and Class&nbsp;B Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares
of common stock, Series C Preferred Stock and warrants comprising such units are immediately separable and will be issued separately
in this offering. The underwriters have the option to purchase additional shares of common stock and/or warrants to purchase shares
of common stock solely to cover over-allotments, if any, at the price to the public less the underwriting discounts and commissions.
The over-allotment option may be used to purchase shares of common stock, or warrants, or any combination thereof, as determined
by the underwriters, but such purchases cannot exceed an aggregate of 15% of the number of shares of common stock (including the
number of shares of common stock issuable upon conversion of shares of Series C Preferred Stock) and warrants sold in the primary
offering. The over-allotment option is exercisable for 45 days from the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our common stock
is listed on the NASDAQ Capital Market under the symbol &ldquo;AYTU.&rdquo; On September 6, 2018, the last reported sale price
of our common stock on the NASDAQ Capital Market was $3.99.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves
a high degree of risk. You should review carefully the risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo;
beginning on page 8 of this prospectus, and under similar headings in any amendments or supplements to this prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per&nbsp;Class&nbsp;A<BR> Unit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per&nbsp;Class&nbsp;B<BR> Unit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Public offering price(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Underwriting discount(2)(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds, before expenses, to AYTU Bioscience, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The public offering price and underwriting discount corresponds to (x)&nbsp;in respect of the Class&nbsp;A Units (i)&nbsp;a public offering price per share of common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and (ii)&nbsp;a public offering price per warrant of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and (y)&nbsp;in respect of the Class&nbsp;B Units (i)&nbsp;a public offering price per share of Series C Preferred Stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and (ii)&nbsp;a public offering price per warrant of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have also agreed to reimburse Ladenburg Thalmann for certain expenses. See &ldquo;Underwriting&rdquo; for additional information. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted a 45-day day option to the underwriters to purchase additional shares of common stock and/or warrants to purchase shares of common stock (up to 15% of the number of shares of common stock (including the number of shares of common stock issuable upon conversion of shares of Series C Preferred Stock) and warrants sold in the primary offering) solely to cover over-allotments, if any. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters expect to deliver the
securities to purchasers in the offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ladenburg Thalmann </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="toc"></A>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt; width: 92%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 7%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_001"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_002"><FONT STYLE="font-size: 10pt">The Offering</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_003"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_004"><FONT STYLE="font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_005"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_006"><FONT STYLE="font-size: 10pt">Market for Common Stock</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_007"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_008"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_009"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_010"><FONT STYLE="font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_011"><FONT STYLE="font-size: 10pt">Underwriting</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_012"><FONT STYLE="font-size: 10pt">Incorporation of Certain Information by Reference</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_013"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#aa_014"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_015"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information
contained in this prospectus or in any related free writing prospectus filed by us with the Securities and Exchange Commission,
or the SEC. We have not, and the underwriters and their affiliates have not, authorized anyone to provide you with any information
or to make any representation not contained in this prospectus. We do not, and the underwriters and their affiliates do not, take
any responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you.
This prospectus is not an offer to sell or an offer to buy units in any jurisdiction where offers and sales are not permitted.
The information in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any
sale of units. You should also read and consider the information in the documents to which we have referred you under the caption
&ldquo;Where You Can Find More Information&rdquo; in the prospectus.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriters have done
anything that would permit a public offering of the units or possession or distribution of this prospectus in any jurisdiction
where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession
of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the units and the distribution
of this prospectus outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you to read carefully this prospectus,
as supplemented and amended, before deciding whether to invest in any of the common stock being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the context indicates otherwise,
as used in this prospectus, the terms &ldquo;Aytu,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo;
and &ldquo;our business&rdquo; refer to Aytu BioScience, Inc. and its subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We own or have rights to various U.S. federal
trademark registrations and applications, and unregistered trademarks and service marks, including Fiera, Natesto, ZolpiMist, ProstaScint,
MiOXSYS, RedoxSYS, Luoxis, Vyrix and Nuelle. All other trade names, trademarks and service marks appearing in this prospectus are
the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating.
Accordingly, such terms, when first mentioned in this prospectus, appear with the trade name, trademark or service mark notice
and then throughout the remainder of this prospectus without trade name, trademark or service mark notices for convenience only
and should not be construed as being used in a descriptive or generic sense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><B><A NAME="aa_001"></A>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><I>This summary highlights certain
information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it does not contain
all of the information that you should consider before investing in shares of our securities and it is qualified in its entirety
by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus and the documents
incorporated by reference including the information referred to under the heading &ldquo;Risk Factors&rdquo; and the financial
statements and related notes in this prospectus and the documents incorporated by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">We are a commercial-stage specialty
pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. We have multiple
approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across
a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales
force and an international distribution network with sales in 29 countries. We are currently concentrating on hypogonadism, male
infertility and, recently, insomnia and plan to expand into other indications for which we believe there are significant medical
needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">We acquired exclusive U.S. rights
to Natesto<SUP>&reg;</SUP> (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use
nasal gel, and we launched Natesto in the U.S. with our direct sales force in late summer 2016. Natesto is approved by the U.S.
Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone
replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes
in a $1.8 billion market accounting for over 6.8 million prescriptions annually. Importantly, as Natesto is delivered via the nasal
mucosa and not the skin, there is no risk of testosterone transference to others, a known potential side effect and black box warning
associated with all other topically applied TRTs, including the market leader AndroGel<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">Outside the U.S. we market MiOXSYS<SUP>&reg;</SUP>,
a novel in vitro diagnostic system that is currently CE marked (which generally enables it to be sold within the European Economic
Area), Health Canada cleared, and Australian TGA and Mexican COFEPRAS-approved, and for which we intend to initiate a clinical
study to enable FDA clearance in the U.S. &nbsp;Our MiOXSYS system is a novel, point-of-care semen analysis system with the potential
to become a standard of care in the diagnosis and management of male infertility. Male infertility is a prevalent and underserved
condition and oxidative stress (the core biological component measured by the MiOXSYS system) is widely implicated in its pathophysiology.
MiOXSYS was developed from our previously developed oxidation-reduction potential research platform known as RedoxSYS<SUP>&reg;</SUP>.
We are advancing MiOXSYS toward FDA clearance as an aid in the assessment of male infertility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">In June 2018 we acquired an exclusive
U.S. license to ZolpiMist&trade;. ZolpiMist is an FDA-approved prescription product that is indicated for the short-term treatment
of insomnia, and is the only oral spray formulation of zolpidem tartrate - the most widely prescribed prescription sleep aid in
the U.S. ZolpiMist is commercially available and competes in the non-benzodiazepine prescription sleep aid category, a $1.8 billion
prescription drug category with over 43 million prescriptions written annually. Thirty million prescriptions of zolpidem tartrate
(Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;, Edluar&reg;, ZolpiMist&trade;, and generic forms of immediate-release, controlled
release, and orally dissolving tablet formulations) are written each year in the U.S., representing almost 70% of the non-benzodiazepine
sleep aid category. Approximately 2.5 million prescriptions are written for novel formulations of zolpidem tartrate products (controlled
release and sublingual tablets). We intend to integrate ZolpiMist into our sales force&rsquo;s promotional efforts as an adjunct
product to Natesto as there is substantial overlap of physician prescribers of both testosterone and prescription sleep aids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">In the future we will look to
acquire additional commercial-stage or near-market products, including existing products we believe can offer distinct commercial
advantages. Our management team&rsquo;s prior experience has involved identifying both clinical-stage and commercial-stage assets
that can be launched or re-launched to increase value, with a focused commercial infrastructure specializing in novel, niche products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">Our management team has extensive
experience across a wide range of business development activities and have in-licensed or acquired products from large, mid-sized,
and small enterprises in the United States and abroad. Through an assertive product and business development approach, we expect
that we will build a substantial portfolio of complementary urology products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Natesto&reg; (testosterone) nasal gel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify">Natesto is a patented, FDA-approved
testosterone replacement therapy, or TRT, and is the only nasally-administered formulation of testosterone available in the U.S.
Natesto is a discreet, easy-to-administer nasal gel that may be appropriate for men with active lifestyles as Natesto is small,
portable, Transportation Security Administration, or TSA-compliant, and easy to use. Importantly, Natesto is not applied directly
to the patient&rsquo;s skin as other topically applied TRTs. Rather, Natesto is delivered directly into the nasal mucosa via a
proprietary nasal applicator. Thus, Natesto does not carry a black box warning related to testosterone transference to a man&rsquo;s
female partner or children &mdash; as other topically (primarily gels and solutions) administered TRTs do by virtue of their delivery
directly onto the skin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify">We launched Natesto in the U.S.
in late summer 2016 with our direct sales force, and we are positioning Natesto as the ideal treatment solution for men with active,
busy lifestyles who suffer from hypogonadism. Natesto is also positioned for men who have previously been prescribed a TRT, including
Androgel, and want a product with a different clinical profile available in a convenient, easy-to-use, effective therapeutic option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of Natesto (testosterone) nasal gel&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="img_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unique delivery of Natesto also enables
simple, discreet use by a single application into each nostril three times daily and may improve compliance over topical forms
that are applied to large sections of the arms, shoulders, and other large areas of the man&rsquo;s upper torso. It also offers
a more discreet method of TRT administration compared to films and patches (such as Androderm&reg;) and doesn&rsquo;t involve the
pain, potential for site injection infections, and the administration inconvenience of the implantable and/or injectable TRTs such
as Testopel&reg; (pellets), Aveed&reg; (injectable testosterone undecanoate) or testosterone cypionate injections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A concern associated with the use of the
currently marketed testosterone gels is the unintentional transfer of testosterone to women (or children) by skin contact with
the man&rsquo;s application site. In the event of a female partner receiving inadvertent testosterone exposure due to intimate
contact with her male partner, she may develop hyperandrogenism, a condition characterized by excess levels of androgens. This
condition may result in women developing acne, scalp hair loss, excessive facial or body hair, breast atrophy, and other symptoms.
Natesto, as it is nasally administered, does not present this potential complication of &lsquo;transference&rsquo; and thus does
not have a black box warning as is associated with the topically applied testosterone supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto is a nasally-administered androgen
indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism,
bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter&rsquo;s syndrome, chemotherapy, or toxic damage
from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating
hormone [FSH] and luteinizing hormone [LH]) above the normal range.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>Hypogonadotropic hypogonadism (congenital or acquired):
gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma,
or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ZolpiMist&trade; (zolpidem tartrate oral spray)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ZolpiMist is an FDA-approved prescription
product that is indicated for the short-term treatment of insomnia, and is the only oral spray formulation of zolpidem tartrate
- the most widely prescribed prescription sleep aid in the U.S. ZolpiMist is commercially available and competes in the non-benzodiazepine
prescription sleep aid category, a $1.8 billion prescription drug category with over 43 million prescriptions written annually.
Thirty million prescriptions of zolpidem tartrate (Ambien&reg;, Ambien&reg; CR, Intermezzo&reg;, Edluar&reg;, ZolpiMist&trade;,
and generic forms of immediate-release, controlled release, and orally dissolving tablet formulations) are written each year in
the U.S., representing almost 70% of the non-benzodiazepine sleep aid category. Approximately 2.5 million prescriptions are written
for novel formulations of zolpidem tartrate products (controlled release and sublingual tablets).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ZolpiMist (5 mg per dose and available
in both a 30-dose and 60-dose canister) was approved for marketing by the FDA in December of 2008 and was shown to be bioequivalent
to Ambien&reg; 5 mg and 10 mg tablets. ZolpiMist is indicated for the short-term treatment of insomnia characterized by difficulties
with sleep initiation and is contraindicated in patients with a known hypersensitivity to zolpidem tartrate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of ZolpiMist in its Child-Resistant Container</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="img_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to ZolpiMist&rsquo;s unique oral spray
delivery and the resulting rapid absorption through the oral mucosa, ZolpiMist has several clinical advantages over oral tablet
formulations, most notably a rapid onset of action that quickly induces sleep. Additionally, and also due to the product&rsquo;s
oral spray formulation, ZolpiMist does not require swallowing and may therefore be easier and more convenient to take than tablets
for patients who have difficulty swallowing or have an aversion to taking tablets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MiOXSYS&reg; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MiOXSYS is a rapid <I>in vitro</I> diagnostic
system that performs a semen analysis test used to measure static oxidation-reduction potential, or sORP, in human semen. MiOXSYS
is a CE marked system (that is also Health Canada, Australian TGA and Mexican COFEPRAS approved) and is an accurate, easy to use,
and fast infertility assessment tool that directly measures oxidative stress in semen though the direct measurement of oxidation-reduction
potential. It is estimated that 72.4 million couples worldwide experience infertility problems. In the U.S., approximately 10%
of couples are defined as infertile. Male infertility is responsible for between 40 &ndash; 50% of all infertility cases and affects
approximately 7% of all men. Male infertility is often unexplained (idiopathic), and this idiopathic infertility is frequently
associated with increased levels of oxidative stress in the semen. As such, having a rapid, easy-to-use diagnostic platform to
measure oxidative stress may provide a practical way for male infertility specialists to improve semen analysis and infertility
assessments without having to refer patients to outside clinical laboratories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Male infertility is prevalent and underserved, and
oxidative stress is widely implicated in its pathophysiology. The global male infertility market is expected to grow to over $300
million by 2020 with a compound annual growth rate, or CAGR, of nearly 5% from 2014 to 2020. Oxidative stress is broadly implicated
in the pathophysiology of idiopathic male infertility, yet very few diagnostic tools exist to effectively measure oxidative stress
levels in men. However, antioxidants are widely available and recommended to infertile men without easy, accurate assessment methods
available for initial evaluation and subsequent response to antioxidant intervention. With the introduction of the MiOXSYS System,
we believe for the first time there will be an easy and effective diagnostic tool to assess the degree of oxidative stress and
potentially enable the monitoring of patients&rsquo; responses to antioxidant therapy as a treatment regimen for infertility.
The MiOXSYS System received CE marking in Europe in January 2016 and obtained Health Canada Class II Medical Device approval in
March 2016. The product subsequently received Australian TGA approval in November of 2017 and clearance in Mexico in March of
2018. We expect to advance MiOXSYS into clinical trials in the U.S. in order to enable 510k de novo clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of the MiOXSYS Analyzer&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><IMG SRC="img_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; color: Red"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The MiOXSYS Disposable Sensors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MiOXSYS disposable sensors, via standard
biological specimen collection techniques, receive 20 &ndash; 40 microliters of a specimen from which the ORP clinical analysis
is performed. The ORP sensor strips are small, disposable, and biocompatible and consist of a ceramic substrate and a five-lead
configuration. Significant intellectual property surrounds the design, construct, and electrochemical algorithms associated with
the sensors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Image of the MiOXSYS Disposable Sensors&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><IMG SRC="img_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><B>Our Strategy&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the near-term, we expect to create value
for shareholders by implementing a focused, four-pronged strategy. Our primary focus is on growing sales of Natesto in the U.S.
and relaunching ZolpiMist through our sales force, expanding the MiOXSYS business both inside and outside the U.S., advancing MiOXSYS
toward FDA clearance, and continuing to build a product pipeline through efficient business development. Upon achieving growth
of our current, revenue-generating products, we intend to build a complementary portfolio of aligned assets that can be efficiently
commercialized through our specialty sales force and, when appropriate, aligned distribution partners outside the U.S. In just
over three years since our formation through the merger, we have acquired or in-licensed four FDA-approved, marketed assets (and
have since divested one asset &ndash; Primsol&reg; Solution and have discontinued another, ProstaScint&reg;), launched a U.S.-based
specialty sales force, advanced our lead diagnostic asset MiOXSYS to CE marking, Health Canada clearance, Australian TGA approval,
and Mexican COFEPRAS clearance, engaged in asset purchase and licensing discussions for products aligned to our strategy, launched
Natesto in the U.S. through our own sales force, licensed ZolpiMist in the U.S. and Canada, and are now preparing for ZolpiMist&rsquo;s
re-launch through our sales force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated as Rosewind Corporation
on August 9, 2002 in the State of Colorado.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vyrix Pharmaceuticals, Inc., or Vyrix,
was incorporated under the laws of the State of Delaware on November 18, 2013 and was wholly owned by Ampio Pharmaceuticals, Inc.
(NYSE American: AMPE), or Ampio, immediately prior to the completion of the Merger (defined below). Vyrix was previously a carve-out
of the sexual dysfunction therapeutics business, including the late-stage men&rsquo;s health product candidates, Zertane and Zertane-ED,
from Ampio, that carve-out was announced in December 2013. Luoxis Diagnostics, Inc., or Luoxis, was incorporated under the laws
of the State of Delaware on January 24, 2013 and was majority owned by Ampio immediately prior to the completion of the Merger.
Luoxis was initially focused on developing and advancing the RedoxSYS System. The MiOXSYS System was developed following the completed
development of the RedoxSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2015, Rosewind formed Rosewind
Merger Sub V, Inc. and Rosewind Merger Sub L, Inc., each a wholly-owned subsidiary formed for the purpose of the Merger, and on
April 16, 2015, Rosewind Merger Sub V, Inc. merged with and into Vyrix and Rosewind Merger Sub L, Inc. merged with and into Luoxis,
and Vyrix and Luoxis became subsidiaries of Rosewind. Immediately thereafter, Vyrix and Luoxis merged with and into Rosewind with
Rosewind as the surviving corporation (herein referred to as the Merger). Concurrent with the closing of the Merger, Rosewind abandoned
its pre-merger business plans, and we now solely pursue the specialty healthcare market, focusing on urological related conditions,
including the business of Vyrix and Luoxis. When we discuss our business in this prospectus, we include the pre-Merger business
of Luoxis and Vyrix.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 8, 2015, we (i) reincorporated
as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu
BioScience, Inc., and (ii) effected a reverse stock split in which each common stock holder received one share of common stock
for each 12.174 shares outstanding. At our annual meeting of stockholders held on May 24, 2016, our stockholders approved (1) an
amendment to our Certificate of Incorporation to reduce the number of authorized shares of common stock from 300.0 million to 100.0
million, which amendment was effective on June 1, 2016, and (2) an amendment to our Certificate of Incorporation to affect a reverse
stock split at a ratio of 1-for-12 which became effective on June 30, 2016. At our special meeting of stockholders held on July
26, 2017, our stockholders approved an amendment to our Certificate of Incorporation to affect a reverse stock split at a ratio
of 1-for-20 which became effective on August 25, 2017. In addition, at our annual meeting of stockholders held on June 27, 2018,
our stockholders approved an amendment to our Certificate of Incorporation to affect a reverse stock split at a ratio of up to
1-for-20, which reverse stock split became effective at a ratio of 1-for-20 on August 10, 2018. All share and per share amounts
in this prospectus have been adjusted to reflect the effect of these four reverse stock splits (hereafter referred to collectively
as the &ldquo;Reverse Stock Splits&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, and our phone number is (720) 437-6580. Our corporate website address
is http://www.aytubio.com. The information contained on, connected to or that can be accessed via our website is not part of this
prospectus. We have included our website address in this prospectus as an inactive textual reference only and not as an active
hyperlink.&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center"><B><A NAME="aa_002"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; text-align: justify"><FONT STYLE="font-size: 10pt">Issuer&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%; padding-right: 6.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Aytu BioScience, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Class A Units offered</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class&nbsp;A Units. Each Class&nbsp;A Unit consists of one share of common stock and a warrant to purchase one half of one share of our common stock (together with the shares of common stock underlying such warrants).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Public offering price per Class A Unit</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Class A Unit.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Class B Units offered</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">We are also offering to those purchasers whose purchase of Class&nbsp;A Units in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of the number of Class&nbsp;A Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class&nbsp;B Units. Each Class&nbsp;B Unit consists of one share of Series&nbsp;C Preferred Stock, par value $0.0001 per share, convertible into one share of common stock and a warrant to purchase one half of one share of our common stock (together with the shares of our common stock underlying such shares of Series C Preferred Stock and warrants).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Public offering price per Class
B Unit</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Class B Unit.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Over-allotment option</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">The underwriters have the option to purchase up to</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">additional shares of common stock, and/or warrants to purchase shares of common stock solely to cover over-allotments, if any, at the price to the public less the underwriting discounts and commissions. The over-allotment option may be used to purchase shares of common stock, or warrants, or any combination thereof, as determined by the underwriters, but such purchases cannot exceed an aggregate of 15% of the number of shares of common stock (including the number of shares of common stock issuable upon conversion of shares of Series C Preferred Stock) and warrants sold in the primary offering. The over-allotment option is exercisable for 45 days from the date of this prospectus.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrants</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">The warrants will be exercisable beginning on the date of issuance and expire on the five (5)&nbsp;year anniversary of the date of issuance at an initial exercise price per share equal to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Series C Preferred Stock</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Series C Preferred Stock
        is convertible at any time at the holder&rsquo;s option into one share of common stock.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, we shall
        not effect any conversion of Series C Preferred Stock, with certain exceptions, to the extent that, after giving effect to an attempted
        conversion, the holder of shares of Series C Preferred Stock (together with such holder&rsquo;s affiliates, and any persons acting
        as a group together with such holder or any of such holder&rsquo;s affiliates) would beneficially own a number of shares of our
        common stock in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of our
        common stock then outstanding after giving effect to such conversion. For additional information, see &ldquo;Description of Capital
        Stock &mdash; Series C Preferred Stock&rdquo; for a discussion of the terms of the Series C Preferred.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

</DIV>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 97%">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify; width: 38%"><FONT STYLE="font-size: 10pt">Common stock outstanding before this offering</FONT></TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify; width: 60%"><FONT STYLE="font-size: 10pt">1,801,411 shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Common stock to be outstanding immediately after this
    offering</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">shares, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise in full their option to purchase additional shares of common stock (on an as-converted to common stock basis with respect to any shares of Series C Preferred Stock sold).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Class A Unit and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Class B Unit, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering for general corporate purposes, including working capital. See &ldquo;Use of Proceeds&rdquo; for additional information.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">This investment involves a high degree of risk. You should read the description of risks set forth under &ldquo;Risk Factors&rdquo; beginning on page 8 of this prospectus and the documents incorporated by reference herein for a discussion of factors to consider before deciding to purchase our securities.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market trading symbol of common stock</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.9pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;AYTU&rdquo;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">No listing of Series C Preferred Stock or warrants</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">There is no established public trading market for the warrants or Series C Preferred Stock, and we do not expect an active trading market to develop. We do not intend to list the warrants or the Series C Preferred Stock on any securities exchange or other trading market. Without an active trading market, the liquidity of the warrants and the Series C Preferred Stock will be limited.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.9pt; text-align: justify"><FONT STYLE="font-size: 10pt">Registered Securities</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt; text-align: justify"><FONT STYLE="font-size: 10pt">This prospectus also relates to the offering of the shares issuable upon conversion of the Series C Preferred Stock and upon exercise of the warrants included in the Units.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all
information in this prospectus assumes no exercise by the underwriters of their option to purchase additional shares of common
stock and/or warrants to cover over-allotments, if any, and excludes as of August 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,798 shares of our common stock issuable upon exercise
of outstanding stock options under our 2015 Stock Option and Incentive Plan at a weighted average exercise price of $325.97 per
share;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,882,661 shares of our common stock issuable upon exercise
of outstanding warrants with a weighted average exercise price of $25.94 per share; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">shares of common stock underlying the warrants and Series
C Preferred Stock included in the Units.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our securities includes
a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific
factors discussed below, together with all of the other information contained in this prospectus and the documents incorporated
by reference, including the risks identified under &ldquo;Item 1A. Risk Factors&rdquo; in our Annual Report on Form 10-K for the
fiscal year ended June 30, 2018. Our business, financial condition, results of operations and prospects could be materially and
adversely affected by these risks.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Financial Condition
and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a limited operating history, have incurred losses,
and can give no assurance of profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a commercial-stage healthcare company
with a limited operating history. Prior to implementing our commercial strategy in the fourth calendar quarter of 2015, we did
not have a focus on profitability. As a result, we have not generated substantial revenue to date and are not profitable and have
incurred losses in each year since our inception. Our net loss for the years ended June 30, 2018 and 2017 was $10.2 million and
$22.5million, respectively. We have not demonstrated the ability to be a profit-generating enterprise to date. Even though we expect
to have revenue growth in the next several fiscal years, it is uncertain that the revenue growth will be significant enough to
offset our expenses and generate a profit in the future. Our ability to generate significant revenue is uncertain, and we may never
achieve profitability. We have a very limited operating history on which investors can evaluate our potential for future success.
Potential investors should evaluate us in light of the expenses, delays, uncertainties, and complications typically encountered
by early-stage healthcare businesses, many of which will be beyond our control. These risks include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">uncertain market acceptance of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lack of sufficient capital;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">U.S. regulatory approval of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">foreign regulatory approval of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unanticipated problems, delays, and expense relating to product development and implementation;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lack of sufficient intellectual property;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the ability to attract and retain qualified employees;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">competition; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">technological changes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our limited operating history,
and the increasingly competitive nature of the markets in which we compete, our historical financial data, is of limited value
in anticipating future operating expenses. Our planned expense levels will be based in part on our expectations concerning future
operations, which is difficult to forecast accurately based on our limited operating history and the recentness of the acquisition
of our products Natesto, ZolpiMist, and MiOXSYS. We may be unable to adjust spending in a timely manner to compensate for any unexpected
budgetary shortfall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not received any substantial revenues
from the commercialization of our current products to date and might not receive significant revenues from the commercialization
of our current products or our product candidates in the near term. Even though Natesto and ZolpiMist are each an approved drug
that we are marketing, we only acquired Natesto in April 2016 and ZolpiMist in June 2018. In addition, we only launched our MiOXSYS
device in early fiscal 2017. As a result, we have limited experience on which to base the revenue we could expect to receive from
sales of these products. To obtain revenues from our products and product candidates, we must succeed, either alone or with others,
in a range of challenging activities, including expanding markets for our existing products and completing clinical trials of our
product candidates, obtaining positive results from those clinical trials, achieving marketing approval for those product candidates,
manufacturing, marketing and selling our existing products and those products for which we, or our collaborators, may obtain marketing
approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government
payors. We, and our collaborators, if any, may never succeed in these activities and, even if we do, or one of our collaborators
does, we may never generate revenues that are sufficient enough for us to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may need to raise additional funding,
which may not be available on acceptable terms, or at all. Failure to obtain necessary capital when needed may force us to delay,
limit or terminate our product expansion and development efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are expending resources to expand the
market for Natesto, ZolpiMist, and MiOXSYS, none of which might be as successful as we anticipate or at all and all of which might
take longer and be more expensive to market than we anticipate. We also are currently advancing our MiOXSYS device through clinical
development. Developing product candidates is expensive, lengthy and risky, and we expect to incur research and development expenses
in connection with our ongoing clinical development activities with the MiOXSYS System. As of June 30, 2018, our cash, cash equivalents
and restricted cash totaling $7.1 million, available to fund our operations offset by an aggregate $2.3 million in accounts payable
and other and accrued liabilities. In November 2016, we conducted a public offering of our common stock and warrants from which
we received gross proceeds of approximately $8.6 million. We closed on a private placement of common stock, Series A preferred
stock and warrants in August 2017 from which we received gross proceeds of approximately $11.8 million. We also closed on an underwritten
public offering of our common stock, warrants, and Series B preferred stock in March 2018 from which we received gross proceeds
of approximately $12.9 million. Our operating plan may change as a result of many factors currently unknown to us, and we may need
to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party
funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a
combination of these approaches. In any event, we will require additional capital to continue the expansion of marketing efforts
for Natesto and ZolpiMist and to obtain regulatory approval for, and to commercialize, our current product candidate, the MiOXSYS
System. Raising funds in the current economic environment, as well our lack of operating history, may present additional challenges.
Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market
conditions are favorable or if we have specific strategic considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any additional fundraising efforts may
divert our management from their day-to-day activities, which may adversely affect our ability to expand any existing product or
develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the
rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such
issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute
all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability
to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or
product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business,
operating results and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to obtain funding on a
timely basis, we may be unable to expand the market for Natesto, ZolpiMist, or MiOXSYS and/or be required to significantly curtail,
delay or discontinue one or more of our research or development programs for the MiOXSYS system, or any future product candidate
or expand our operations generally or otherwise capitalize on our business opportunities, as desired, which could materially affect
our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not obtain the capital necessary
to fund our operations, we will be unable to successfully expand the commercialization of Natesto and ZolpiMist and to develop,
obtain regulatory approval of, and commercialize, our current product candidate, the MiOXSYS System.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expansion of marketing and commercialization
activities for our existing products and the development of pharmaceutical products, medical diagnostics and medical devices is
capital-intensive. We anticipate we may require additional financing to continue to fund our operations. Our future capital requirements
will depend on, and could increase significantly as a result of, many factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs, progress and timing of our efforts to expand the marketing of Natesto and ZolpiMist;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">progress in, and the costs of, our pre-clinical studies
and clinical trials and other research and development programs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs of securing manufacturing arrangements for commercial production;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the scope, prioritization and number of our research and development programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the achievement of milestones or occurrence of other developments that trigger payments under any
collaboration agreements we obtain;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs of establishing, expanding or contracting for sales and marketing capabilities for any
existing products and if we obtain regulatory clearances to market our current product candidate, the MiOXSYS system;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial
costs under future collaboration agreements, if any; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the costs involved in filing, prosecuting, enforcing and defending patent claims and other intellectual
property rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If funds are not available, we may be required
to delay, reduce the scope of, or eliminate one or more of our commercialization efforts or our technologies, research or development
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur increased costs associated
with, and our management will need to devote substantial time and effort to, compliance with public company reporting and other
requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a public company, we incur significant
legal, accounting and other expenses. In addition, the rules and regulations of the SEC and any national securities exchange to
which we may be subject in the future impose numerous requirements on public companies, including requirements relating to our
corporate governance practices, with which we will need to comply. Further, we will continue to be required to, among other things,
file annual, quarterly and current reports with respect to our business and operating results. Based on currently available information
and assumptions, we estimate that we will incur up to approximately $500,000 in expenses on an annual basis as a direct result
of the requirements of being a publicly traded company. Our management and other personnel will need to devote substantial time
to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations, and our efforts
and initiatives to comply with those requirements could be expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish and maintain
proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting. Pursuant to Section 404 of the Sarbanes-Oxley Act, our management
conducted an assessment of the effectiveness of our internal controls over financial reporting for the year ended June 30, 2018
and concluded that such control was effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if in the future we were to conclude
that our internal control over financial reporting were not effective, we cannot be certain as to the timing of completion of our
evaluation, testing and remediation actions or their effect on our operations because there is presently no precedent available
by which to measure compliance adequacy. As a consequence, we may not be able to complete any necessary remediation process in
time to meet our deadline for compliance with Section 404 of the Sarbanes-Oxley Act. Also, there can be no assurance that we will
not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section
404 of the Sarbanes-Oxley Act. The presence of material weaknesses could result in financial statement errors which, in turn, could
require us to restate our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to conclude that we have
effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us, when
required, with an attestation report on the effectiveness of internal control over financial reporting as required by Section 404
of the Sarbanes-Oxley Act, investors may lose confidence in our operating results, our stock price could decline and we may be
subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404
of the Sarbanes-Oxley Act, we may not be able to maintain listing on the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Product Development,
Regulatory Approval and Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Natesto, ZolpiMist, and MiOXSYS may
prove to be difficult to effectively commercialize as planned.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various commercial, regulatory, and manufacturing
factors may impact our ability to maintain or grow revenues from sales of Natesto, MiOXSYS, ProstaScint and Fiera. Specifically,
we may encounter difficulty by virtue of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our inability to adequately market and increase sales of
any of these products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our inability to secure continuing prescribing of any of
these products by current or previous users of the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our inability to effectively transfer and scale manufacturing
as needed to maintain an adequate commercial supply of these products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">reimbursement and medical policy changes that may adversely
affect the pricing, profitability or commercial appeal of Natesto, ZolpiMist, or MiOXSYS; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our inability to effectively identify and align with commercial
partners outside the U.S., or the inability of those selected partners to gain the required regulatory, reimbursement, and other
approvals needed to enable commercial success of MiOXSYS.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited experience selling
our current products as they were acquired from other companies or were recently approved for sale. As a result, we may be unable
to successfully commercialize our products and product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite our management&rsquo;s extensive
experience in launching and managing commercial-stage healthcare companies, we have limited marketing, sales and distribution experience
with our current products. Our ability to achieve profitability depends on attracting and retaining customers for our current products,
and building brand loyalty for Natesto, ZolpiMist, and MiOXSYS. To successfully perform sales, marketing, distribution and customer
support functions, we will face a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to attract and retain skilled support team,
marketing staff and sales force necessary to increase the market for our approved products and to maintain market acceptance for
our product candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the ability of our sales and marketing team to identify
and penetrate the potential customer base; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the difficulty of establishing brand recognition and loyalty
for our products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may seek to enlist one
or more third parties to assist with sales, distribution and customer support globally or in certain regions of the world. If we
do seek to enter into these arrangements, we may not be successful in attracting desirable sales and distribution partners, or
we may not be able to enter into these arrangements on favorable terms, or at all. If our sales and marketing efforts, or those
of any third-party sales and distribution partners, are not successful, our currently approved products may not achieve increased
market acceptance and our product candidates may not gain market acceptance, which would materially impact our business and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be certain that we will
be able to obtain regulatory approval for, or successfully commercialize, any of our current or future product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to develop our current
or any future product candidates. Our product candidates will require substantial additional clinical development, testing, and
regulatory approval before we are permitted to commence commercialization. The clinical trials of our product candidates are,
and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation
by numerous government authorities in the U.S. and in other countries where we intend to test and, if approved, market any product
candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through
pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This
process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial
resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory
approval process and is commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund
our development and clinical programs, we cannot assure you that any of our product candidates will be successfully developed
or commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not permitted to market a product
in the U.S. until we receive approval of a New Drug Application, or an NDA, for that product from the FDA, or in any foreign countries
until we receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and
uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not be able to demonstrate that a product candidate is safe and effective to the satisfaction
of the FDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results of our clinical trials may not meet the level of statistical or clinical significance
required by the FDA for marketing approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may require that we conduct additional clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may not approve the formulation, labeling or specifications of any product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the clinical research organizations, or CROs, that we retain to conduct our clinical trials may
take actions outside of our control that materially adversely impact our clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate
that a product candidate&rsquo;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients
or the public in general;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may disagree with our interpretation of data from our pre-clinical studies and clinical
trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may not accept data generated at our clinical trial sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">if an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties
scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application
or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations
on approved labeling or distribution and use restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
of approval or post-approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may not approve the manufacturing processes or facilities of third-party manufacturers
with which we contract; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA may change its approval policies or adopt new regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These same risks apply to applicable foreign
regulatory agencies from which we may seek approval for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these factors, many of which are
beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market any product candidate.
Moreover, because a substantial portion of our business is or may be dependent upon our product candidates, any such setback in
our pursuit of initial or additional regulatory approval would have a material adverse effect on our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to successfully acquire
new products, we may lose market position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquiring new products is an important
factor in our planned sales growth, including products that already have been developed and found market acceptance. If we fail
to identify existing or emerging consumer markets and trends and to acquire new products, we will not develop a strong revenue
source to help pay for our development activities as well as possible acquisitions. This failure would delay implementation of
our business plan, which could have a negative adverse effect on our business and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not secure collaborations
with strategic partners to test, commercialize and manufacture product candidates, we may not be able to successfully develop products
and generate meaningful revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may enter into collaborations with third
parties to conduct clinical testing, as well as to commercialize and manufacture our products and product candidates. If we are
able to identify and reach an agreement with one or more collaborators, our ability to generate revenues from these arrangements
will depend on our collaborators&rsquo; abilities to successfully perform the functions assigned to them in these arrangements.
Collaboration agreements typically call for milestone payments that depend on successful demonstration of efficacy and safety,
obtaining regulatory approvals, and clinical trial results. Collaboration revenues are not guaranteed, even when efficacy and safety
are demonstrated. Further, the economic environment at any given time may result in potential collaborators electing to reduce
their external spending, which may prevent us from developing our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we succeed in securing collaborators,
the collaborators may fail to develop or effectively commercialize our products or product candidates. Collaborations involving
our product candidates pose a number of risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may not have sufficient resources or may decide not to devote the necessary resources
due to internal constraints such as budget limitations, lack of human resources, or a change in strategic focus;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may believe our intellectual property is not valid or is unenforceable or the product
candidate infringes on the intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may dispute their responsibility to conduct development and commercialization activities
pursuant to the applicable collaboration, including the payment of related costs or the division of any revenues;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may decide to pursue a competitive product developed outside of the collaboration
arrangement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may not be able to obtain, or believe they cannot obtain, the necessary regulatory
approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may delay the development or commercialization of our product candidates in favor
of developing or commercializing their own or another party&rsquo;s product candidate; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">collaborators may decide to terminate or not to renew the collaboration for these or other reasons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, collaboration agreements may
not lead to development or commercialization of our product candidates in the most efficient manner or at all. For example, our
former collaborator that licensed our former product candidate, Zertane conducted clinical trials which we believe demonstrated
efficacy in treating PE, but the collaborator undertook a merger that we believe altered its strategic focus and thereafter terminated
the collaboration agreement. The Merger also created a potential conflict with a principal customer of the acquired company, which
sells a product to treat premature ejaculation in certain European markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaboration agreements are generally
terminable without cause on short notice. Once a collaboration agreement is signed, it may not lead to commercialization of a product
candidate. We also face competition in seeking out collaborators. If we are unable to secure collaborations that achieve the collaborator&rsquo;s
objectives and meet our expectations, we may be unable to advance our products or product candidates and may not generate meaningful
revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We or our strategic partners may
choose not to continue an existing product or choose not to develop a product candidate at any time during development, which would
reduce or eliminate our potential return on investment for that product.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time and for any reason, we or our
strategic partners may decide to discontinue the development or commercialization of a product or product candidate. If we terminate
a program in which we have invested significant resources, we will reduce the return, or not receive any return, on our investment
and we will have missed the opportunity to have allocated those resources to potentially more productive uses. If one of our strategic
partners terminates a program, we will not receive any future milestone payments or royalties relating to that program under our
agreement with that party. As an example, we discontinued the development of Zertane in June 2016, sold Primsol in March 2017,
and abandoned Fiera and ProstaScint in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our pre-commercial product candidates
are expected to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for
which there is a high risk of failure. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and
efficacy to the FDA and other regulators, we or our collaborators may incur additional costs or experience delays in completing,
or ultimately be unable to complete, the development and commercialization of these product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-clinical testing and clinical trials
are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical
studies will be conducted as planned or completed on schedule, if at all. It may take several years to complete the pre-clinical
testing and clinical development necessary to commercialize a drug, and delays or failure can occur at any stage. Interim results
of clinical trials do not necessarily predict final results, and success in pre-clinical testing and early clinical trials does
not ensure that later clinical trials will be successful. A number of companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced clinical trials even after promising results in earlier trials and we cannot be
certain that we will not face similar setbacks. The design of a clinical trial can determine whether its results will support approval
of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. An
unfavorable outcome in one or more trials would be a major set-back for that product candidate and for us. Due to our limited financial
resources, an unfavorable outcome in one or more trials may require us to delay, reduce the scope of, or eliminate one or more
product development programs, which could have a material adverse effect on our business, prospects and financial condition and
on the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with clinical testing and
trials, we face a number of risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a product candidate is ineffective, inferior to existing approved medicines, unacceptably toxic,
or has unacceptable side effects;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">patients may die or suffer other adverse effects for reasons that may or may not be related to
the product candidate being tested;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results may not confirm the positive results of earlier testing or trials; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the results may not meet the level of statistical significance required by the FDA or other regulatory
agencies to establish the safety and efficacy of the product candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not successfully complete pre-clinical
and clinical development, we will be unable to market and sell products derived from our product candidates and generate revenues.
Even if we do successfully complete clinical trials, those results are not necessarily predictive of results of additional trials
that may be needed before an NDA may be submitted to the FDA. Although there are a large number of drugs in development in the
U.S. and other countries, only a small percentage result in the submission of an NDA to the FDA, even fewer are approved for commercialization,
and only a small number achieve widespread physician and consumer acceptance following regulatory approval. If our clinical trials
are substantially delayed or fail to prove the safety and effectiveness of our product candidates in development, we may not receive
regulatory approval of any of these product candidates and our business, prospects and financial condition will be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays, suspensions and terminations
in any clinical trial we undertake could result in increased costs to us and delay or prevent our ability to generate revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are very expensive,
time-consuming, and difficult to design, implement and complete. Should we undertake the development of a pharmaceutical product
candidate, we would expect the necessary clinical trials to take up to 24 months to complete, but the completion of trials for
any product candidates may be delayed for a variety of reasons, including delays in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">demonstrating sufficient safety and efficacy to obtain regulatory approval to commence a clinical
trial;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">validating test methods to support quality testing of the drug substance and drug product;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtaining sufficient quantities of the drug substance or device parts;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">manufacturing sufficient quantities of a product candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtaining approval of an IND from the FDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtaining institutional review board approval to conduct a clinical trial at a prospective clinical
trial site;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">determining dosing and clinical design and making related adjustments; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">patient enrollment, which is a function of many factors, including the size of the patient population,
the nature of the protocol, the proximity of patients to clinical trial sites, the availability of effective treatments for the
relevant disease and the eligibility criteria for the clinical trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commencement and completion of clinical
trials for our product candidates may be delayed, suspended or terminated due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">lack of effectiveness of product candidates during clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>adverse events, safety issues or side effects relating
to the product candidates or their formulation or design;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">inability to raise additional capital in sufficient amounts to continue clinical trials or development
programs, which are very expensive;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the need to sequence clinical trials as opposed to conducting them concomitantly in order to conserve
resources;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability to enter into collaborations relating to the development and commercialization of
our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure by us or our collaborators to conduct clinical trials in accordance with regulatory requirements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability or the inability of our collaborators to manufacture or obtain from third parties
materials sufficient for use in pre-clinical studies and clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines,
including mandated changes in the scope or design of clinical trials or requests for supplemental information with respect to clinical
trial results;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure of our collaborators to advance our product candidates through clinical development;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">delays in patient enrollment, variability in the number and types of patients available for clinical
trials, and lower-than anticipated retention rates for patients in clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">difficulty in patient monitoring and data collection due to failure of patients to maintain contact
after treatment;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a regional disturbance where we or our collaborative partners are enrolling patients in our clinical
trials, such as a pandemic, terrorist activities or war, or a natural disaster; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">varying interpretations of our data, and regulatory commitments and requirements by the FDA and
similar foreign regulatory agencies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of these factors may also ultimately
lead to denial of an NDA for a product candidate. If we experience delay, suspensions or terminations in a clinical trial, the
commercial prospects for the related product candidate will be harmed, and our ability to generate product revenues will be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may encounter delays or
product candidate rejections based on new governmental regulations, future legislative or administrative actions, or changes in
FDA policy or interpretation during the period of product development. If we obtain required regulatory approvals, such approvals
may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">diminishment of any competitive advantages that such product candidates may have or attain.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, if we fail to comply with
applicable FDA and other regulatory requirements at any stage during this regulatory process, we may encounter or be subject to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">diminishment of any competitive advantages that such product candidates may have or attain;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">delays or termination in clinical trials or commercialization;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements
to approved applications;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">product recalls or seizures;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">suspension of manufacturing;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawals of previously approved marketing applications; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">fines, civil penalties, and criminal prosecutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The medical device regulatory clearance
or approval process is expensive, time consuming and uncertain, and the failure to obtain and maintain required clearances or approvals
could prevent us from broadly commercializing the MiOXSYS System for clinical use.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MiOXSYS System is subject to 510k de
novo clearance by the FDA prior to its marketing for commercial use in the U.S., and to regulatory approvals beyond CE marking
required by certain foreign governmental entities prior to its marketing outside the U.S. In addition, any changes or modifications
to a device that has received regulatory clearance or approval that could significantly affect its safety or effectiveness, or
would constitute a major change in its intended use, may require the submission of a new application for 510k de novo clearance,
pre-market approval, or foreign regulatory approvals. The 510k de novo clearance and pre-market approval processes, as well as
the process of obtaining foreign approvals, can be expensive, time consuming and uncertain. It generally takes from four to twelve
months from submission to obtain 510k de novo clearance, and from one to three years from submission to obtain pre-market approval;
however, it may take longer, and 510k de novo clearance or pre-market approval may never be obtained. We have limited experience
in filing FDA applications for 510k de novo clearance and pre-market approval. In addition, we are required to continue to comply
with applicable FDA and other regulatory requirements even after obtaining clearance or approval. There can be no assurance that
we will obtain or maintain any required clearance or approval on a timely basis, or at all. Any failure to obtain or any material
delay in obtaining FDA clearance or any failure to maintain compliance with FDA regulatory requirements could harm our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The approval process for pharmaceutical
and medical device products outside the U.S. varies among countries and may limit our ability to develop, manufacture and sell
our products internationally. Failure to obtain marketing approval in international jurisdictions would prevent our product candidates
from being marketed abroad.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market and sell our products
in the European Union and many other jurisdictions, we, and our collaborators, must obtain separate marketing approvals and comply
with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional testing.
We may conduct clinical trials for, and seek regulatory approval to market, our product candidates in countries other than the
U.S. Depending on the results of clinical trials and the process for obtaining regulatory approvals in other countries, we may
decide to first seek regulatory approvals of a product candidate in countries other than the U.S., or we may simultaneously seek
regulatory approvals in the U.S. and other countries. If we or our collaborators seek marketing approval for a product candidate
outside the U.S., we will be subject to the regulatory requirements of health authorities in each country in which we seek approval.
With respect to marketing authorizations in Europe, we will be required to submit a European Marketing Authorisation Application,
or MAA, to the European Medicines Agency, or EMA, which conducts a validation and scientific approval process in evaluating a product
for safety and efficacy. The approval procedure varies among regions and countries and may involve additional testing, and the
time required to obtain approval may differ from that required to obtain FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining regulatory approvals from health
authorities in countries outside the U.S. is likely to subject us to all of the risks associated with obtaining FDA approval described
above. In addition, marketing approval by the FDA does not ensure approval by the health authorities of any other country, and
approval by foreign health authorities does not ensure marketing approval by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we, or our collaborators,
obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit
how we or they market our products, which could materially impair our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we receive regulatory approval
for a product candidate, this approval may carry conditions that limit the market for the product or put the product at a competitive
disadvantage relative to alternative therapies. For instance, a regulatory approval may limit the indicated uses for which we can
market a product or the patient population that may utilize the product, or may be required to carry a warning in its labeling
and on its packaging. Products with black box warnings are subject to more restrictive advertising regulations than products without
such warnings. These restrictions could make it more difficult to market any product candidate effectively. Accordingly, assuming
we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators expect
to continue to expend time, money and effort in all areas of regulatory compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any of our products and product
candidates for which we, or our collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions
or withdrawal from the market and we, and our collaborators, may be subject to substantial penalties if we, or they, fail to comply
with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of our approved products and product
candidates for which we, or our collaborators, obtain marketing approval, as well as the manufacturing processes, post approval
studies and measures, labeling, advertising and promotional activities for such products, among other things, are or will be subject
to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of
safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing,
quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution
of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject
to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the FDA
requirement to implement a REMS to ensure that the benefits of a drug outweigh its risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may also impose requirements for
costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other
agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products
to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions
of the approved labeling. The FDA imposes stringent restrictions on manufacturers&rsquo; communications regarding off-label use
and if we, or our collaborators, do not market any of our product candidates for which we, or they, receive marketing approval
for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation
of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs
may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer
protection laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not achieve our projected
development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates
may be delayed, and our business will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sometimes estimate for planning purposes
the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones
may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission
of regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some
of these milestones, such as the initiation or completion of an ongoing clinical trial, the initiation of other clinical programs,
receipt of marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be outside
of our control. All of such milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones
to vary considerably from our estimates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our available capital resources or capital constraints we experience;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the rate of progress, costs and results of our clinical trials and research and development activities,
including the extent of scheduling conflicts with participating clinicians and collaborators, and our ability to identify and enroll
patients who meet clinical trial eligibility criteria;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our receipt of approvals from the FDA and other regulatory agencies and the timing thereof;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other actions, decisions or rules issued by regulators;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to access sufficient, reliable and affordable supplies of compounds used in the manufacture
of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the efforts of our collaborators with respect to the commercialization of our products; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the securing of, costs related to, and timing issues associated with, product manufacturing as
well as sales and marketing activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to achieve announced milestones
in the timeframes we announce and expect, the commercialization of our product candidates may be delayed and our business, prospects
and results of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on third parties to conduct
our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully
commercializing product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely, and will rely in the future,
on medical institutions, clinical investigators, contract research organizations, contract laboratories, and collaborators to
perform data collection and analysis and others to carry out our clinical trials. Our development activities or clinical trials
conducted in reliance on third parties may be delayed, suspended, or terminated if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the third parties do not successfully carry out their contractual duties or fail to meet regulatory
obligations or expected deadlines;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we replace a third party; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the quality or accuracy of the data obtained by third parties is compromised due to their failure
to adhere to clinical protocols, regulatory requirements, or for other reasons.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third party performance failures may increase
our development costs, delay our ability to obtain regulatory approval, and delay or prevent the commercialization of our product
candidates. While we believe that there are numerous alternative sources to provide these services, in the event that we seek such
alternative sources, we may not be able to enter into replacement arrangements without incurring delays or additional costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if collaborators with which
we contract in the future successfully complete clinical trials of our product candidates, those product candidates may not be
commercialized successfully for other reasons.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we contract with collaborators
that successfully complete clinical trials for one or more of our product candidates, those candidates may not be commercialized
for other reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to receive regulatory clearances required to market them as drugs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being subject to proprietary rights held by others;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">being difficult or expensive to manufacture on a commercial scale;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">having adverse side effects that make their use less desirable; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failing to compete effectively with products or treatments commercialized by competitors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any third-party manufacturers we
engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays
in, our product commercialization as a result of these regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacturing processes and facilities
of third-party manufacturers we have engaged for our current approved products are, and any future third-party manufacturer will
be, required to comply with the federal Quality System Regulation, or QSR, which covers procedures and documentation of the design,
testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces
the QSR through periodic unannounced inspections of manufacturing facilities. Any inspection by the FDA could lead to additional
compliance requests that could cause delays in our product commercialization. Failure to comply with applicable FDA requirements,
or later discovery of previously unknown problems with the manufacturing processes and facilities of third-party manufacturers
we engage, including the failure to take satisfactory corrective actions in response to an adverse QSR inspection, can result in,
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">administrative or judicially imposed sanctions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctions or the imposition of civil penalties;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">recall or seizure of the product in question;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">total or partial suspension of production or distribution;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawal or suspension of marketing clearances or approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">clinical holds;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">warning letters;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal to permit the export of the product in question; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">criminal prosecution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these actions, in combination or
alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a product defect or regulatory
violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary
recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have
similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger
health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims,
and harm our reputation with customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face substantial competition from
companies with considerably more resources and experience than we have, which may result in others discovering, developing, receiving
approval for, or commercializing products before or more successfully than us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete with companies that design,
manufacture and market already-existing and new urology and sexual wellbeing products. We anticipate that we will face increased
competition in the future as new companies enter the market with new technologies and/or our competitors improve their current
products. One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical.
Most of our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial
intellectual property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more
substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing
capabilities and the distribution channels to deliver products to customers. If we are not able to compete successfully, we may
not generate sufficient revenue to become profitable. Our ability to compete successfully will depend largely on our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">expand the market for our approved products, especially Natesto, MiOXSYS and Fiera;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">successfully commercialize our product candidates alone or with commercial partners;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">discover and develop product candidates that are superior to other products in the market;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtain required regulatory approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">attract and retain qualified personnel; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">obtain patent and/or other proprietary protection for our product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Established pharmaceutical companies devote
significant financial resources to discovering, developing or licensing novel compounds that could make our products and product
candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before us.
Other companies are or may become engaged in the discovery of compounds that may compete with the product candidates we are developing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto competes in a large, growing market.
The U.S. prescription testosterone market is comprised primarily of topically applied treatments in the form of gels, solutions,
and patches. Testopel&reg; and Aveed&reg;, injectable products typically implanted directly under the skin by a physician, are
also FDA-approved. AndroGel is the market-leading TRT and is marketed by AbbVie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For ZolpiMist, we compete with companies
that design, manufacture and market treatments for insomnia, some of which have a large market share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the MiOXSYS System, we compete with
companies that design, manufacture and market already existing and new in-vitro diagnostics and diagnostic imaging systems and
radio-imaging agents for cancer detection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that we will face increased
competition in the future as new companies enter the market with new technologies and our competitors improve their current products.
One or more of our competitors may offer technology superior to ours and render our technology obsolete or uneconomical. Most of
our current competitors, as well as many of our potential competitors, have greater name recognition, more substantial intellectual
property portfolios, longer operating histories, significantly greater resources to invest in new technologies, more substantial
experience in new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution
channels to deliver products to customers. If we are not able to compete successfully, we may not generate sufficient revenue to
become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any new product we develop or commercialize
that competes with a currently-approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and/or
safety in order to address price competition and be commercially successful. If we are not able to compete effectively against
our current and future competitors, our business will not grow and our financial condition and operations will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Government restrictions on pricing
and reimbursement, as well as other healthcare payor cost-containment initiatives, may negatively impact our ability to generate
revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continuing efforts of the government,
insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care
may adversely affect one or more of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our or our collaborators&rsquo; ability to set a price
we believe is fair for our approved products;</TD>
</TR></TABLE>





<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>our ability to generate revenue from our approved products
and achieve profitability; and</TD>
</TR></TABLE>






<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the availability of capital.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2010 enactments of the Patient Protection
and Affordable Care Act, or PPACA, and the Health Care and Education Reconciliation Act, or the Health Care Reconciliation Act,
significantly impacted the provision of, and payment for, health care in the U.S. Various provisions of these laws are designed
to expand Medicaid eligibility, subsidize insurance premiums, provide incentives for businesses to provide health care benefits,
prohibit denials of coverage due to pre-existing conditions, establish health insurance exchanges, and provide additional support
for medical research. Amendments to the PPACA and/or the Health Care Reconciliation Act, as well as new legislative proposals to
reform healthcare and government insurance programs, along with the trend toward managed healthcare in the U.S., could influence
the purchase of medicines and medical devices and reduce demand and prices for our products and product candidates, if approved.
This could harm our or our collaborators&rsquo; ability to market any approved products and generate revenues. As we expect to
receive significant revenues from reimbursement of our Natesto and ProstaScint products by commercial third-party payors and government
payors, cost containment measures that health care payors and providers are instituting and the effect of further health care reform
could significantly reduce potential revenues from the sale of any of our products and product candidates approved in the future,
and could cause an increase in our compliance, manufacturing, or other operating expenses. In addition, in certain foreign markets,
the pricing of prescription drugs and devices is subject to government control and reimbursement may in some cases be unavailable.
We believe that pricing pressures at the federal and state level, as well as internationally, will continue and may increase, which
may make it difficult for us to sell any approved product at a price acceptable to us or any of our future collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in some foreign countries,
the proposed pricing for a drug or medical device must be approved before it may be lawfully marketed. The requirements governing
pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict
the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices
of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt
a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. A member
state may require that physicians prescribe the generic version of a drug instead of our approved branded product. There can be
no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products or product candidates. Historically, pharmaceutical products launched
in the European Union do not follow price structures of the U.S. and generally tend to have significantly lower prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our financial results will depend
on the acceptance among hospitals, third-party payors and the medical community of our products and product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success depends on the acceptance
by our target customers, third-party payors and the medical community that our products and product candidates are reliable, safe
and cost-effective. Many factors may affect the market acceptance and commercial success of our products and product candidates,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to convince our potential customers of the advantages and economic value our products
and product candidates over existing technologies and products;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the relative convenience and ease of our products and product
candidates over existing technologies and products;</TD>
</TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the introduction of new technologies and competing products that may make our products and product
candidates less attractive for our target customers;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our success in training medical personnel on the proper use of our products and product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the willingness of third-party payors to reimburse our target customers that adopt our products
and product candidates;</TD></TR>                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the acceptance in the medical community of our products and product candidates;</TD></TR>                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the extent and success of our marketing and sales efforts; and</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">general economic conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If third-party payors do not reimburse
our customers for the products we sell or if reimbursement levels are set too low for us to sell one or more of our products at
a profit, our ability to sell those products and our results of operations will be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While Natesto and ZolpiMist are already
FDA-approved and generating revenues in the U.S., they may not receive, or continue to receive, physician or hospital acceptance,
or they may not maintain adequate reimbursement from third party payors. Additionally, even if one of our product candidates is
approved and reaches the market, the product may not achieve physician or hospital acceptance, or it may not obtain adequate reimbursement
from third party payors. In the future, we might possibly sell other product candidates to target customers substantially all of
whom receive reimbursement for the health care services they provide to their patients from third-party payors, such as Medicare,
Medicaid, other domestic and foreign government programs, private insurance plans and managed care programs. Reimbursement decisions
by particular third-party payors depend upon a number of factors, including each third-party payor&rsquo;s determination that use
of a product is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a covered benefit under its health plan;</TD></TR>                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">appropriate and medically necessary for the specific indication;</TD></TR>                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">cost effective; and</TD></TR>                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">neither experimental nor investigational.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors may deny reimbursement
for covered products if they determine that a medical product was not used in accordance with cost-effective diagnosis methods,
as determined by the third-party payor, or was used for an unapproved indication. Third-party payors also may refuse to reimburse
for procedures and devices deemed to be experimental.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining coverage and reimbursement approval
for a product from each government or third-party payor is a time consuming and costly process that could require us to provide
supporting scientific, clinical and cost-effectiveness data for the use of our potential product to each government or third-party
payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. In addition,
eligibility for coverage does not imply that any product will be covered and reimbursed in all cases or reimbursed at a rate that
allows our potential customers to make a profit or even cover their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payors are increasingly attempting
to contain health care costs by limiting both coverage and the level of reimbursement for medical products and services. Levels
of reimbursement may decrease in the future, and future legislation, regulation or reimbursement policies of third-party payors
may adversely affect the demand for and reimbursement available for any product or product candidate, which in turn, could negatively
impact pricing. If our customers are not adequately reimbursed for our products, they may reduce or discontinue purchases of our
products, which would result in a significant shortfall in achieving revenue expectations and negatively impact our business, prospects
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Manufacturing risks and inefficiencies
may adversely affect our ability to produce our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to engage third parties to manufacture
components of the MiOXSYS and RedoxSYS systems. We have an agreement for supplies of Natesto with Acerus, from whom we license
Natesto. We have an agreement with a third-party manufacturer for our ZolpiMist product as well. For any future product, we expect
to use third-party manufacturers because we do not have our own manufacturing capabilities. In determining the required quantities
of any product and the manufacturing schedule, we must make significant judgments and estimates based on inventory levels, current
market trends and other related factors. Because of the inherent nature of estimates and our limited experience in marketing our
current products, there could be significant differences between our estimates and the actual amounts of product we require. If
we do not effectively maintain our supply agreements for Natesto and Fiera, we will face difficulty finding replacement suppliers,
which could harm sales of those products. If we do not secure collaborations with manufacturing and development partners to enable
production to scale of the MiOXSYS System, we may not be successful in selling or in commercializing the MiOXSYS System in the
event we receive regulatory approval of the MiOXSYS System. If we fail in similar endeavors for future products, we may not be
successful in establishing or continuing the commercialization of our products and product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reliance on third-party manufacturers entails
risks to which we would not be subject if we manufactured these components ourselves, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reliance on third parties for regulatory compliance and quality assurance;</TD></TR>                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">possible breaches of manufacturing agreements by the third parties because of factors beyond our
control;</TD></TR>                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">possible regulatory violations or manufacturing problems experienced by our suppliers; and</TD></TR>                                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">possible termination or non-renewal of agreements by third parties, based on their own business
priorities, at times that are costly or inconvenient for us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, if we are unable to secure the
needed financing to fund our internal operations, we may not have adequate resources required to effectively and rapidly transition
our third party manufacturing. We may not be able to meet the demand for our products if one or more of any third-party manufacturers
is unable to supply us with the necessary components that meet our specifications. It may be difficult to find alternate suppliers
for any of our products or product candidates in a timely manner and on terms acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any third-party manufacturers we
engage are subject to various governmental regulations, and we may incur significant expenses to comply with, and experience delays
in, our product commercialization as a result of these regulations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacturing processes and facilities
of third-party manufacturers we engage for our current and any future FDA-approved products are required to comply with the federal
Quality System Regulation, or QSR, which covers procedures and documentation of the design, testing, production, control, quality
assurance, labeling, packaging, sterilization, storage and shipping of devices. The FDA enforces the QSR through periodic unannounced
inspections of manufacturing facilities. Any inspection by the FDA could lead to additional compliance requests that could cause
delays in our product commercialization. Failure to comply with applicable FDA requirements, or later discovery of previously unknown
problems with the manufacturing processes and facilities of third-party manufacturers we engage, including the failure to take
satisfactory corrective actions in response to an adverse QSR inspection, can result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">administrative or judicially imposed sanctions;</TD></TR>                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctions or the imposition of civil penalties;</TD></TR>                                                                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">recall or seizure of the product in question;</TD></TR>                                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">total or partial suspension of production or distribution;</TD></TR>                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the FDA&rsquo;s refusal to grant pending future clearance or pre-market approval;</TD></TR>                                                                                                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">withdrawal or suspension of marketing clearances or approvals;</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">clinical holds;</TD></TR>                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">warning letters;</TD></TR>                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">refusal to permit the export of the product in question; and</TD></TR>                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">criminal prosecution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these actions, in combination or
alone, could prevent us from marketing, distributing or selling our products, and would likely harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, a product defect or regulatory
violation could lead to a government-mandated or voluntary recall by us. We believe the FDA would request that we initiate a voluntary
recall if a product was defective or presented a risk of injury or gross deception. Regulatory agencies in other countries have
similar authority to recall drugs or devices because of material deficiencies or defects in design or manufacture that could endanger
health. Any recall would divert our management attention and financial resources, expose us to product liability or other claims,
and harm our reputation with customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future growth depends, in part,
on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future profitability will depend, in
part, on our ability to commercialize our products and product candidates in foreign markets for which we intend to primarily rely
on collaboration with third parties. If we commercialize our products or product candidates in foreign markets, we would be subject
to additional risks and uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our inability to directly control commercial activities because we are relying on third parties;</TD></TR>                                                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal
requirements;</TD></TR>                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</TD></TR>                                                                                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">import or export licensing requirements;</TD></TR>                                                                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">longer accounts receivable collection times;</TD></TR>                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">longer lead times for shipping;</TD></TR>                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">language barriers for technical training;</TD></TR>                                                                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">reduced protection of intellectual property rights in some foreign countries, and related prevalence
of generic alternatives to our products;</TD></TR>                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">foreign currency exchange rate fluctuations;</TD></TR>                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our customers&rsquo; ability to obtain reimbursement for our products in foreign markets; and</TD></TR>                                                                                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the interpretation of contractual provisions governed by foreign laws in the event of a contract
dispute.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign sales of our products or product
candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade
restrictions and changes in tariffs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to various regulations
pertaining to the marketing of our approved products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to various federal and state
laws pertaining to healthcare fraud and abuse, including prohibitions on the offer of payment or acceptance of kickbacks or other
remuneration for the purchase of our products, including inducements to potential patients to request our products and services.
Additionally, any product promotion educational activities, support of continuing medical education programs, and other interactions
with health-care professionals must be conducted in a manner consistent with the FDA regulations and the Anti-Kickback Statute.
The Anti-Kickback Statute prohibits persons or entities from knowingly and willfully soliciting, receiving, offering or providing
remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging
for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs.
Violations of the Anti-Kickback Statute can also carry potential federal False Claims Act liability. Additionally, many states
have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare
items or services reimbursed by any third party payer, not only the Medicare and Medicaid programs, and do not contain identical
safe harbors. These and any new regulations or requirements may be difficult and expensive for us to comply with, may adversely
impact the marketing of our existing products or delay introduction of our product candidates, which may have a material adverse
effect on our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our products and product candidates
may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved
label, or result in significant negative consequences following marketing approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Undesirable side effects caused by our
product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, if a product candidate receives
marketing approval and we or others identify undesirable side effects caused by the product after the approval, or if drug abuse
is determined to be a significant problem with an approved product, a number of potentially significant negative consequences could
result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">regulatory authorities may withdraw or limit their approval of the product;</TD></TR>                                                                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">regulatory authorities may require the addition of labeling statements, such as a &ldquo;Black
Box warning&rdquo; or a contraindication;</TD></TR>                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may be required to change the way the product is distributed or administered, conduct additional
clinical trials or change the labeling of the product;</TD></TR>                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may decide to remove the product from the marketplace;</TD></TR>                                                                                                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we could be sued and held liable for injury caused to individuals exposed to or taking the product;
and</TD></TR>             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of these events could prevent us from
achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing
an affected product or product candidates and significantly impact our ability to successfully commercialize or maintain sales
of our product or product candidates and generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Natesto and ZolpiMist contain, and
future other product candidates may contain, controlled substances, the manufacture, use, sale, importation, exportation, prescribing
and distribution of which are subject to regulation by the DEA.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto and ZolpiMist, which are both approved
by the FDA, are regulated by the DEA as Schedule III controlled substances. Before any commercialization of any product candidate
that contains a controlled substance, the DEA will need to determine the controlled substance schedule, taking into account the
recommendation of the FDA. This may be a lengthy process that could delay our marketing of a product candidate and could potentially
diminish any regulatory exclusivity periods for which we may be eligible. Natesto and ZolpiMist are, and our other product candidates
may, if approved, be regulated as &ldquo;controlled substances&rdquo; as defined in the Controlled Substances Act of 1970, or CSA,
and the implementing regulations of the DEA, which establish registration, security, recordkeeping, reporting, storage, distribution,
importation, exportation, inventory, quota and other requirements administered by the DEA. These requirements are applicable to
us, to our third-party manufacturers and to distributors, prescribers and dispensers of our product candidates. The DEA regulates
the handling of controlled substances through a closed chain of distribution. This control extends to the equipment and raw materials
used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A number of
states and foreign countries also independently regulate these drugs as controlled substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The DEA regulates controlled substances
as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use, and may not
be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances
considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Natesto is regulated by the DEA as a Schedule
III controlled substance, and ZolpiMist as a Schedule IV controlled substance. Consequently, the manufacturing, shipping, storing,
selling and using of the products are subject to a high degree of regulation. Also, distribution, prescribing and dispensing of
these drugs are highly regulated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual registration is required for any
facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to
the particular location, activity and controlled substance schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of their restrictive nature, these
laws and regulations could limit commercialization of our product candidates containing controlled substances. Failure to comply
with these laws and regulations could also result in withdrawal of our DEA registrations, disruption in manufacturing and distribution
activities, consent decrees, criminal and civil penalties and state actions, among other consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If testosterone replacement therapies
are found, or are perceived, to create health risks, our ability to sell Natesto could be materially adversely affected and our
business could be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent publications have suggested potential
health risks associated with testosterone replacement therapy, such as increased cardiovascular disease risk, including increased
risk of heart attack or stroke, fluid retention, sleep apnea, breast tenderness or enlargement, increased red blood cells, development
of clinical prostate disease, including prostate cancer, and the suppression of sperm production. Prompted by these events, the
FDA held a T-class Advisory Committee meeting on September 17, 2014 to discuss this topic further. The FDA has also asked health
care professionals and patients to report side effects involving prescription testosterone products to the agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the T-class Advisory Committee meeting
held on September 17, 2014, the Advisory Committee discussed (i) the identification of the appropriate patient population for whom
testosterone replacement therapy should be indicated and (ii) the potential risk of major adverse cardiovascular events, defined
as non-fatal stroke, non-fatal myocardial infarction and cardiovascular death associated with testosterone replacement therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the meeting, the Advisory Committee
voted that the FDA should require sponsors of testosterone products to conduct a post marketing study (e.g. observational study
or controlled clinical trial) to further assess the potential cardiovascular risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is possible that the FDA&rsquo;s evaluation
of this topic and further studies on the effects of testosterone replacement therapies could demonstrate the risk of major adverse
cardiovascular events or other health risks or could impose requirements that impact the marketing and sale of Natesto, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">mandate that certain warnings or precautions be included in our product labeling;</TD></TR>                                                                                                                                                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">require that our product carry a &ldquo;black box warning&rdquo;; and</TD></TR>                                                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">limit use of Natesto to certain populations, such as men without specified conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Demonstrated testosterone replacement therapy
safety risks, as well as negative publicity about the risks of hormone replacement therapy, including testosterone replacement,
could hurt sales of and impair our ability to successfully relaunch Natesto, which could have a materially adverse impact on our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>FDA action regarding testosterone
replacement therapies could add to the cost of producing and marketing Natesto.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA is requiring post-marketing safety
studies for all testosterone replacement therapies approved in the U.S. to assess long-term cardiovascular events related to testosterone
use. Depending on the total cost and structure of the FDA&rsquo;s proposed safety studies there may be a substantial cost associated
with conducting these studies. Pursuant to our license agreement with Acerus Pharmaceuticals, Acerus is obligated to reimburse
us for the entire cost of any studies required for Natesto by the FDA. However, in the event that Acerus is not able to reimburse
us for the cost of any required safety studies, we may be forced to incur this cost, which could have a material adverse impact
on our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our approved products may not be
accepted by physicians, patients, or the medical community in general.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if the medical community accepts a
product as safe and efficacious for its indicated use, physicians may choose to restrict the use of the product if we or any collaborator
is unable to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our product is preferable
to any existing medicines or treatments. We cannot predict the degree of market acceptance of any of our approved products, which
will depend on a number of factors, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the efficacy and safety of the product;</TD></TR>                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the approved labeling for the product and any required warnings;</TD></TR>                                                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD>the advantages and disadvantages of the product compared
to alternative treatments;</TD>
</TR>     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our and any collaborator&rsquo;s ability to educate the medical community about the safety and
effectiveness of the product;</TD></TR>                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the reimbursement policies of government and third-party payors pertaining to the product; and</TD></TR>                                                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the market price of our product relative to competing treatments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may use hazardous chemicals and
biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be
time consuming and costly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development processes
may involve the controlled use of hazardous materials, including chemicals and biological materials. We cannot eliminate the risk
of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination
that results from our use or the use by third parties of these materials, and our liability may exceed any insurance coverage and
our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of
these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health
and safety matters. Compliance with environmental laws and regulations may be expensive and may impair our research and development
efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and
penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain
compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any
changes in the way existing and future laws and regulations are interpreted and enforced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intellectual Property Risks Related to
Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on our relationships
and license agreements, and we rely on the patent rights granted to us pursuant to the license agreements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A number of our patent rights for are derived
from our license agreements with third parties. Pursuant to these license agreements, we have licensed rights to various patents
and patent applications within and outside of the United States. We may lose our rights to these patents and patent applications
if we breach our obligations under such license agreements, including, without limitation, our financial obligations to the licensors.
If we violate or fail to perform any term or covenant of the license agreements, the licensors may terminate the license agreements
upon satisfaction of applicable notice requirements and expiration of any applicable cure periods. Additionally, any termination
of license agreements, whether by us or the licensors will not relieve us of our obligation to pay any license fees owing at the
time of such termination. If we fail to retain our rights under these license agreements, we will not be able to commercialize
certain products subject to patent or patent application, and our business, results of operations, financial condition and prospects
would be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercial success of our products
depends, in large part, on our ability to use patents licensed to us by third parties in order to exclude others from competing
with our products. The patent position of emerging pharmaceutical companies like us can be highly uncertain and involve complex
legal and technical issues. Until our licensed patents are interpreted by a court, either because we have sought to enforce them
against a competitor or because a competitor has preemptively challenged them, we will not know the breadth of protection that
they will afford us. Our patents may not contain claims sufficiently broad to prevent others from practicing our technologies or
marketing competing products. Third parties may intentionally attempt to design around our patents or design around our patents
so as to compete with us without infringing our patents. Moreover, the issuance of a patent is not conclusive as to its validity
or enforceability, and so our patents may be invalidated or rendered unenforceable if challenged by others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to compete may decline
if we do not adequately protect our proprietary rights or if we are barred by the patent rights of others.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success depends on obtaining
and maintaining proprietary rights to our products and product candidates as well as successfully defending these rights against
third-party challenges. We will only be able to protect our products and product candidates from unauthorized use by third parties
to the extent that valid and enforceable patents, or effectively protected trade secrets, cover them. Our ability to obtain patent
protection for our products and product candidates is uncertain due to a number of factors, including that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not have been the first to make the inventions covered by pending patent applications or
issued patents;</TD></TR>                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not have been the first to file patent applications for our products and product candidates;</TD></TR>                                                                                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may independently develop identical, similar or alternative products, compositions or devices
and uses thereof;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our disclosures in patent applications may not be sufficient to meet the statutory requirements
for patentability;</TD></TR>                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any or all of our pending patent applications may not result in issued patents;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we may not seek or obtain patent protection in countries that may eventually provide us a significant
business opportunity;</TD></TR>                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any patents issued to us may not provide a basis for commercially viable products, may not provide
any competitive advantages, or may be successfully challenged by third parties;</TD></TR>                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our compositions, devices and methods may not be patentable;</TD></TR>                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may design around our patent claims to produce competitive products which fall outside of
the scope of our patents; or</TD></TR>                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">others may identify prior art or other bases which could invalidate our patents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if we have or obtain patents covering
our products and product candidates, we may still be barred from making, using and selling them because of the patent rights of
others. Others may have filed, and in the future may file, patent applications covering products that are similar or identical
to ours. There are many issued U.S. and foreign patents relating to chemical compounds, therapeutic products, diagnostic devices,
personal care products and devices and some of these relate to our products and product candidates. These could materially affect
our ability to sell our products and develop our product candidates. Because patent applications can take many years to issue,
there may be currently pending applications unknown to us that may later result in issued patents that our products and product
candidates may infringe. These patent applications may have priority over patent applications filed by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Obtaining and maintaining a patent portfolio
entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees,
various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications,
as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may
or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure
to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of
a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose
to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position
could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal actions to enforce our patent rights
can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful
and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to
pursue litigation or other actions against those that have infringed on our patents, or used them without authorization, due to
the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual
property rights successfully, our competitive position could suffer, which could harm our business, prospects, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pharmaceutical and medical device
patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could
negatively impact our patent position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical
and medical device companies can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth
of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine and are often
affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The
standards of the U.S. Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently,
the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented.
U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to re-examination
proceedings, post-grant review and/or inter partes review in the USPTO. Foreign patents may be subject to opposition or comparable
proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent
application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such
interference, re-examination, post-grant review, inter partes review and opposition proceedings may be costly. Accordingly, rights
under any issued patents may not provide us with sufficient protection against competitive products or processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changes in or different interpretations
of patent laws in the U.S. and foreign countries may permit others to use our discoveries or to develop and commercialize our technology
and products and product candidates without providing any compensation to us or may limit the number of patents or claims we can
obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries
may lack adequate rules and procedures for defending our intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to obtain and maintain patent
protection and trade secret protection of our products and product candidates, we could lose our competitive advantage and competition
we face would increase, reducing any potential revenues and adversely affecting our ability to attain or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Developments in patent law could
have a negative impact on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the U.S. Supreme Court,
other federal courts, the U.S. Congress or the USPTO may change the standards of patentability and any such changes could have
a negative impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Leahy-Smith America Invents
Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law.
These changes include a transition from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-to-file&rdquo; system, changes
the way issued patents are challenged, and changes the way patent applications are disputed during the examination process. These
changes may favor larger and more established companies that have greater resources to devote to patent application filing and
prosecution. The USPTO has developed regulations and procedures to govern the full implementation of the America Invents Act, and
many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions,
became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability
to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents
Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries
and our ability to enforce or defend any patents that may issue from our patent applications, all of which could have a material
adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to patent protection, because
we operate in the highly technical field of discovery and development of therapies and medical devices, we rely in part on trade
secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect.
We expect to enter into confidentiality and intellectual property assignment agreements with our employees, consultants, outside
scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the
other party keep confidential and not disclose to third parties all confidential information developed by the party or made known
to the party by us during the course of the party&rsquo;s relationship with us. These agreements also generally provide that inventions
conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may
not be honored and may not effectively assign intellectual property rights to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to contractual measures, we
try to protect the confidential nature of our proprietary information using physical and technological security measures. Such
measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized
access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant
from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not
provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the
U.S. may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could
prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed
or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to enforce our
intellectual property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The laws of some foreign countries do not
protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems
in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially
those relating to pharmaceuticals and medical devices. This could make it difficult for us to stop the infringement of some of
our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many foreign countries
have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit
the enforceability of patents against third parties, including government agencies or government contractors. In these countries,
patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is
an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.
Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes
in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain adequate protection
for our technology and the enforcement of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may assert ownership
or commercial rights to inventions we develop.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties may in the future make claims
challenging the inventorship or ownership of our intellectual property. We have or expect to have written agreements with collaborators
that provide for the ownership of intellectual property arising from our collaborations. These agreements provide that we must
negotiate certain commercial rights with collaborators with respect to joint inventions or inventions made by our collaborators
that arise from the results of the collaboration. In some instances, there may not be adequate written provisions to address clearly
the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient
ownership and commercial rights to the inventions that result from our use of a third-party collaborator&rsquo;s materials where
required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator&rsquo;s
samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims
by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property
to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership
disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial
value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be
precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome
could have an adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may assert that our
employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We might employ individuals who were previously
employed at universities or other biopharmaceutical or medical device companies, including our competitors or potential competitors.
Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their
work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or
otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer
or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A dispute concerning the infringement
or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable
outcome could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is significant litigation in the
pharmaceutical and medical device industries regarding patent and other intellectual property rights. While we are not currently
subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed
to future litigation by third parties based on claims that our products or product candidates infringe the intellectual property
rights of others. If our development and commercialization activities are found to infringe any such patents, we may have to pay
significant damages or seek licenses to such patents. A patentee could prevent us from using the patented drugs, compositions or
devices. We may need to resort to litigation to enforce a patent issued to us, to protect our trade secrets, or to determine the
scope and validity of third-party proprietary rights. From time to time, we may hire scientific personnel or consultants formerly
employed by other companies involved in one or more areas similar to the activities conducted by us. Either we or these individuals
may be subject to allegations of trade secret misappropriation or other similar claims as a result of prior affiliations. If we
become involved in litigation, it could consume a substantial portion of our managerial and financial resources, regardless of
whether we win or lose. We may not be able to afford the costs of litigation. Any adverse ruling or perception of an adverse ruling
in defending ourselves against these claims could have a material adverse impact on our cash position and stock price. Any legal
action against us or our collaborators could lead to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">payment of damages, potentially treble damages, if we are found to have willfully infringed a party&rsquo;s
patent rights;</TD></TR>                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">injunctive or other equitable relief that may effectively block our ability to further develop,
commercialize, and sell products; or</TD></TR>                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we or our collaborators having to enter into license arrangements that may not be available on
commercially acceptable terms, if at all, all of which could have a material adverse impact on our cash position and business,
prospects and financial condition. As a result, we could be prevented from commercializing our products and product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Our Organization, Structure
and Operation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We intend to acquire, through asset
purchases or in-licensing, businesses or products, or form strategic alliances, in the future, and we may not realize the intended
benefits of such acquisitions or alliances.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to acquire, through asset purchases
or in-licensing, additional businesses or products, form strategic alliances and/or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses or assets with promising markets or technologies,
we may not be able to realize the benefit of acquiring such businesses or assets if we are unable to successfully integrate them
with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing
any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits
or enhancing our business. We cannot assure you that, following any such acquisition or alliance, we will achieve the expected
synergies to justify the transaction. These risks apply to our acquisition of Natesto in April 2016 and ZolpiMist in June 2018.
As an example, we acquired Primsol in October 2015, but sold it in March 2017. Depending on the success or lack thereof of any
of our existing or future acquired products and product candidates, we might seek to out-license, sell or otherwise dispose of
any of those products or product candidates, which could adversely impact our operations if the dispositions triggers a loss, accounting
charge or other negative impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>In fiscal 2018, the great majority
of our gross revenue and gross accounts receivable were due to three significant customers, the loss of which could materially
and adversely affect our results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following
customers contributed greater than&nbsp;10%&nbsp;of the Company's gross revenue during the year ended June 30, 2018 and 2017, respectively.
As of June 30, 2018, three customers accounted for 86% of gross revenue. The revenue from these customers as a percentage of gross
revenue was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Customer A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">32</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Customer B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The loss of one or more of the Company's
significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are also subject
to credit risk from our accounts receivable related to our product sales. As of June 30, 2018, three customers accounted for 81%
of gross accounts receivable. As of June 30, 2017, three customers accounted for 60% of gross accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Customer C</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">35</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Customer A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Customer B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to develop and expand
our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2018, we had 52 full-time
employees, and in connection with being a public company, we expect to continue to increase our number of employees and the scope
of our operations. To manage our anticipated development and expansion, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also,
our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial
amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage
the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure,
give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees.
The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects,
such as the planned expanded commercialization of our approved products and the development of our product candidates. If our management
is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability
to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial
performance and our ability to expand the market for our approved products and develop our product candidates, if approved, and
compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on key personnel and attracting
qualified management personnel and our business could be harmed if we lose personnel and cannot attract new personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success depends to a significant degree
upon the technical and management skills of our directors, officers and key personnel. Any of our directors could resign from our
board at any time and for any reason. Although our executive officers Joshua Disbrow, Jarrett Disbrow and David Green have employment
agreements, the existence of an employment agreement does not guarantee the retention of the executive officer for any period of
time, and each agreement obligates us to pay the officer lump sum severance of two years of salary if we terminate him without
cause, as defined in the agreement, which could hurt our liquidity. The loss of the services of any of these individuals would
likely have a material adverse effect on us. Our success also will depend upon our ability to attract and retain additional qualified
management, marketing, technical, and sales executives and personnel. We do not maintain key person life insurance for any of our
officers or key personnel. The loss of any of our directors or key executives, or the failure to attract, integrate, motivate,
and retain additional key personnel could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We compete for such personnel, including
directors, against numerous companies, including larger, more established companies with significantly greater financial resources
than we possess. There can be no assurance that we will be successful in attracting or retaining such personnel, and the failure
to do so could have a material adverse effect on our business, prospects, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product liability and other lawsuits
could divert our resources, result in substantial liabilities and reduce the commercial potential of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk that we may be sued on product
liability claims is inherent in the development and commercialization of pharmaceutical, medical device and personal care products
and devices. Side effects of, or manufacturing defects in, products that we develop and commercialized could result in the deterioration
of a patient&rsquo;s condition, injury or even death. Once a product is approved for sale and commercialized, the likelihood of
product liability lawsuits increases. Claims may be brought by individuals seeking relief for themselves or by individuals or groups
seeking to represent a class. These lawsuits may divert our management from pursuing our business strategy and may be costly to
defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and may be forced to
limit or forgo further commercialization of the affected products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be subject to legal or administrative
proceedings and litigation other than product liability lawsuits which may be costly to defend and could materially harm our business,
financial condition and operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we maintain general liability,
clinical trial liability and product liability insurance, this insurance may not fully cover potential liabilities. In addition,
inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product
or other legal or administrative liability claims could prevent or inhibit the commercial production and sale of any of our products
and product candidates that receive regulatory approval, which could adversely affect our business. Product liability claims could
also harm our reputation, which may adversely affect our collaborators&rsquo; ability to commercialize our products successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our internal computer systems, or
those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption
of our product development programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Despite the implementation of security
measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from
computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we
do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to
occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our product candidates which
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or
applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information,
we could incur liabilities and the further development of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to use our net operating
loss carryforwards and certain other tax attributes may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2018, we had federal net
operating loss carryforwards of approximately $59.3 million. The available net operating losses, if not utilized to offset taxable
income in future periods, will begin to expire in 2031 and will completely expire in 2037. Under the Internal Revenue Code of 1986,
as amended (the &ldquo;Code&rdquo;) and the regulations promulgated thereunder, including, without limitation, the consolidated
income tax return regulations, various corporate changes could limit our ability to use our net operating loss carryforwards and
other tax attributes (such as research tax credits) to offset our income. Because Ampio&rsquo;s equity ownership interest in our
company fell to below 80% in January 2016, we were deconsolidated from Ampio&rsquo;s consolidated federal income tax group. As
a result, certain of our net operating loss carryforwards may not be available to us and we may not be able to use them to offset
our U.S. federal taxable income. As a consequence of the deconsolidation, it is possible that certain other tax attributes and
benefits resulting from U.S. federal income tax consolidation may no longer be available to us. Our company and Ampio do not have
a tax sharing agreement that could mitigate the loss of net operating losses and other tax attributes resulting from the deconsolidation
or our incurrence of liability for the taxes of other members of the consolidated group by reason of the joint and several liability
of group members. In addition to the deconsolidation risk, an &ldquo;ownership change&rdquo; (generally a 50% change (by value)
in equity ownership over a three-year period) under Section 382 of the Code could limit our ability to offset, post-change, our
U.S. federal taxable income. Section 382 of the Code imposes an annual limitation on the amount of post-ownership change taxable
income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses.
We believe that the August 2017 financing created over a 50% change in our equity ownership so our current tax loss carryforward
will be limited in the future. Either the deconsolidation or the ownership change scenario could result in increased future tax
liability to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Several stockholders potentially
own a significant percentage of our stock and could be able to exert significant control over matters subject to stockholder approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our August 2017 and March 2018 offerings,
some entities who invested in our common and preferred stock and warrant financing owned common and/or preferred stock and warrants
that potentially would enable them to beneficially own in excess of 4.99% or 9.99% of our common stock. The preferred stock and
warrants held by these investors contain a provision that prohibits the conversion or exercise of the preferred stock or warrants
should the holder beneficially own in excess of 4.99% or 9.99%, as elected by the investor, after giving effect to such conversion
or exercise. However, the significant ownership potential of these investors, and the significant investment that they have made
in our company, could give these stockholders the ability to influence us through their ownership positions, even if they are prohibited
from converting or exercising their preferred stock or warrants to acquire more than 4.99% or 9.99% of our common stock at any
time. Further, this significant ownership potential may prevent or discourage unsolicited acquisition proposals or offers for our
common stock that you may feel are in your best interest as one of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Restrictions under our August 2017
Securities Purchase Agreement may limit our ability to raise funds and operate our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The August 2017 Securities Purchase Agreement
contains the covenant described below that may restrict our ability to finance future operations or capital needs or to engage
in other business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until such time as
no investor in the August 2017 offering holds any of the warrants, we are prohibited from effecting or entering into an agreement
to affect any issuance by us of our common stock or common stock equivalents involving a Variable Rate Transaction, as defined
in the Securities Purchase Agreement. &ldquo;Variable Rate Transaction&rdquo; means a transaction in which we (i) issue any debt
or equity securities that are convertible into common stock either (A) at a conversion price, exercise price or exchange rate or
other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of our common stock at any
time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is
subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of
specified or contingent events directly or indirectly related to our business or the market for our common stock or (ii) enter
into any transaction under, any agreement, including, but not limited to, an equity line of credit, an &ldquo;at-the-market&rdquo;
offering or similar agreement, whereby we may issue securities at a future determined price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The restrictions and covenants in the August
2017 Securities Purchase Agreement, as well as any future financing agreements that we may enter into, may restrict our ability
to finance our operations, engage in business activities or expand or fully pursue our business strategies. Our ability to comply
with these covenants may be affected by events beyond our control and we may not be able to meet those covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to Securities Markets and
Investment in our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to meet the continued
listing requirements of the NASDAQ Capital Market could result in a delisting of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to satisfy the continued listing
requirements of the NASDAQ Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement,
the exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our
common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting,
we anticipate that we would take actions to restore our compliance with applicable exchange requirements, such as stabilize our
market price, improve the liquidity of our common stock, prevent our common stock from dropping below such exchange&rsquo;s minimum
bid price requirement, or prevent future non-compliance with such exchange&rsquo;s listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2018, we received a letter
from NASDAQ indicating that the Company has failed to comply with the minimum bid price requirement of NASDAQ Listing Rule 5550(a)(2).
NASDAQ Listing Rule 5550(a)(2) requires that companies listed on the NASDAQ Capital Market maintain a minimum closing bid price
of at least $1.00 per share. However, on August 10, 2018, we effected a 1-for-20 reverse stock split, which has brought us back
into compliance with NASDAQ Listing Rule 5550(a)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales and issuances of our
equity securities or rights to purchase our equity securities, including pursuant to equity incentive plans, would result in additional
dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent we raise additional capital
by issuing equity securities, our stockholders may experience substantial dilution. We may, as we have in the past, sell common
stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from
time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors
may be further diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new
investors could gain rights superior to existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our 2015 Stock Plan, our Board
of Directors is currently authorized to award up to a total of 3.0 million shares of common stock or options to purchase shares
of common stock to our officers, directors, employees and non-employee consultants. As of June 30, 2018, options to purchase 1,798
shares of common stock issued under our 2015 Stock Plan at a weighted average exercise price of $325.97 per share were outstanding.
In addition, at June 30, 2018, there were outstanding warrants to purchase an aggregate of 1,882,661 shares of our common stock
at a weighted average exercise price of $25.94. Stockholders will experience dilution in the event that additional shares of common
stock are issued under our 2015 Stock Plan, or options issued under our 2015 Stock Plan are exercised, or any warrants are exercised
for shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our share price is volatile and may
be influenced by numerous factors, some of which are beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading price of our common stock is
likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond
our control. In addition to the factors discussed in this &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus and
the documents incorporated by reference herein, these factors include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the products or product candidates we acquire for commercialization;</TD></TR>                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the products and product candidates we seek to pursue, and our ability to obtain rights to develop,
commercialize and market those product candidates;</TD></TR>                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an
existing clinical trial;</TD></TR>                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated adverse results or delays in our clinical trials;</TD></TR>                                                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our failure to expand the market for our currently approved products or commercialize our product
candidates, if approved;</TD></TR>                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">unanticipated serious safety concerns related to the use of any of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">overall performance of the equity markets and other factors that may be unrelated to our operating
performance or the operating performance of our competitors, including changes in market valuations of similar companies;</TD></TR>                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">conditions or trends in the healthcare, biotechnology and pharmaceutical industries;</TD></TR>                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">introduction of new products offered by us or our competitors;</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments
by us or our competitors;</TD></TR>                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain an adequate rate of growth and manage such growth;</TD></TR>                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">issuances of debt or equity securities;</TD></TR>                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">sales of our common stock by us or our stockholders in the future, or the perception that such
sales could occur;</TD></TR>                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">trading volume of our common stock;</TD></TR>                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</TD></TR>                                                                                                                                                                                                                      <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">general political and economic conditions;</TD></TR>                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">effects of natural or man-made catastrophic events;</TD></TR>                                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">other events or factors, many of which are beyond our control;</TD></TR>                                                                                                                                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">adverse regulatory decisions;</TD></TR>                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">additions or departures of key scientific or management personnel;</TD></TR>                                                                                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">changes in laws or regulations applicable to our product candidates, including without limitation
clinical trial requirements for approvals;</TD></TR>                                                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">disputes or other developments relating to patents and other proprietary rights and our ability
to obtain patent protection for our product candidates;</TD></TR>                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our dependence on third parties, including CROs and scientific and medical advisors;</TD></TR>                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to meet or exceed any financial guidance or expectations regarding development milestones
that we may provide to the public;</TD></TR>                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">actual or anticipated variations in quarterly operating results; and</TD></TR>                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">failure to meet or exceed the estimates and projections of the investment community.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the stock market in general,
and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad
market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.
The realization of any of the above risks or any of a broad range of other risks, including those described in these &ldquo;Risk
Factors,&rdquo; could have a dramatic and material adverse impact on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities or industry analysts
do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume
could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any trading market for our common stock
that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our
business. Securities and industry analysts do not currently, and may never, publish research on us or our business. If no securities
or industry analysts commence coverage of our company, the trading price for our stock could be negatively affected. If securities
or industry analysts initiate coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable
research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company
or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and any trading
volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We effected a reverse stock split
at a ratio of 1-for-20 on August 10, 2018, which may not achieve one or more of our objectives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have effected four reverse stock splits
since June 8, 2015, each of which has impacted the trading liquidity of the shares of our common stock. There can be no assurance
that the market price per share of our common stock after a reverse stock split will remain unchanged or increase in proportion
to the reduction in the number of shares of our common stock outstanding before the reverse stock split. The market price of our
shares may fluctuate and potentially decline after a reverse stock split. Accordingly, the total market capitalization of our common
stock after a reverse stock split may be lower than the total market capitalization before the reverse stock split. Moreover, the
market price of our common stock following a reverse stock split may not exceed or remain higher than the market price prior to
the reverse stock split.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, there can be no assurance
that a reverse stock split will result in a per-share market price that will attract institutional investors or investment funds
or that such share price will satisfy investing guidelines of institutional investors or investment funds. As a result, the trading
liquidity of our common stock may not necessarily improve. Further, if a reverse stock split is effected and the market price of
our common stock declines, the percentage decline may be greater than would occur in the absence of a reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales and issuances of our
common stock or rights to purchase common stock, including pursuant to our equity incentive plan or otherwise, could result in
dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We could need significant additional capital
in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity
securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible
securities or other equity securities in more than one transaction, investors in a prior transaction may be materially diluted
by subsequent sales. Additionally, any such sales may result in material dilution to our existing stockholders, and new investors
could gain rights, preferences and privileges senior to those of holders of our common stock. Further, any future sales of our
common stock by us or resales of our common stock by our existing stockholders could cause the market price of our common stock
to decline. Any future grants of options, warrants or other securities exercisable or convertible into our common stock, or the
exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Some provisions of our charter documents
and applicable Delaware law may discourage an acquisition of us by others, even if the acquisition may be beneficial to some of
our stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provisions in our Certificate of Incorporation
and Amended and Restated Bylaws, as well as certain provisions of Delaware law, could make it more difficult for a third-party
to acquire us, even if doing so may benefit some of our stockholders. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the authorization of 50.0 million shares of &ldquo;blank check&rdquo; preferred stock, the rights,
preferences and privileges of which may be established and shares of which may be issued by our Board of Directors at its discretion
from time to time and without stockholder approval;</TD></TR>                                                             <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">limiting the removal of directors by the stockholders;</TD></TR>                                                                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">allowing for the creation of a staggered board of directors;</TD></TR>                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">eliminating the ability of stockholders to call a special meeting of stockholders; and</TD></TR>                                                                                                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">establishing advance notice requirements for nominations for election to the board of directors
or for proposing matters that can be acted upon at stockholder meetings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These provisions may frustrate or prevent
any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace
members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject
to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of
a broad range of business combinations with an interested stockholder for a period of three years following the date on which the
stockholder became an interested stockholder, unless such transactions are approved by the board of directors. This provision could
have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whether or not it is desired
by or beneficial to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any provision of our Certificate of Incorporation
or Bylaws or of Delaware law that is applicable to us that has the effect of delaying or deterring a change in control could limit
the opportunity for our stockholders to receive a premium for their shares of our common stock in the event that a potentially
beneficial acquisition is discouraged, and could also affect the price that some investors are willing to pay for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The elimination of personal liability
against our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers
and employees may result in substantial expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation and our
Bylaws eliminate the personal liability of our directors and officers to us and our stockholders for damages for breach of fiduciary
duty as a director or officer to the extent permissible under Delaware law. Further, our Certificate of Incorporation and our Bylaws
provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by the Delaware law
and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action, suit or proceeding
prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to cover the cost
of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and
resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former directors or
officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay cash dividends
on our capital stock in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid any dividends
on our common stock and do not anticipate paying any dividends in the foreseeable future. Any future payment of cash dividends
in the future would depend on our financial condition, contractual restrictions, solvency tests imposed by applicable corporate
laws, results of operations, anticipated cash requirements and other factors and will be at the discretion of our Board of Directors.
Our stockholders should not expect that we will ever pay cash or other dividends on our outstanding capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is a limited trading market
for our common stock, which could make it difficult to liquidate an investment in our common stock, in a timely manner.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is currently traded on
the NASDAQ Capital Market. Because there is a limited public market for our common stock, investors may not be able to liquidate
their investment whenever desired. We cannot assure that there will be an active trading market for our common stock and the lack
of an active public trading market could mean that investors may be exposed to increased risk. In addition, if we failed to meet
the criteria set forth in SEC regulations, various requirements would be imposed by law on broker-dealers who sell our securities
to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from
recommending or selling our common stock, which may further affect its liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The terms of the Series C Preferred
Stock and the warrants could impede our ability to enter into certain transactions or obtain additional financing.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series C Preferred Stock
and the warrants require us, upon the consummation of any &ldquo;fundamental transaction&rdquo; (as defined in the securities),
to, among other obligations, cause any successor entity resulting from the fundamental transaction to assume all of our obligations
under the Series C Preferred Stock and the warrants and the associated transaction documents. In addition, holders of Series C
Preferred Stock and warrants are entitled to participate in any fundamental transaction on an as-converted or as-exercised basis,
which could result in the holders of our common stock receiving a lesser portion of the consideration from a fundamental transaction.
The terms of the Series C Preferred Stock and the warrants could also impede our ability to enter into certain transactions or
obtain additional financing in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and
substantial dilution as a result of this offering and may experience additional dilution in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You will incur immediate and substantial
dilution as a result of this offering. After giving effect to the sale by us of shares offered in this offering at an assumed public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable
by us, investors in this offering can expect an immediate dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. See &ldquo;Dilution&rdquo; below
for a more detailed discussion of the dilution you will incur if you purchase our common stock in the offering. In addition, the
conversion of shares of Series C Preferred Stock and exercise of the warrants will result in the issuance of additional shares
of common stock that will result in significant dilution to holders of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Management will have broad discretion
as to the use of the proceeds from this offering and may not use the proceeds effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion
in the application of the net proceeds from this offering and could spend the proceeds in ways that may not improve our results
of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse
effect on our business and cause the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The Series C Preferred Stock and
warrants will not be listed on any securities exchange and as such there will not be a public market for such securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for the Series C Preferred Stock or warrants, and we do not expect a market to develop. In addition, we do not intend to
apply for listing of the Series C Preferred Stock or warrants on any securities exchange or trading system. Without an active market,
the liquidity of the Series C Preferred Stock and warrants will be limited, and investors may be unable to liquidate their investments
in the Series C Preferred Stock and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The offering price will be set by
our Board of Directors and does not necessarily indicate the actual or market value of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors will approve the
offering price and other terms of this offering after considering, among other things: the number of shares authorized in our certificate
of incorporation; the current market price of our common stock; trading prices of our common stock over time; the volatility of
our common stock; our current financial condition and the prospects for our future cash flows; the availability of and likely cost
of capital of other potential sources of capital; and market and economic conditions at the time of the offering. The offering
price is not intended to bear any relationship to the book value of our assets or our past operations, cash flows, losses, financial
condition, net worth or any other established criteria used to value securities. The offering price may not be indicative of the
fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants may not have any value.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants will be exercisable for five
years from the closing date at an initial exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
In the event that the price of a share of our common stock does not exceed the exercise price of the warrants during the period
when the warrants are exercisable, the warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants are subject to an issuer
call. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, after the closing date, (i)&nbsp;the
volume weighted average price for each of 30 consecutive trading days (the &ldquo;Measurement Period&rdquo;), which Measurement
Period commences on the closing date, exceeds 250% of the exercise price (subject to adjustment for forward and reverse stock splits,
recapitalizations, stock dividends and the like after the initial exercise date), (ii) the average daily volume for such Measurement
Period exceeds $600,000 per trading day and, (iii)&nbsp;the warrant holder is not in possession of any material non-public information
which was provided by the Company, then the Company may, within one trading day of the end of such Measurement Period, call for
cancellation of all or any portion of the warrants for which an exercise notice has not yet been delivered for consideration equal
to $0.001 per warrant share. The Company&rsquo;s right to call the warrants shall be exercised ratably among the holders based
on the then outstanding warrants. You may be unable to reinvest your proceeds from the call in an investment with a return that
is as high as the return on the warrants would have been if they had not been called.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A warrant does not entitle the holder
to any rights as common stockholders until the holder exercises the warrant for shares of our common stock. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until you acquire shares of our common
stock upon exercise of your warrants, the warrants will not provide you any rights as a common stockholder. Upon exercise of your
warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs
on or after the exercise date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus includes forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy
and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally
written in the future tense and/or are preceded by words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; or similar words, or the negatives of such terms or other variations
on such terms or comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are subject
to a number of risks, uncertainties and assumptions, including without limitation the risks described in &ldquo;Risk Factors&rdquo;
in this prospectus and the documents incorporated by reference herein. These risks are not exhaustive. Moreover, we operate in
a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management
to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You
should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those projected
in the forward-looking statements. We assume no obligation to update or supplement forward-looking statements, except as may be
required under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds from
this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;million, based on an assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Class&nbsp;A Unit and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Class&nbsp;B
Unit, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters
exercise their over-allotment option in full, we estimate that our net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;million, after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us. We will not receive any additional proceeds
from any future conversions of the Series&nbsp;C Preferred Stock. We will only receive additional proceeds from the exercise of
the warrants issuable in connection with this offering if the warrants are exercised and the holders of such warrants pay the exercise
price in cash upon such exercise and do not utilize the cashless exercise provision of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds from
this offering for general corporate purposes, including working capital to support ongoing and new commercial activities primarily
related to Natesto and ZolpiMist and to complete clinical studies around our MiOXSYS System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This expected use of the net proceeds from
this offering represents our intentions based upon our current plans and business conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_006"></A>MARKET FOR COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has been listed on the
NASDAQ Capital Market under the symbol &ldquo;AYTU&rdquo; since October 20, 2017. Prior to October 20, 2017, our common stock was
quoted on the OTCQX and prior to that, on the OTCQB. The following table sets forth the range of high and low bid prices for our
common stock on the OTCQX or OTCQB, or high and low sales prices on the NASDAQ Capital Market, as applicable, for the periods shown.
The quotations for the OTCQX or OTCQB represent inter-dealer prices without retail markup, markdown or commission, and may not
necessarily represent actual transactions. All share prices give effect to our 1-for-20 reverse stock splits completed in each
of August 2017 and August 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Fiscal Year ended June 30, 2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">First Quarter (ended September 30, 2016)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,000.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,204.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Second Quarter (ended December 31, 2016)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,556.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">408.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Third Quarter (ended March 31, 2017)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">504.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">296.44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Fourth Quarter (ended June 30, 2017)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">364.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">204.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Fiscal Year ended June 30, 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">First Quarter (ended September 30, 2017)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">240.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">66.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Second Quarter (ended December 31, 2017)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">136.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">41.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Third Quarter (ended March 31, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">85.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Fourth Quarter (ended June 30, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Fiscal Year ended June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">First Quarter (through September 6, 2018)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.70</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of August 31, 2018, there were 496 holders of record of our
common stock. <B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not paid any cash dividends on
our common stock and our Board of Directors presently intends to continue a policy of retaining earnings, if any, for use in our
operations. The declaration and payment of dividends in the future, of which there can be no assurance, will be determined by the
Board of Directors in light of conditions then existing, including earnings, financial condition, capital requirements and other
factors. Delaware law prohibits us from declaring dividends where, if after giving effect to the distribution of the dividend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">we would not be able to pay our debts as they become due in the usual course of business; or</TD></TR>                                                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">our total assets would be less than the sum of our total liabilities plus the amount that would
be needed to satisfy the rights of stockholders who have preferential rights superior to those receiving the distribution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth above, there are no
restrictions that currently materially limit our ability to pay dividends or which we reasonably believe are likely to limit materially
the future payment of dividends on common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors has the right to
authorize the issuance of preferred stock, without further stockholder approval, the holders of which may have preferences over
the holders of our common stock as to payment of dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_008"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you purchase shares in this offering, your interest will be diluted to the extent of the difference between the public offering
price per Class A Unit and the net tangible book value per share of our common stock after this offering. Our net tangible book
value as of June 30, 2018 was $2.1 million, or $1.15 per share of common stock (based upon 1,794,762 outstanding shares of common
stock). &ldquo;Net tangible book value&rdquo; is total assets minus the sum of liabilities and intangible assets. &ldquo;Net tangible
book value per share&rdquo; is net tangible book value divided by the total number of shares of common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
giving effect to the sale by us in this offering of  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A Units at
an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Class A Unit (the
closing price of our common stock as quoted on the NASDAQ Capital
Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018)
and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class B Units at an assumed public offering price of
$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Class B Unit, and assuming all shares of Series C Preferred
Stock included in the Class B Units were converted to common stock, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses that we will pay, our net tangible book value as of June 30, 2018
would have been approximately $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock.
This amount represents an immediate increase in net tangible book value of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and an
immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to purchasers in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following
table illustrates the dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Assumed public offering price per Class A Unit</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in net tangible book value per share attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pro forma net tangible book value per share after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dilution per share to new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
dilution information set forth in the table above is illustrative only and will be adjusted based on the actual public offering
price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
above table is based on 1,794,762 shares of common stock outstanding as of June 30, 2018, and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of options to purchase an aggregate of 1,798 shares of common stock with
                                         a weighted average exercise price of $325.97, issued and outstanding under our 2015 Stock
                                         Plan and outstanding and exercisable on June 30, 2018;</FONT></TD></TR>                                                                                                                <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of warrants to purchase 1,882,661 shares of common stock with a weighted
                                         average exercise price of $25.94 per share outstanding on June 30, 2018; and</FONT></TD></TR>                                                                                                                                      <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise by the underwriters of their over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the underwriters exercise in full their over-allotment option, our net tangible book value per share after giving effect to this
offering would be approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which amount represents an immediate increase in net tangible book
value of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and a dilution to new investors of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we issue any additional shares in connection with outstanding options or warrants, there will be additional dilution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_009"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2018 on:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         actual basis; and</FONT></TD></TR>                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                         a pro forma basis to give effect to the sale by us in this offering of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A Units,
                                         at the assumed public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Class A Unit and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class B Units, at the
                                         assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
                                         Class B Unit, assuming conversion of all shares of Series C Preferred Stock included
                                         in the Class B Units, after deducting underwriting discounts and commissions and estimated
                                         offering expenses payable by us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
pro forma information set forth in the table below is illustrative only and will be adjusted based on the actual public offering
price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should read this table in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations,&rdquo; our audited financial statements for the fiscal years ended June 30, 2018 and 2017, and the related notes
thereto, included by reference in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of June 30, 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Cash, cash equivalents and restricted cash</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">7,112,527</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Long-term contingent consideration</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,146,829</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt; text-indent: -10pt">Preferred Stock, par value $0.0001; 50,000,000 shares authorized; 0 shares of Series A issued and outstanding; 0 shares of Series B issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt; text-indent: -10pt">Common Stock, par value $0.0001; 100,000,000 shares authorized; 1,794,762 shares issued and outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding pro forma</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,681,918</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(79,257,592</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,424,505</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
number of shares to be outstanding immediately after giving effect to this offering as shown above is based on 1,794,762 shares
outstanding as of June 30, 2018 and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of options to purchase an aggregate of 1,798 shares of common stock with
                                         a weighted average exercise price of $325.97, issued under our 2015 Stock Plan and outstanding
                                         on June 30, 2018;</FONT></TD></TR>                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise of warrants to purchase 1,882,661 shares of common stock with a weighted
                                         average exercise price of $25.94 per share outstanding on June 30, 2018; and</FONT></TD></TR>                                                                                                                                      <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">assumes
                                         no exercise by the underwriters of their over-allotment option.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_010"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are authorized to issue up to 100,000,000 shares of common stock, $0.0001 par value per share, and 50,000,000 shares of preferred
stock, $0.0001 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of August 31, 2018, a total of 1,801,411 shares of our common stock were issued and outstanding, no shares of our Series A Preferred
Stock were issued and outstanding, and no shares of our Series B Preferred Stock were issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
holders of common stock are entitled to one vote per share. Our Certificate of Incorporation does not expressly prohibit cumulative
voting. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by the Board
of Directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are
entitled to share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive,
subscription, redemption or conversion rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights
of the holders of any series of preferred stock, which may be designated solely by action of the Board of Directors and issued
in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Securities
to be Issued in this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Units</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are offering Class&nbsp;A Units, with each Class&nbsp;A Unit consisting of one share of common stock and a warrant to purchase
one half of one share of our common stock at an exercise price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
together with the shares of common stock underlying such warrants, at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Class&nbsp;A Unit. The Class&nbsp;A Units will not be certificated and the shares of common stock and warrants part of such
units are immediately separable and will be issued separately in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are also offering to those purchasers whose purchase of Class&nbsp;A Units in this offering would result in the purchaser, together
with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%)
of our outstanding common stock following the consummation of this offering, the opportunity to purchase, in lieu of the number
of Class&nbsp;A Units that would result in ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%), Class&nbsp;B
Units. Each Class&nbsp;B Unit will consist of one share of Series C Preferred Stock, par value $0.0001 per share, convertible
into one share of common stock and a warrant to purchase one half of one share of our common stock at an exercise price per share
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
together with the shares of common stock underlying such shares of Series C Preferred Stock and warrants, at an assumed public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Class&nbsp;B Unit. The Class&nbsp;B Units will not be certificated and the shares of Series C Preferred Stock and the warrants
part of such units are immediately separable and will be issued separately in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Series
C Preferred Stock</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General</I>.
In connection with this offering, our board of directors will designate shares of our preferred stock as Series C Preferred Stock.
The preferences and rights of the Series C Preferred Stock will be as set forth in a Certificate of Designation (the &ldquo;<U>Series
C Certificate of Designation</U>&rdquo;) filed as an exhibit to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Conversion</I>.
Each share of Series C Preferred Stock will be convertible at any time at the holder&rsquo;s option into one share of common stock,
which conversion ratio will be subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.
Notwithstanding the foregoing, the Series C Certificate of Designation will further provide that we shall not effect any conversion
of the Series C Preferred Stock, with certain exceptions, to the extent that, after giving effect to an attempted conversion,
the holder of Series C Preferred Stock (together with such holder&rsquo;s affiliates, and any persons acting as a group together
with such holder or any of such holder&rsquo;s affiliates) would beneficially own a number of shares of Common Stock in excess
of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of our common stock then outstanding
after giving effect to such exercise (the &ldquo;<U>Series C Preferred Stock Beneficial Ownership Limitation</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Liquidation
Preference</I>. In the event of a liquidation, the holders of Series C Preferred Stock will be entitled to participate on an as-converted-to-common-stock
basis with holders of the common stock in any distribution of assets of the Company to the holders of the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Voting
Rights</I>. With certain exceptions, as described in the Series C Certificate of Designation, the Series C Preferred Stock will
have no voting rights. However, as long as any shares of Series C Preferred Stock remain outstanding, the Series C Certificate
of Designation will provide that we shall not, without the affirmative vote of holders of a majority of the then-outstanding shares
of Series C Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series C Preferred Stock
or alter or amend the Series C Certificate of Designation, (b) increase the number of authorized shares of Series C Preferred
Stock or (c) effect a stock split or reverse stock split of the Series C Preferred Stock or any like event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dividends</I>.
The Series C Certificate of Designation will provide, among other things, that we shall not pay any dividends on shares of common
stock (other than dividends in the form of common stock) unless and until such time as we pay dividends on each share of Series
C Preferred Stock on an as-converted basis. Other than as set forth in the previous sentence, the Series C Certificate of Designation
will provide that no other dividends shall be paid on shares of Series C Preferred Stock and that we shall pay no dividends (other
than dividends in the form of common stock) on shares of common stock unless we simultaneously comply with the previous sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Repurchase
Restrictions</I>. The Series C Certificate of Designation will not provide for any restriction on the repurchase of Series C Preferred
Stock by us while there is any arrearage in the payment of dividends on the Series C Preferred Stock. There will be no sinking
fund provisions applicable to the Series C Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Redemption.
</I>We will not be obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock
will not otherwise be entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exchange Listing.</I> We do not intend
to apply for listing of the Series C Preferred Stock on any securities exchange or other trading system.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>General</I>.
The material terms and provisions of the warrants being offered pursuant to this prospectus are summarized below. This summary
of some provisions of the warrants is not complete. For the complete terms of the warrants, you should refer to the form of warrant
filed as an exhibit to the registration statement of which this prospectus is a part. Pursuant to a warrant agency agreement between
us and VStock Transfer, as warrant agent, the warrants will be issued in book-entry form and shall initially be represented only
by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company, or DTC,
and registered in the name of Cede&nbsp;&amp; Co., a nominee of DTC, or as otherwise directed by DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Exercise
of Warrants</I>. Each Class&nbsp;A Unit and each Class B Unit includes a warrant to purchase one half of one share of our common
stock, with an exercise price equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share at any time for up to five (5)&nbsp;years after the date of the closing of this offering. . The warrants are exercisable
in increments of two warrants for one full share of common stock. The warrants issued in this offering will be governed by the
terms of a global warrant held in book-entry form. The holder of a warrant will not be deemed a holder of our underlying common
stock until the warrant is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
to certain limitations as described below the warrants are immediately exercisable upon issuance on the closing date and expire
on the five (5)&nbsp;year anniversary of the closing date. Subject to limited exceptions, a holder of warrants will not have the
right to exercise any portion of its warrants if the holder (together with such holder&rsquo;s affiliates, and any persons acting
as a group together with such holder or any of such holder&rsquo;s affiliates) would beneficially own a number of shares of common
stock in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance, 9.99%) of the shares of our common
stock then outstanding after giving effect to such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event
of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events
affecting our common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such
warrant holders are utilizing the cashless exercise provision of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the holder&rsquo;s exercise of a warrant,
we will issue the shares of common stock issuable upon exercise of the warrant within two trading days following our receipt of
a notice of exercise, provided that payment of the exercise price has been made (unless exercised to the extent permitted via the
&ldquo;cashless&rdquo; exercise provision). Prior to the exercise of any warrants to purchase common stock, holders of the warrants
will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as
set forth therein.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
holders may exercise warrants only if the issuance of the shares of common stock upon exercise of the warrants is covered by an
effective registration statement, or an exemption from registration is available under the Securities Act and the securities laws
of the state in which the holder resides. We intend to use commercially reasonable efforts to have the registration statement,
of which this prospectus forms a part, effective when the warrants are exercised. The warrant holders must pay the exercise price
in cash upon exercise of the warrants unless there is not an effective registration statement or, if required, there is not an
effective state law registration or exemption covering the issuance of the shares underlying the warrants (in which case, the
warrants may only be exercised via a &ldquo;cashless&rdquo; exercise provision).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Fundamental
Transaction</I>. In the event we consummate a merger or consolidation with or into another person or other reorganization event
in which our common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign,
transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of
our outstanding shares of common stock, then following such event, the holders of the warrants will be entitled to receive upon
exercise of such warrants the same kind and amount of securities, cash or property which the holders would have received had they
exercised their warrants immediately prior to such fundamental transaction. Any successor to us or surviving entity shall assume
the obligations under the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, in the event of a change of control as described above, the holder may, subject to certain conditions, require
the Company or a successor entity to purchase the warrant from the holder by paying to the holder an amount in cash equal to the
Black-Scholes value of the remaining unexercised portion of the warrant on the effective date of such change of control; provided,
however, that, if the change of control is not within the Company's control, including not approved by the Company's board of
directors, the holder will only be entitled to receive from the Company or any successor entity, as of the date of consummation
of such change of control, the same type or form of consideration (and in the same proportion), at the Black-Scholes value of
the unexercised portion of the warrant, that is being offered and paid to the holders of our common stock in connection with the
change of control, whether that consideration is in the form of cash, stock or any combination thereof, or whether the holders
of common stock are given the choice to receive from among alternative forms of consideration in connection with the change of
control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Call Feature</I>. The warrants are callable
by us in certain circumstances. Subject to certain exceptions, in the event that the warrants are outstanding, if, after the closing
date, (i)&nbsp;the volume weighted average price of our common stock for 30 consecutive trading days (the &ldquo;Measurement Period&rdquo;),
which Measurement Period commences on the closing date, exceeds 250% of the exercise price (subject to adjustment for forward and
reverse stock splits, recapitalizations, stock dividends and similar transactions after the initial exercise date), (ii) the average
daily trading volume for such Measurement Period exceeds $600,000 per trading day and (iii)&nbsp;the warrant holder is not in possession
of any information that constitutes or might constitute, material non-public information which was provided by the Company, and
subject to the Beneficial Ownership Limitation, then we may, within one trading day of the end of such Measurement Period, upon
notice (a &ldquo;<U>Call Notice</U>&rdquo;), call for cancellation of all or any portion of the warrants for which a notice of
exercise has not yet been delivered (a &ldquo;<U>Call</U>&rdquo;) for consideration equal to $0.001 per warrant share. Any portion
of a warrant subject to such Call Notice for which a notice of exercise shall not have been received by the Call Date (as hereinafter
defined) will be canceled at 6:30 p.m. (New York City time) on the tenth trading day after the date the Call Notice is sent by
the Company (such date and time, the &ldquo;Call Date&rdquo;). Our right to call the warrants shall be exercised ratably among
the holders based on the then outstanding warrants</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Exchange
Listing</I>. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Representative Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of this
offering, will issue Ladenburg Thalmann &amp; Co. Inc. (the &ldquo;Representative&rdquo;) a warrant to purchase a number of
shares of common stock equal to 3% of the number of shares of common stock and preferred stock sold in this offering. The
terms of the Representative&rsquo;s warrant are identical to the terms of the warrants in this offering, except that the
exercise price will be 125% of the public offering price of the Class A Units and the Representative&rsquo;s warrant and any
shares issued upon exercise of the Representative&rsquo;s warrant shall not be sold, transferred, assigned, pledged, or
hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the
effective economic disposition of the securities by any person for a period of 180 days immediately following the
effectiveness date of this prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Certificate of Incorporation provides our Board of Directors with the authority to divide the preferred stock into series and
to fix and determine the rights and preferences of the shares of any series of preferred stock established to the full extent
permitted by the laws of the State of Delaware and the Certificate of Incorporation. We previously designated 10,000 shares as
Series A Preferred Stock. No shares of Series A Preferred Stock are outstanding as of August 31, 2018. We also previously designated
3,216 shares as Series B Preferred Stock. No shares of Series B Preferred Stock are outstanding as of August 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of August 31, 2018, we had outstanding warrants to purchase an aggregate of 1,882,661 shares of our common stock, consisting of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 35 shares of our common stock that were issued in February 2016 to the placement
                                         agents in our private placement of convertible notes that we conducted in July and August
                                         2015. These placement agents&rsquo; warrants have a term of five years from the date
                                         of issuance of the related notes in July and August 2015, have an exercise price of $3,120.00,
                                         and provide for cashless exercise;</FONT></TD></TR>                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 22 shares of our common stock that were issued in February 2016 to the placement
                                         agents in our private placement of convertible notes that we conducted in July and August
                                         2015. These placement agents&rsquo; warrants have a term of five years from the date
                                         of issuance of the related notes in July and August 2015, have an exercise price of $300.00,
                                         and provide for cashless exercise;</FONT></TD></TR>                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 58 shares of our common stock that were issued in May 2016 to the placement
                                         agents in our private placement of convertible notes that we conducted in July and August
                                         2015. These placement agents&rsquo; warrants have a term of five years from the date
                                         of issuance of the related notes in July and August 2015, have an exercise price of $1,920.00,
                                         and provide for cashless exercise;</FONT></TD></TR>                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 1,361 shares of our common stock that were issued in the public offering
                                         of common stock and warrants we completed on May 6, 2016. These warrants are exercisable
                                         for five years from issuance and have an exercise price equal to $2,400.00;</FONT></TD></TR>                                                                                                                                     <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 767 shares of our common stock that were issued upon the closing of our public
                                         offering on May 5, 2016. These warrants are exercisable for five years from issuance
                                         and have an exercise price equal to $2,400.00;</FONT></TD></TR>                                                                                                        <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to 279 shares of common stock issued to the underwriters of our public offering. These
                                         warrants are exercisable beginning May 2, 2017 until May 2, 2021 and have an exercise
                                         price equal to $300.00;</FONT></TD></TR>                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         with a release to purchase 221 shares of common stock issued to the Luoxis stockholders.
                                         These warrants expire on July 7, 2021 and have an exercise price equal to $1,600.00;</FONT></TD></TR>                                                                                                                                              <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 10,548 shares of our common stock that were issued upon the closing of our
                                         public offering on November 2, 2016. These warrants are exercisable for five years from
                                         issuance and have an exercise price equal to $744.00;</FONT></TD></TR>                                                                                                               <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 1,009 shares of common stock issued to the underwriters of our November public
                                         offering. These warrants are exercisable beginning October 27, 2016 until October 27,
                                         2021 and have an exercise price equal to $300.00;</FONT></TD></TR>                                                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 221,006 shares of our common stock that were issued in the public offering
                                         of common stock, preferred stock and warrants we completed on August 15, 2017. These
                                         warrants are exercisable for five years from issuance and have an exercise price equal
                                         to $72.00;</FONT></TD></TR>                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 19,749 shares of our common stock that were issued in August 2017 to the
                                         placement agents in our public offering of common stock, preferred stock and warrants
                                         we completed on August 15, 2017. These placement agents&rsquo; warrants have a term of
                                         five years from August 25, 2017, and have an exercise price of $72.00, and provide for
                                         cashless exercise;</FONT></TD></TR>                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 1,527,606 shares of our common stock that were issued in the public offering
                                         of common stock, preferred stock and warrants we completed on March 6, 2018. These warrants
                                         are exercisable for five years from issuance and have an exercise price equal to $10.80;
                                         and</FONT></TD></TR>                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants
                                         to purchase 100,000 shares of our common stock were issued in on March 23, 2018. These
                                         warrants are exercisable for five years from issuance and have an exercise price equal
                                         to $10.80.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 1, 2015, our stockholders approved the 2015 Stock Option and Incentive Plan, which provides for the award of stock options,
stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 3.0 million shares of common stock.
The shares of common stock underlying any awards that are forfeited, canceled, reacquired by us prior to vesting, satisfied without
any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2015 Plan will be added back to the
shares of common stock available for issuance under the 2015 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of August 31, 2018, we had outstanding options to purchase an aggregate of 1,798 shares of our common stock at a weighted average
exercise price of $325.97 per share. Of these, an aggregate of 1,527 are exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
271 options that are unvested, will vest per the following schedule: 100 options on November 11, 2018, 18 options on November
11, 2019, an aggregate of three options on August 7, 2019, 150 options on July 7, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2015 Plan is administered by our Board or a committee designated by the Board (as applicable, the Administrator). The Administrator
has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make
any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions
of the 2015 Plan. The Administrator may delegate to our Chief Executive Officer the authority to grant stock options and other
awards to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange Act and not subject
to Section 162(m) of the Code, subject to certain limitations and guidelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Persons
eligible to participate in the 2015 Plan are full or part-time officers, employees, non-employee directors, directors and other
key persons (including consultants and prospective officers) of our company and its subsidiaries as selected from time to time
by the Administrator in its discretion. Approximately 35 individuals are currently eligible to participate in the 2015 Plan, which
includes officers, employees who are not officers, non-employee director, former employees and other individuals who are primarily
consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2015 Plan provides that upon the effectiveness of a &ldquo;sale event&rdquo; as defined in the 2015 Plan, except as otherwise
provided by the Administrator in the award agreement, all stock options, stock appreciation rights and other awards will be assumed
or continued by the successor entity and adjusted accordingly to take into account the impact of the transaction. To the extent,
however, that the parties to such sale event do not agree that all stock options, stock appreciation rights or any other awards
shall be assumed or continued, then such stock options and stock appreciation rights shall become fully exercisable and the restrictions
and conditions on all such other awards with time-based conditions will automatically be deemed waived. Awards with conditions
and restrictions relating to the attainment of performance goals may become vested and non-forfeitable in connection with a sale
event in the Administrator&rsquo;s discretion. In addition, in the case of a sale event in which our stockholders will receive
cash consideration, we may make or provide for a cash payment to participants holding options and stock appreciation rights equal
to the difference between the per share cash consideration and the exercise price of the options or stock appreciation rights
in exchange for the cancellation thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Quotation
on the NASDAQ Capital Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock is quoted on the NASDAQ Capital Market under the symbol &ldquo;AYTU&rdquo;. We have two series of warrants quoted
on the OTCQB under the symbols &ldquo;AYTUW&rdquo; and &ldquo;AYTUZ&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent of our common stock is VStock Transfer. Their address is 18 Lafayette Place, Woodmere, NY 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Delaware
Anti-Takeover Law and Provisions of Our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Delaware
Anti-Takeover Law.</I> We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits
a public Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo;
for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">prior
                                         to the date of the transaction, the board of directors of the corporation approved either
                                         the business combination or the transaction which resulted in the stockholder becoming
                                         an interested stockholder;</FONT></TD></TR>                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">upon
                                         consummation of the transaction that resulted in the stockholder becoming an interested
                                         stockholder, the interested stockholder owned at least 85% of the voting stock of the
                                         corporation outstanding at the time the transaction commenced, excluding specified shares;
                                         or</FONT></TD></TR>                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">at
                                         or subsequent to the date of the transaction, the business combination is approved by
                                         the board of directors and authorized at an annual or special meeting of stockholders,
                                         and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
                                         voting stock which is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
203 defines a &ldquo;business combination&rdquo; to include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>                                                                                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                         sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more
                                         of the assets of the corporation to or with the interested stockholder;</FONT></TD></TR>                                                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
                                         to exceptions, any transaction that results in the issuance or transfer by the corporation
                                         of any stock of the corporation to the interested stockholder;</FONT></TD></TR>                                                                                                                        <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
                                         to exceptions, any transaction involving the corporation that has the effect of increasing
                                         the proportionate share of the stock of any class or series of the corporation beneficially
                                         owned by the interested stockholder; or</FONT></TD></TR>                                                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
                                         pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In general,
Section 203 defines an &ldquo;interested stockholder&rdquo; as any person that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         owner of 15% or more of the outstanding voting stock of the corporation;</FONT></TD></TR>                                                                                                                                  <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                         affiliate or associate of the corporation who was the owner of 15% or more of the outstanding
                                         voting stock of the corporation at any time within three years immediately prior to the
                                         relevant date; or</FONT></TD></TR>                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         affiliates and associates of the above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
specific circumstances, Section 203 makes it more difficult for an &ldquo;interested stockholder&rdquo; to effect various business
combinations with a corporation for a three-year period, although the stockholders may, by adopting an amendment to the corporation&rsquo;s
certificate of incorporation or bylaws, elect not to be governed by this section, effective 12 months after adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation and bylaws do not exclude us from the restrictions of Section 203. We anticipate that the provisions
of Section 203 might encourage companies interested in acquiring us to negotiate in advance with our board of directors since
the stockholder approval requirement would be avoided if a majority of the directors then in office approve either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Certificate
of Incorporation and Bylaw. </I>Provisions of our certificate of incorporation and bylaws may delay or discourage transactions
involving an actual or potential change of control or change in our management, including transactions in which stockholders might
otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests.
Therefore, these provisions could adversely affect the price of our common stock. Among other things, these provisions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         authorization of 50,000,000 shares of &ldquo;blank check&rdquo; preferred stock, the
                                         rights, preferences and privileges of which may be established and shares of which may
                                         be issued by our Board of Directors at its discretion from time to time and without stockholder
                                         approval;</FONT></TD></TR>                                                                   <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">limiting
                                         the removal of directors by the stockholders;</FONT></TD></TR>                                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">allowing
                                         for the creation of a staggered board of directors;</FONT></TD></TR>                                                                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">eliminating
                                         the ability of stockholders to call a special meeting of stockholders; and</FONT></TD></TR>                                                                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing
                                         advance notice requirements for nominations for election to the board of directors or
                                         for proposing matters that can be acted upon at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_011"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered into an underwriting agreement dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 with Ladenburg Thalmann&nbsp;&amp; Co. Inc., as the representative of
the underwriters (the &ldquo;representative&rdquo;) named below and the sole book-running manager of this offering. Subject to
the terms and conditions of the underwriting agreement, the underwriters have agreed to purchase the number of our securities
set forth opposite its name below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Underwriters</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Class&nbsp;A</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Units</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Class&nbsp;B</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Units</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font-size: 0.75pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 0.75pt; text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font-size: 0.75pt; text-align: right; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font-size: 0.75pt; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font-size: 0.75pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 0.75pt; text-align: left; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font-size: 0.75pt; text-align: right; border-bottom: Black 4pt double">&nbsp;</TD><TD STYLE="font-size: 0.75pt; text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
copy of the underwriting agreement will be filed as an exhibit to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have been advised by the underwriters that they propose to offer the units directly to the public at the public offering price
set forth on the cover page of this prospectus. The underwriters may sell Class&nbsp;A Units or Class&nbsp;B Units separately
to purchasers or may sell a combination of Class&nbsp;A Units and Class&nbsp;B Units to purchasers in any proportion. Any securities
sold by the underwriters to securities dealers will be sold at the public offering price less a selling concession not in excess
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriting agreement provides that subject to the satisfaction or waiver by the representative of the conditions contained in
the underwriting agreement, the underwriters are obligated to purchase and pay for all of the units offered by this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
action has been taken by us or the underwriters that would permit a public offering of the units, or the shares of common stock,
shares of Series C Preferred Stock, shares of common stock underlying the Series C Preferred Stock and warrants to purchase common
stock included in the units, in any jurisdiction outside the United States where action for that purpose is required. None of
our securities included in this offering may be offered or sold, directly or indirectly, nor may this prospectus or any other
offering material or advertisements in connection with the offer and sales of any of the securities offered hereby be distributed
or published in any jurisdiction except under circumstances that will result in compliance with the applicable rules and regulations
of that jurisdiction. Persons who receive this prospectus are advised to inform themselves about and to observe any restrictions
relating to this offering of securities and the distribution of this prospectus. This prospectus is neither an offer to sell nor
a solicitation of any offer to buy the securities in any jurisdiction where that would not be permitted or legal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Underwriting
Discount and Expenses </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes the underwriting discount and commission to be paid to the underwriter assuming the no exercise of
the over-allotment option and the full exercise of the over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Per&nbsp;Class&nbsp;</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>A&nbsp;Unit(1)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Per&nbsp;Class&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">B&nbsp;Unit(1)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total With No Exercise of the Over-Allotment Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    With Full Exercise of the Over-Allotment Option</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discount to be paid to the underwriters by us(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds to us (before expenses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding: 0; text-align: left">(1)</TD>
    <TD STYLE="width: 96%; text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    public offering price and underwriting discount corresponds to (x)&nbsp;in respect of the Class&nbsp;A Units (i)&nbsp;a public
    offering price per share of common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and (ii)&nbsp;a public offering
    price per warrant of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and (y)&nbsp;in respect of the Class&nbsp;B Units (i)&nbsp;a
    public offering price per share of Series C Preferred Stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and (ii)&nbsp;a
    public offering price per warrant of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: left">(2)</TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted a 45-day option to the underwriter to purchase additional shares of common stock and/or warrants to purchase
    shares of common stock (up to 15% of the number of shares of common stock (including the number of shares of common stock
    issuable upon conversion of shares of Series C Preferred Stock) and the number of shares of common stock underlying the warrants
    sold in the primary offering) at the public offering price per share of common stock and the public offering price per warrant
    set forth above less the underwriting discounts and commissions, solely to cover over-allotments, if any. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We estimate
the total expenses payable by us for this offering to be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which amount includes (i)&nbsp;the underwriting discount
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ($ if the underwriters&rsquo; over-allotment option is exercised in full) and (ii)&nbsp;reimbursement of the accountable
expenses of the representative equal to $85,000 including the legal fees of the representative being paid by us and (iii)&nbsp;other
estimated company expenses of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which includes legal, accounting, printing costs and various fees associated with
the registration and listing of our shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities we are offering are being offered by the underwriters subject to certain conditions specified in the underwriting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: justify; text-indent: -10pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Representative
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">We have agreed to issue to
the representative warrants to purchase 3% of the aggregate number of shares of common stock sold in this offering (including
the shares of common stock issuable upon conversion of the Series C Preferred Stock). The representative warrants will have a
term of five years from the effective date of this prospectus and an exercise price per share equal to 125% of the public offering
price for the Class A Units sold in this offering. Pursuant to FINRA Rule&nbsp;5110(g), the representative warrants and any shares
issued upon exercise of the representative warrants shall not be sold, transferred, assigned, pledged, or hypothecated, or be
the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of the securities by any person for a period of 180&nbsp;days immediately following the date of effectiveness or commencement
of sales of this offering, except the transfer of any security: (i)&nbsp;by operation of law or by reason of our reorganization;
(ii)&nbsp;to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii)&nbsp;if the aggregate amount
of our securities held by the underwriter or related persons do not exceed 1% of the securities being offered; (iv)&nbsp;that
is beneficially owned on a pro rata basis by all equity owners of an investment fund, provided that no participating member manages
or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity
in the fund; or (v)&nbsp;the exercise or conversion of any security, if all securities remain subject to the lock-up restriction
set forth above for the remainder of the time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Over-allotment
Option </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have granted to the underwriters an option exercisable not later than 45 days after the date of this prospectus to purchase up
to a number of additional shares of common stock and/or warrants to purchase shares of common stock not to exceed 15% of the number
of shares of common stock sold in the primary offering (including the number of shares of common stock issuable upon conversion
of shares of Series C Preferred Stock, but excluding shares of common stock underlying the warrants issued in this offering and
any shares of common stock issued upon any exercise of the underwriter&rsquo;s over-allotment option) and/or 15% of the warrants
sold in the primary offering at the public offering price per share of common stock and the public offering price per warrant
set forth on the cover page hereto less the underwriting discounts and commissions. The underwriters may exercise the option solely
to cover overallotments, if any, made in connection with this offering. If any additional shares of common stock and/or warrants
are purchased pursuant to the over-allotment option, the underwriters will offer these shares of common stock and/or warrants
on the same terms as those on which the other securities are being offered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Determination
of Offering Price </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock is currently traded on The NASDAQ Capital Market under the symbol &ldquo;AYTU.&rdquo; On September 6, 2018 the closing
price of our common stock was $3.99 per share. We do not intend to apply for listing of the Series&nbsp;C Preferred Stock or the
warrants on any securities exchange or other trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
public offering price of the securities offered by this prospectus will be determined by negotiation between us and the underwriters.
Among the factors that will be considered in determining the public offering price of the shares:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         history and our prospects;</FONT></TD></TR>                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         industry in which we operate;</FONT></TD></TR>                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         past and present operating results;</FONT></TD></TR>                                                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         previous experience of our executive officers; and</FONT></TD></TR>                                                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         general condition of the securities markets at the time of this offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
offering price stated on the cover page of this prospectus should not be considered an indication of the actual value of the shares
of common stock or shares of preferred stock sold in this offering. That price is subject to change as a result of market conditions
and other factors and we cannot assure you that the shares of common stock sold in this offering can be resold at or above the
public offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
officers and directors have agreed with the representative to be subject to a lock-up period of 90 days following the date of
this prospectus. This means that, during the applicable lock-up period, such persons may not offer for sale, contract to sell,
sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly,
any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock.
Certain limited transfers are permitted during the lock-up period if the transferee agrees to these lock-up restrictions. We have
also agreed, in the underwriting agreement, to similar lock-up restrictions on the issuance and sale of our securities for 90
days following the effectiveness of the underwriting agreement, although we will be permitted to issue stock options or stock
awards to directors, officers and employees under our existing plans. The lock-up period is subject to an additional extension
to accommodate for our reports of financial results or material news releases. The representative may, in its sole discretion
and without notice, waive the terms of any of these lock-up agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other
Relationships </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the satisfaction of certain
conditions, we have granted the representative a right of first refusal to act as lead or sole bookrunner or exclusive placement
agent in connection with any subsequent public or private offering of equity securities or other capital markets financing by us.
This right of first refusal extends for 12 months from the closing date of this offering. The terms of any such engagement of the
representative will be determined by separate agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent and Registrar </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent of our common stock is VStock Transfer. Its address is 18 Lafayette Place, Woodmere, New York 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stabilization,
Short Positions and Penalty Bids </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriters may engage in syndicate covering transactions stabilizing transactions and penalty bids or purchases for the purpose
of pegging, fixing or maintaining the price of our common stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Syndicate
                                         covering transactions involve purchases of securities in the open market after the distribution
                                         has been completed in order to cover syndicate short positions. Such a naked short position
                                         would be closed out by buying securities in the open market. A naked short position is
                                         more likely to be created if the underwriters are concerned that there could be downward
                                         pressure on the price of the securities in the open market after pricing that could adversely
                                         affect investors who purchase in the offering.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stabilizing
                                         transactions permit bids to purchase the underlying security so long as the stabilizing
                                         bids do not exceed a specific maximum and are engaged in for the purpose of preventing
                                         or retarding a decline in the market price of the shares of common stock while this offering
                                         is in progress.</FONT></TD></TR>                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Penalty
                                         bids permit the underwriters to reclaim a selling concession from a syndicate member
                                         when the securities originally sold by the syndicate member are purchased in a stabilizing
                                         or syndicate covering transaction to cover syndicate short positions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
syndicate covering transactions, stabilizing transactions, and penalty bids may have the effect of raising or maintaining the
market prices of our securities or preventing or retarding a decline in the market prices of our securities. As a result the price
of our common stock may be higher than the price that might otherwise exist in the open market. Neither we nor the underwriters
make any representation or prediction as to the effect that the transactions described above may have on the price of our common
stock. These transactions may be effected on The NASDAQ Capital Market, in the over-the-counter market or on any other trading
market and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with this offering, the underwriters also may engage in passive market making transactions in our common stock in accordance
with Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and
extending through the completion of the distribution. In general, a passive market maker must display its bid at a price not in
excess of the highest independent bid for that security. However, if all independent bids are lowered below the passive market
maker&rsquo;s bid that bid must then be lowered when specific purchase limits are exceeded. Passive market making may stabilize
the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may
be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neither
we, nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions
described above may have on the prices of our securities. In addition, neither we nor the underwriters make any representation
that the underwriters will engage in these transactions or that any transactions, once commenced will not be discontinued without
notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Indemnification
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have
agreed to indemnify the underwriters against certain liabilities, including certain liabilities arising under the Securities Act
or to contribute to payments that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_012"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have elected to incorporate the following documents into this prospectus, together with all exhibits filed therewith or incorporated
therein by reference, to the extent not otherwise amended or superseded by the contents of this prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         Annual Report on Form 10-K for the year ended June 30, 2018, as filed with the SEC on
                                         September 6, 2018; and</FONT></TD></TR>                                                                                <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                         Current Reports on Form 8-K filed with the SEC on July 2, 2018 and August 10, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we incorporate by reference in this prospectus any future filings we make with the SEC under Sections 13(a), 13(c),
14, or 15(d) of the Exchange Act (excluding any information furnished and not filed with the SEC) after the date on which the
registration statement that includes this prospectus was initially filed with the SEC (including all such documents we may file
with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement)
and until all offerings under this prospectus are terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for all purposes
to the extent that a statement contained in this prospectus or in any other subsequently filed document which is also incorporated
or deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall
not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You may request a copy of these filings
(other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost
by writing, telephoning or e-mailing us at the following address or telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aytu BioScience,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">373 Inverness
Parkway, Suite 206</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Englewood,
CO 80112</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel: (720)
437-6580</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attn:
Elizabeth Creason</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">ecreason@aytubio.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Copies
of these filings are also available through the &ldquo;Investors&rdquo; section of our website at www.aytubio.com. For other ways
to obtain a copy of these filings, please refer to &ldquo;Where You Can Find More Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_013"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus, which constitutes a part of the registration statement on Form S-1 that we have filed with the SEC under the Securities
Act, does not contain all of the information in the registration statement and its exhibits. For further information with respect
to us and the common stock offered by this prospectus, you should refer to the registration statement and the exhibits filed as
part of that document. Statements contained in this prospectus as to the contents of any contract or any other document referred
to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an
exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, and file annual, quarterly and current
reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement,
over the Internet at the SEC&rsquo;s website at <I>http://www.sec.gov</I>. We also maintain a website at <I>http://www.aytubio.com</I>,
at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with,
or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street, N.E., Room 1580,
Washington, DC 20549. You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section
of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the
operation of the public reference facilities. You may also request a copy of these filings, at no cost, by writing or telephoning
us at: 373 Inverness Parkway, Suite 206, Englewood, Colorado 80112, (720) 437-6580.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_014"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
validity of the securities being offered by this prospectus will be passed upon for us by Dorsey &amp; Whitney LLP, Salt Lake
City, Utah. Certain legal matters in connection with this offering have been passed upon for the underwriters by Ellenoff Grossman
&amp; Schole LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_015"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of Aytu BioScience, Inc. at June 30, 2018 and 2017, and for each of the two years in the period
ended June 30, 2018 have been audited by EKS&amp;H LLLP, independent registered public accounting firm. Such financial statements
have been incorporated herein by reference in reliance on the report of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Class&nbsp;A
Units consisting of common stock and warrants and </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Class&nbsp;B
Units consisting of shares of Series C Preferred Stock and warrants </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock underlying shares of Series C Preferred Stock and warrants)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="img_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Ladenburg
Thalmann</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>,
2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;13.
Other Expenses of Issuance and Distribution. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth all costs and expenses paid or payable by us in connection with the sale of the securities being registered,
other than underwriting discounts and commissions. All amounts shown are estimates except for the Securities Exchange Commission,
or SEC, registration fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount Paid or<BR> to be Paid</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">996</TD>
    <TD STYLE="width: 2%; text-align: right">.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,700</TD>
    <TD STYLE="text-align: right">.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD>
    <TD STYLE="text-align: right">.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD>
    <TD STYLE="text-align: right">.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD>
    <TD STYLE="text-align: right">.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Miscellaneous expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,304</TD>
    <TD STYLE="text-align: right">.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Expense reimbursement to underwriters</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">85,000</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; padding-left: 0.125in">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">225,000</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: right">.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;14.
Indemnification of Directors and Officers. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law provides that a
Delaware corporation may indemnify any persons who are, or are threatened to be made, parties to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right
of such corporation), by reason of the fact that such person was an officer, director, employee or agent of such corporation,
or is or was serving at the request of such person as an officer, director, employee or agent of another corporation or enterprise.
The indemnity may include expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually
and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in
good faith and in a manner he reasonably believed to be in or not opposed to the corporation&rsquo;s best interests and, with
respect to any criminal action or proceeding, had no reasonable cause to believe that his conduct was illegal. A Delaware corporation
may indemnify any persons who are, or are threatened to be made, a party to any threatened, pending or completed action or suit
by or in the right of the corporation by reason of the fact that such person was a director, officer, employee or agent of such
corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation
or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees) actually and reasonably incurred by such person
in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the corporation&rsquo;s best interests except that no indemnification is
permitted without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or
director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify
him against the expenses which such officer or director has actually and reasonably incurred. Our certificate of incorporation
and bylaws provide for the indemnification of our directors and officers to the fullest extent permitted under the Delaware General
Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section
102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a
director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach
of fiduciary duties as a director, except for liability for any:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">transaction
                                         from which the director derives an improper personal benefit;</FONT></TD></TR>                                                                                                                       <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">act
                                         or omission not in good faith or that involves intentional misconduct or a knowing violation
                                         of law;</FONT></TD></TR>                                                                 <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">unlawful
                                         payment of dividends or redemption of shares; or</FONT></TD></TR>                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">breach
                                         of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation includes such a provision. Expenses incurred by any officer or director in defending any such action,
suit or proceeding in advance of its final disposition shall be paid by us upon delivery to us of an undertaking, by or on behalf
of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer
is not entitled to be indemnified by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
permitted by the Delaware General Corporation Law, we have entered into indemnity agreements with each of our directors and executive
officers. These agreements, among other things, require us to indemnify each director and officer to the fullest extent permitted
by law and advance expenses to each indemnitee in connection with any proceeding in which indemnification is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising
under the Securities Act of 1933, as amended, or the Securities Act, or otherwise.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;15.
Recent Sales of Unregistered Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following transactions give effect to the 1-for-12.174 reverse stock split effected on June 8, 2015, the 1-for-12 reverse stock
split effected on June 30, 2016, the 1-for-20 reverse stock split effected on August 25, 2017, and the 1-for-20 reverse stock
split effected on August 10, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Aytu
BioScience, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         February 10, 2016, we completed the conversion of $4,125,000 in convertible notes and
                                         $143,000 of accrued interest. The notes were issued in financings that closed in July
                                         and August 2015. Upon the conversion, we issued an aggregate of 1,642 shares common stock.
                                         After this conversion, an aggregate of $1,050,000 of principal of convertible notes remained
                                         outstanding.</FONT></TD></TR>                                                                      <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         May 5, 2016, as an inducement to enter into lock up agreements with the underwriters
                                         of our public offering, we issued 767 shares of common stock and warrants to purchase
                                         767 shares of common stock to holders of convertible notes that automatically converted
                                         into shares of common stock and warrants to purchase common stock, which conversion was
                                         triggered by the closing of our public offering of common stock and warrants on May 6,
                                         2016.</FONT></TD></TR>                                                               <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         July 27, 2016, we issued 131 shares of common stock to Lincoln Park Capital Fund, LLC
                                         as a commitment fee and sold 335 shares of common stock to Lincoln Park Capital Fund,
                                         LLC, both pursuant to the Purchase Agreement dated July 27, 2016 between us and Lincoln
                                         Park Capital Fund, LLC.&nbsp;&nbsp;Between September 2016 and June 2017, Lincoln Park
                                         purchased an additional 500 shares.</FONT></TD></TR>                                                                                             <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         May 3, 2017, we issued 6,250 shares of common stock to the preferred stockholders of
                                         Nuelle, Inc. pursuant to the Merger Agreement dated May 3, 2017 between us and Nuelle,
                                         Inc.</FONT></TD></TR>                                                              <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         August 11, 2017, we issued an aggregate of 159,834 shares of common stock, 113 shares
                                         of Series A Preferred Stock and warrants to purchase up to an aggregate of 315,755 shares
                                         of common stock to investors pursuant to the Securities Purchase Agreement dated August
                                         11, 2017 between us and various investors.</FONT></TD></TR>                                                                                                    <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         March 23, 2018, the Company entered into a Warrant Exercise Agreement with a holder (&ldquo;Holder&rdquo;)
                                         of the Company&rsquo;s outstanding warrants (the &ldquo;Warrant&rdquo;). Pursuant to
                                         the Exercise Agreement, the Company agreed to reduce the exercise price of the Holder&rsquo;s
                                         Warrant from $72.00 to one cent less than the closing price on the last trading day prior
                                         to the exercise date ($8.20 per share) provided that the Holder exercised the Warrant
                                         for cash by March 23, 2018 and the Company also agreed to issue the Holder a new Warrant
                                         to purchase 100,000 shares of the Company&rsquo;s common stock at an exercise price of
                                         $10.80 per share. In accordance with the Exercise Agreement, the Holder exercised the
                                         Warrant and the Company received net proceeds of $615,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
offers, sales and issuances of the securities described in this section were exempt from registration under Section 4(a)(2) of
the Securities Act, and where noted above, pursuant to Rule 506 of Regulation D, in that the transactions were between an issuer
and sophisticated investors and did not involve any public offering within the meaning of Section 4(a)(2). The sales of these
securities were made without any general solicitation or advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;16.
Exhibits and Financial Statement Schedules. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(a)</B></FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibits.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: left; width: 9%; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; vertical-align: bottom; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 51%; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registrant&rsquo;s
                                         Form</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 10%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Date
                                         Filed</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
                                         Number</B></FONT></P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Filed
                                         Herewith</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting
    Agreement</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex31.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Incorporation</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/09/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416106487/v441568_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation effective June 1, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/02/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416111027/v443180_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation, effective June 30, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/01/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed on August 11, 2017.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417045636/v474281_ex3-1.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation, effective August 25, 2017</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/29/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018002319/fs12018a3ex3-6_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock filed on March 2, 2018</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/27/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018010718/f8k081018ex3-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Certificate
    of Amendment of Certificate of Incorporation, effective August 10, 2018</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/10/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515217957/d939908dex32.htm"><FONT STYLE="font-size: 10pt">Bylaws</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/09/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Certificate
    of Designation of Preferences, Rights and Limitations of Series C Preferred Stock</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515262003/d50939dex42.htm"><FONT STYLE="font-size: 10pt">Form
    of Placement Agent Warrant issued in 2015 Convertible Note Financing</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/24/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416099585/v439153_ex4-1.htm"><FONT STYLE="font-size: 10pt">Warrant
    Agent Agreement, dated May 6, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/06/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416124782/v449009_ex4-5.htm"><FONT STYLE="font-size: 10pt">First
    Amendment to May 6, 2016 Warrant Agent Agreement between Aytu BioScience, Inc. and VStock Transfer LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/21/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416131142/v450891_ex4-1.htm"><FONT STYLE="font-size: 10pt">Warrant
    Agent Agreement, dated November 2, 2016 by and between Aytu BioScience, Inc. and VStock Transfer, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/02/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417011968/v460775_ex4-1.htm"><FONT STYLE="font-size: 10pt">Form
    of Amended and Restated Underwriters&rsquo; Warrant (May 2016 Financing)</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/01/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417011968/v460775_ex4-2.htm"><FONT STYLE="font-size: 10pt">Form
    of Amended and Restated Underwriters&rsquo; Warrant (October 2016 Financing)</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/01/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex4-1.htm"><FONT STYLE="font-size: 10pt">Common
    Stock Purchase Warrant</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018002319/fs12018a3ex4-8_aytubio.htm"><FONT STYLE="font-size: 10pt">Form
    of Warrant for March 2018 Offering </FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/27/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant
    for Offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of
    Dorsey &amp; Whitney LLP</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex105.htm"><FONT STYLE="font-size: 10pt">Manufacturing
    and Supply Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Ethypharm S.A., dated September 10, 2012</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-4_aytubio.htm">License, Development and Commercialization Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Daewoong Pharmaceuticals Co., Ltd., effective as of August 23, 2011</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/06/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3#</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex107.htm"><FONT STYLE="font-size: 10pt">Distribution
    Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and FBM Industria Farmaceutica, Ltda., dated as of March&nbsp;1,
    2012</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex108.htm" ><FONT STYLE="font-size: 10pt">Distribution
    and License Agreement between the Registrant (as assigned to it by Ampio/Vyrix) and Endo Ventures Limited, dated April 9,
    2014</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex109.htm"><FONT STYLE="font-size: 10pt">Sponsored
    Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC, dated September 1,
    2009</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515216481/d935226dex1010.htm" ><FONT STYLE="font-size: 10pt">Addendum
    No. 4 to Sponsored Research Agreement between the Registrant (as assigned to it by Ampio/Luoxis) and Trauma Research LLC,
    dated March 17, 2014</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K/A</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/08/2015</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-11_aytubio.htm">Voting Agreement between the Registrant and Ampio, dated April 21, 2015</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/06/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000119312515342680/d58016dex1019.htm" ><FONT STYLE="font-size: 10pt">Master
    Services Agreement between Biovest International, Inc. and Aytu BioScience, Inc., entered into on October 8, 2015, and effective
    October 5, 2015</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/13/2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416076273/v429234_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Form
    of Subscription Agreement for January 2016 common stock purchases</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01/20/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416095924/v437781_ex10-1.htm" ><FONT STYLE="font-size: 10pt">License
    and Supply Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/25/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416095924/v437781_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Subscription
    Agreement between the Registrant and Acerus Pharmaceuticals Corporation, dated April 22, 2016</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/25/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416102582/v440068_ex10-1.htm" ><FONT STYLE="font-size: 10pt">First
    Amendment, dated May 15, 2016, to Employment Agreement dated September 16, 2015 between Aytu BioScience, Inc. and Jonathan
    McGrael</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/16/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Purchase
    Agreement, dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420416114818/v445153_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Registration
    Rights Agreement dated July 27, 2016, by and between Aytu BioScience, Inc. and Lincoln Park Capital Fund, LLC.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/28/2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417020925/v464415_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, effective as of April 16, 2017, between Aytu BioScience, Inc. and Joshua R. Disbrow.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/18/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417020925/v464415_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, effective as of April 16, 2017, between Aytu BioScience, Inc. and Jarrett T. Disbrow.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/18/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417026452/v465720_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Asset
    Purchase Agreement, dated March 31, 2017, between Allegis Holdings, LLC&nbsp;and Aytu BioScience, Inc.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/11/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417053230/tv477229_ex10-25.htm" ><FONT STYLE="font-size: 10pt">Merger
    Agreement, dated May 3, 2017, between Nuelle, Inc. and Aytu BioScience, Inc.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K/A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/19/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417032942/v469126_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, effective as of June, 2017, between Aytu BioScience, Inc. and Gregory A. Gould.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/19/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417038709/v471569_ex10-1.htm" ><FONT STYLE="font-size: 10pt">2015
    Stock Option and Incentive Plan, as amended on July 26, 2017.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/27/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-1.htm" ><FONT STYLE="font-size: 10pt">Securities
    Purchase Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000114420417043700/v473390_ex10-2.htm" ><FONT STYLE="font-size: 10pt">Registration
    Rights Agreement, dated August 11, 2017, between Aytu BioScience, Inc. and the investors named therein.</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08/16/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390017013436/f8k121717ex10-1_aytubio.htm" ><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated December 18, 2017 between Aytu BioScience, Inc. and David A. Green</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018003557/f8k032318ex10-1_aytubio.htm"><FONT STYLE="font-size: 10pt">Warrant
    Exercise Agreement dated March 23, 2018</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03/28/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018012209/f10k2018ex10-31_aytubio.htm">Amended and Restated Exclusive License Agreement between Aytu BioScience, Inc. and Magna Pharmaceuticals, Inc.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/06/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1385818/000121390018001614/fs12018ex21-1_aytubioscience.htm" ><FONT STYLE="font-size: 10pt">Subsidiaries</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02/12/2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="fs12018ex23-1_aytubioscience.htm">Consent of EKS&amp;H LLLP, Independent Registered Public Accounting Firm.</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of
    Dorsey &amp; Whitney LLP (included in Exhibit 5.1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#sign">Power of Attorney (included on signature page)</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed
    by amendment</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="9" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    is a management contract or compensatory plan or arrangement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="9" STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         company has received confidential treatment of certain portions of this agreement. These
                                         portions have been omitted and filed separately with the Securities and Exchange Commission
                                         pursuant to a confidential treatment request.</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(b)
Financial statement schedule. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item&nbsp;17.
Undertakings. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The undersigned registrant hereby
    undertakes:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         file, during any period in which offers or sales are being made, a post-effective amendment
                                         to this registration statement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         reflect in the prospectus any facts or events arising after the effective date of the
                                         registration statement (or the most recent post-effective amendment thereof) which, individually
                                         or in the aggregate, represent a fundamental change in the information set forth in the
                                         registration statement. Notwithstanding the foregoing, any increase or decrease in volume
                                         of securities offered (if the total dollar value of securities offered would not exceed
                                         that which was registered) and any deviation from the low or high end of the estimated
                                         maximum offering range may be reflected in the form of prospectus filed with the Commission
                                         pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
                                         no more than 20 percent change in the maximum aggregate offering price set forth in the
                                         &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         include any material information with respect to the plan of distribution not previously
                                         disclosed in the registration statement or any material change to such information in
                                         the registration statement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">That,
                                         for the purpose of determining any liability under the Securities Act of 1933, each such
                                         post-effective amendment shall be deemed to be a new registration statement relating
                                         to the securities offered therein, and the offering of such securities at that time shall
                                         be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
                                         remove from registration by means of a post-effective amendment any of the securities
                                         being registered which remain unsold at the termination of the offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">That,
                                         for the purpose of determining liability of the registrant under the Securities Act of
                                         1933 to any purchaser in the initial distribution of the securities: The undersigned
                                         registrant undertakes that in a primary offering of securities of the undersigned registrant
                                         pursuant to this registration statement, regardless of the underwriting method used to
                                         sell the securities to the purchaser, if the securities are offered or sold to such purchaser
                                         by means of any of the following communications, the undersigned registrant will be a
                                         seller to the purchaser and will be considered to offer or sell such securities to such
                                         purchaser:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         preliminary prospectus or prospectus of the undersigned registrant relating to the offering
                                         required to be filed pursuant to Rule 424;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         free writing prospectus relating to the offering prepared by or on behalf of the undersigned
                                         registrant or used or referred to by the undersigned registrant;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         portion of any other free writing prospectus relating to the offering containing material
                                         information about the undersigned registrant or its securities provided by or on behalf
                                         of the undersigned registrant; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         other communication that is an offer in the offering made by the undersigned registrant
                                         to the purchaser.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         undersigned registrant hereby undertakes that, for purposes of determining any liability
                                         under the Securities Act of 1933, each filing of the registrant's annual report pursuant
                                         to&nbsp;Section 13(a)&nbsp;or&nbsp;15(d) of the Securities Exchange Act of 1934&nbsp;(and,
                                         where applicable, each filing of an employee benefit plan's annual report pursuant to&nbsp;Section
                                         15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
                                         registration statement shall be deemed to be a new registration statement relating to
                                         the securities offered therein, and the offering of such securities at that time shall
                                         be deemed to be the initial&nbsp;<I>bona fide</I>&nbsp;offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Insofar
                                         as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
                                         to directors, officers and controlling persons of the registrant pursuant to the foregoing
                                         provisions, or otherwise, the registrant has been advised that in the opinion of the
                                         Securities and Exchange Commission such indemnification is against public policy as expressed
                                         in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
                                         against such liabilities (other than the payment by the registrant of expenses incurred
                                         or paid by a director, officer or controlling person of the registrant in the successful
                                         defense of any action, suit or proceeding) is asserted by such director, officer or controlling
                                         person in connection with the securities being registered, the registrant will, unless
                                         in the opinion of its counsel the matter has been settled by controlling precedent, submit
                                         to a court of appropriate jurisdiction the question whether such indemnification by it
                                         is against public policy as expressed in the Act and will be governed by the final adjudication
                                         of such issue.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.5in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         undersigned registrant hereby undertakes that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         purposes of determining any liability under the Securities Act of 1933, the information
                                         omitted from the form of prospectus filed as part of this registration statement in reliance
                                         upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
                                         to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
                                         part of this registration statement as of the time it was declared effective.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.35in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         the purpose of determining any liability under the Securities Act of 1933, each post-effective
                                         amendment that contains a form of prospectus shall be deemed to be a new registration
                                         statement relating to the securities offered therein, and the offering of such securities
                                         at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"><A HREF="#toc">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="sign"></A><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereunto duly authorized, in the City of Englewood, State of Colorado, on September 7, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AYTU
    BIOSCIENCE, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 37%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua R. Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua R.
    Disbrow</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">KNOW
ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Joshua R. Disbrow and David A.
Green as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name,
place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective
amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto
said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do
or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-align: center; width: 35%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding: 0; width: 1%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-align: center; width: 43%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding: 0; width: 1%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-align: center; width: 20%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joshua R. Disbrow</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    7, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua R.
    Disbrow</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David A. Green</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial
    Officer </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    7, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David A.
    Green</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Financial and Accounting Officer)</I></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gary Cantrell </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    7, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary V. Cantrell</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Carl C. Dockery</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    7, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl C. Dockery</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    John Donofrio, Jr.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    7, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John A. Donofrio,
    Jr.</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Michael Macaluso </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    7, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Macaluso</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">II-6</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; margin-right: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%; margin-top: 0; margin-right: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>fs12018ex23-1_aytubioscience.htm
<DESCRIPTION>CONSENT OF EKS&H LLLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We hereby consent to
the inclusion in this Registration Statement (No. 333-) on Form S-1 and related prospectus of Aytu BioScience, Inc. (the &ldquo;Company&rdquo;)
of our report dated September 6, 2018, with respect to the consolidated balance sheets of the Company as of June 30, 2018 and 2017,
and the related consolidated statements of operations, stockholders&rsquo; deficit, and cash flows for the years then ended. We
also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Registration Statement and prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our report dated September 6, 2018 contains
an explanatory paragraph that states that the Company's recurring losses from operations and accumulated deficit raise substantial
doubt about the Company's ability to continue as a going concern, as discussed in Note 3 to the consolidated financial statements.
The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">/s/ EKS&amp;H LLLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Denver, Colorado</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September 7, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ +$# 2(  A$! Q$!_\0
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MDBE+B-5:X*&M6VFD=(?,>-G<98(5?:?+5RC2)A'*DG#JD:LNTA.<G_#RU/\
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M DDG<><GEFX.,NV68]2S,>YS_ G_ ,'Q)\I?^":X5R$DF_:J5HBY"$ ?L_\
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M:AJFGZ/)I]]H_B7PS%KZ6'B'29;NUBFBL/%6C//Y=FX_UZO@W\:?"7[1_P
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/]+_Y]?\ R/<?_'J* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "@ &L# 2(  A$! Q$!_\0
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M3M*&-6VNJIM!( <8"JY8A2O]LP*7C$Y5XR"Z H0FS:NU]SMM;;L#R\LQ!V#
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MYA<;XS%=JTMON!$MG-;S*Q60&N:\/7J:IIWV8NK2;/.MCNR"P!\R(9R,,OS
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M>L9*UMCB/^"UO@WX1?&?]AS]@7XZ_!3PS?\ @&W^&'A3Q?\ !35?">H7XO\
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MAIXJ%W#+Y41UF^.J^&;F>XC4^3%<W9O]/5Y/W:W#V\>Y7E3=_,/\'/'7CO\
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M6'3?!GQ$\/PKIWBGPT+2P5!:Z7::PBZAID=K&C2>'=3TRY@3_2$)^E/AK?\
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M<L;2]B565B2/T(N]#T72M(C:SC)FMK5BTSOYMS/*%.9+B0GS'F=ADL>Y ^5
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M<[B,F.XN[6_:+/\ RS52,;AG]"JY+P'X/TGX?>#?#'@?0HA#I'A71-/T2Q7
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MLT>M:4DN+2ZFAC6S?_/=T;Q&VI6EM<--:ZA;RHC*6/S(&0$,0!AE!Y&Y2<$
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M%.4*C?- _N+^T0"V\ZXF6&.'<1)(ZHA1@68MN/)7'RJ!GT!) K\_/VTOVN?
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+3DFF]HPM\+9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "2 &T# 2(  A$! Q$!_\0
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MP?7G QTU(0"@*!=BAB00.0/N@#&0>.V><=<50F3.94W+N)S@XQSR2ISC/?C
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D?S8Y;:V7[MO O^[%&.G3HM2"-!T1!]% _D***!CZ*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "6 .$# 2(  A$! Q$!_\0
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M?V-1F9<9+  CVZ9QV[].G./:HS=1K_&,#ONQV'\ACZ=Z )6C X('/H<_S_\
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M_P R>;RC]R/IRQT]E9-L;*0%S@'[P4!E 4E<,5Y4?>#'DC@=;9V3K][=E?F
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MI%.#:RP2'6,DTGW^?G_2Z=2XRYO7MKI\^I]'A,C("_E_]:H'B!!X.?< ]_\
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M'Z4RBFX[_GR!_P#7S]/2JDB<<<C/3C^?Y]NV*ON1SC &#CH.U4W'0_A_G]:
M,MUQGC/U!^N!@CT_^MTK.F4'.!V Q@<YXQ].>A[UK2=N3[#/&.?\_C6>^,'/
M;G/OVP#P3]>G4T 9^P>I_3_"BI_+']YO_'?_ (FB@!J'IVSUR?;@8XSS]?PJ
MV@/?OC'?UJ*-<,,XZ 9P.?4?CZ]^.XJR%'0=@".,#GMU [^_YXH+F[M^3M\M
M'^90O!^Z<GT..IV@C/3H<<''/..@YKXH_:OTB'7?@=\9-(GMWNHK_P  Z]$U
MNB!VE)MP[!<\9"*V<,I"\DC >ON*YMR86Z D>G?_ !P3C..I'.:^:/C'I3WG
M@GQW:@;C<>$/$D94JQC*_P!DW3/NV%6(*(><@KG Z<S-7A)?W7^3(/\ 'TOH
M3I/Q%\?:5,4\RWU+Q IY!(DL?$BW!$9(+;T0R)D,>C@D,37[^?L3:Q'J_@?3
M;4R)']GA^6>)7F,)F5  ZNP!\Z920CJPD(^5MSJH_"3XYVD?AO\ :<^+&B3*
M8G@^(?C[3V#EODEFN]0<*2?WBDSL JO\P8!6;Y<G]<?^">?B6/4O#YL)"+B6
M&:&-$8<LK9D0(264KE4+(5=G>(F,1 O)7ITY<]*+[P@UNM>6-]]-^E["77\=
M3]:)='D2Z^U0R11NLEF;5K<(BQ7EK.KQ7,K,[2Q212H8EN493;R9(5'5&;],
M_P!G3XDV]S+::E(B6ND>.[J+2?%-C"\7V;P_\5;:");/5 OEHMOI_C33&BD1
MI)3 VK$G:)%D"_G7(]G<1)-N\F_;S5%P,Q*9'C5Y5,Y2,*&=29(Y,+&T:-&X
MC:!W[3X-_$71O#'C)_#WB#49X_"GCKR]!\0W$VU(]+U$RPVOASQ';'B".Z\/
MZP8Y/.B8O/;R73!A(2S95(<R:6_K?;IJW^%A35U?JM?EK?\  _<C1M9U/P;X
M@T[Q=H\%[>ZGH$MV;G0H9%ADU_P[>K'#X@\.3*X96NKV*UM-5T5@"RZ_HVD%
MIK>QENI)/T6T;4],U[2=,UW1[N*^TC6;"UU/3;N(YCNK*\B2:"0!<A) I\NX
MA9M]O.DEO-MFBD0?E?X#U>[U30SIWB"1'\3^&KM-)\3K%'Y1NKJUC1;;6;$,
MS.+'6[01WL;B1=KB=8T\M21]4?L_^,3X?U^;X=:A)LT/Q/>:CK/@IY"D<5AX
MB2.6_P#$OA:&,NYCMM:@BN?%.AQ(L<$=];>*K:-1]IT^%O/J1>_;1F)YQ\;?
M"WBSPQX]G\>7^GSZ_P"'$L(!!J6G6$,EYX5M([+[)-'.Z3P7LT!U>*\\13VJ
MS6L%_P#VM):RW,EY8PQ#5_9\U;5[+QP/#_A_P]J/A[PQ-:Q:EXEL-6\/R>&;
M2..XT[6;I]?;3&MMNE7][X@&FKID5R]MJ7B&+5=;U*Y?4+>R2>U^Z=66\CTK
M49=+L(-5U6VL;V?2]-N;F.RAO]1BMY9+.SFOI$E2RCO+E8K1KUDVVR2-.X*1
ML#\^K+^U-XHL_#MQ:>%_A9\/FU#PGHTGB>VU:^U'Q9XL\->+I=2O%\2V_AJ&
MTMKSPIJEI8Z2MK+X:N=8O8K6ZU:4MJT,FFK-!4.HDH0:NYN?*U!RY?9I2;G)
M*U.,E-1IN;7M*D9PIJ7+)K)4I2JU)J52,80ISDY-*E)U)SI1C"\TZDX^SE.I
M"$'[*DZ=6<XJI&+[R\^&7PVU&\U2\U#07URZU35SK.H175[KFHP2:BBQ^68K
M6.^2P@2W^SQK:VX"I&IV9\N7![;3-,MM$MUT_0?#]EHMFL:HL-O'9Z? RH B
M;[6S1Y9"JM]Z5=^<H2'+%O(]/\3_ /"MM7UV_P#BS\=_#&I6NIV>EV6D^$I[
M30M(OM$O-/DN);N[T_2-%N=0UZ^N]5_M!;:Y@%O/&+:ST1((UNUN;O5(-2_:
M4\$HYB\.>'_&OBWY!)#J$.BQ^%O#THD4+$J:UXPN=%EE#R,B.MCI6H2PL94>
M(SVUQ!&EZ-Z-;O9[WL_S-'&VZ^=M^_JGO;KH>U7-C=72217$ULMO*KI- ELE
MQOB9<&-_M9DA9'RP<&V(8 9&"R'%LO"NBZ-;1V6GV$%G9IYCI8V,$=A8":5U
MDDE%CIT=I:)))* \C+#EP[*6*#8?FS6OC[\1K]HX]!T#P;X3M+AI4BN=6.M>
M,-562)"YB>UA;PCI<!*&(R@3:@%!GC#$"&[;R74O&OC[Q'<)_;?Q%\73B>::
M(:3I.I:?X/TUH?+6= EOX2L=+OF^S&-4=M0O;[SU%TKD1S7,+6HRVV]79?J'
M*EV^3;M][3^YH^PO&5_X'\-Z?+>^,-2\-^%;&&*:9M0\0ZMIGA^V2".VF\ZX
M:YU2XLH91';07!\U&,JK;S;&S$P3\N?VB_VNO^"=EC8MI'C;XPZ'\0+ZSD:W
MBT/X>6&N>--?2:VEN)(K>SU'14ATX-]KTV:*,W/B"#3V,MA+$Z-=VNH3_P [
M_P#P4-\'_$GX7_M'W^I^,-6UOQ9\*/BYXHN/$OPI\3ZG<RW$&F7$,.GR:S\)
M]6N]:<VF@7'AMM.CU+1[QW@N=6T-YKG=/J 5Q^=/QA^(%I\.[FUNM0TVRCM]
M2VW%OJ-O(7LD\B:X5;.:U17O+B>2!DU&$-(MM+;QR1* ?,C;KIX6/Q2J.ZVY
M%:U]+7O=[M:K\"73C*]US<R6C=EIV;<FOOUV/Z3?%'_!:WX)_#2PM]!^!/[.
M'C'6K'2H5L-'O/'NO6?AS1XDM[B**U9=/TE-=U6YN%2>>.W2\U>RCMIY[74'
MMO-^VQ1_ ?C_ /X+@?MO^)M5TV3P[;_#GP!HEM>076H>'_#WA74Q-KFGH\=O
M>Z!)XIU&^U#7]/2]GBO8AK&D:A87=FU_;PQ^=<Z=%<M_/IXO_:NT)X1:G6[0
MW=Q+*+2QTZVC@N5:YE@CCBDL[1)[J$>3%L,KS+,N<O+A-]>&>,/C3XVMQ#K5
MA>W]I(FNV+0!(I9+14ACFN)Q,94,5XLOVBW:5Y=^[='(1%(T;5K&EAH:<O,[
M/24E?S]U-)/KIJ4J3C:UHJ^J5G:R]&^VWW']\?P4^,G@;]IGX;6'QB\ >(M6
MUF35=MIXKM]<U2_U;Q-X>\3V%O$VJ^%_$<VH7$VH"33KRX673VB*Z9J6F7J:
MKIJ)'J-PE?9_[//[0&L?!/Q0FDZY>7E_\.-;N;<ZYI<L<LT^A7=T@23Q)HJK
M$&,L!51J=DB1PZE9@@QMJ-O!)7\3/[#7[>VM_!_QG;?$?P\FI:IX=U(6>E_&
M3X3V>J06MEK]D/*ALM;T>">%X8?$>G2I-<>&M:E"8:6[T/4YTT[4)E3^MCP]
MXH\)_%3P7X=^(OP_UFR\2>%/$^GIJ>A:MI<L-]&]O<;A+;WB(\L]CJ]A="XL
M=4LKB-9;.\M[NRN$$D2H_-4I\C5OA:_=R>]OY7T36SLE=='9LM7B[]M'_79]
M.WD?T=Z#KFG:QIUAJND7]KJ>EZG:PWVG:C8SI<V5]9W"B2&YMIXRRR12)G:<
M[E(:-PLBL@ZF.3>OX @]\YYQQZCM_P#K_%+]E3]HFY^$M[:^!/%\ES=?#W6-
M1;R-0EE&?!.HW)1&NHA*%>30[M_+FU6SC#&V9FU:R0*MW#-^S5C<I+'&\<B2
M1R+'+%+$XEBFCD57CDCD0E)8I$(DCD0LLB,KH2IS4)WT>C7]7]'T-4TU=&HP
M!'8]#].>>N.V>E5).WX_TJRQXR#P>.G)Z^N,#]:K/_+G]?S],'IUYSBF,I2X
M/3UZGC_/;\LGH36=+GG/7/U'0X^M:<@SGC!P< =3UYZ=^A[U1E YSUY!Z>XX
M]^N3G  YH H9/]UO^^FHJ;:/7_T'_P"*HH <B GD$@C/')YZ_K^G3VNQA  #
M_@.W/7K^.,5G&4#J1T7MCCMSP.>X)[]LU4N+[RU8ELX /!)/4>GY]>#[T%2^
M)^O^1O2R0A"&.00<]A^><<=#@YZX.17B/Q/U7PQI?AOQ)<:U=)%9RZ)J\$B*
M#))(MQIUS;^4L:-DF0R^7GA!G<SJN2-W6=:F2%@CG!SR#C&%[9*CU YSC. 2
M,'Y/^*%O=:]:W%M.&ECEBW/&Q+1D.Y.UQ(&!C548-@';OQ@#HFKJW?3Y-.Y)
M_F)?MF_L9?'S6?VG_C=K=KX-E\,^%-6\?:WJ^BZUKTDD+7^GWMT91J-E:6*W
M]P]O+([K!(\B><<%'PXIGP'NO'O[,MU%'>ZJ^NJ\P%WNTVYL7MXG41F-#*\C
M7:0-\RNT:21*VY59D"G^Y'XV_LTZ)XICO4N=*LYO,,K(=L3/$P=V1[679O4J
MY5888Y/+BW,3&[,V/R-^.'[$.A7\%Y;+ILL2F,,TOV>*&Z1"<+)!( ?.=<N1
M+&4D<JJC?Y@W]-.<HQBDV^2*CJK7LET=U\[;=B>9*]]-?FWW]#\]]$_:4N/$
MEB&6[D96ME=RD[L#$A64QB63+L6(*9,?F$X?.XA8_3+7XK7.IB-F>'R9X L<
M"_-%:QF1BX!"2QRE497;#,VPK'CS'8U\B_$C]G+QI\(-5N&L;::XTO 9Y%CV
MA'4C;;W<2EO)G(Y>5%?>5!*(TBQ'#\->)Y+,^5<R/%/$P $CL)RBC<5$:NB+
M'O 21B< . 2G[P+<9J3>REV:6C[IZ7OOU$Y6\[^J:/ZG?V+OVA1\1?!6DZC<
MW4<GBKX8Q6?@CXCVRRM_:?B/P-)&J>#O%\<<VZ[:XT:2-]/U"5C'&[6<_P [
MW-W'%)^G%S9+=VT<5O/-:3)]EO=.U33)4CO-'O\ 3YEU+2M9TZX^<27NG7D4
M5[#&\;PS*GV:Z%Q#-=)+_(/^RY^T+<_!#XN>'?',1^T^'9Q_8?CW2R[/!J7@
MO6+J,:[%'$ZN7NM-3[/K.GSHDC&ZL42/*R2K7]8_PVUZRUG3H=(M=2@U?3H=
M-L=8\*ZS#(CVOB+P;JT*W>C7]O*@7S%2.ZB3>H#^5-:*%&R5%RK1N^9[2LG;
M:Z^2WTM\]3"]I6Z.[3Z^A]$2_&KXNW]K#')J?@/0G6&$75YH'A?4]0N[QM@1
MKM3XDUB72M'><EY?LJ:7JUO:R@)%<W$*O$_F^K3:YXF!7Q=XS\;>*X'E3SK;
M4/$UWHVB1M*=S!?#OAA/#NA&!54#?>:=.(WV+O8VD7EW4AD1 (VVJY*'RW)7
MR@00K!B6P5BEC"H%\P.6WJ,.716WVAD4N@\F-\+Y2.DQ(64/(KJ5::-G/DR,
MZXD1F1P$8OSJ,5T^^[_-VOYVOYE>7Z:_?O\ +1>3W,_3-)TS0+:4Z+HMAIGS
M3*?[+L].LY)\,TJ22O;P0/+;QJS"0R&5V5Y C/$V7FN"56=KB-5P8E#QN##(
M/DDCF"H 4\M!L.Y6=@'?9Y?5X27(9E>7>D>YX%\AG)$8*2,SD(4&%V@Q*TN9
M"Q$94SWB2$;MD*K)& QCVQ+%%%+&WD*"@$<K^85#_(V2YWA)6WT%VS%$T8@5
MG1"Z220R2G<]RRF*!MPB7>\<<A8J$A#&;*,L4:J"^5):R/<"2.26+YTCVRLJ
MS F2)(XQ(!YDL43AO.$@B%P2ENZK&2*Z$1QI:AY_*$R-$ 7C<^:&)"NN6'R,
MT !C\M&W1L\A,;2&LF=)K=[UPPE8Q9$D?E29,<JO%/"H&+C#W'FS*-CYB41,
MTD,,<AMJ!X!\?OV?? W[2/PE\6_"?XDV#SZ)XB@C:PU>WMHVU/P=XAB+2Z!X
MDTF[AE-Y%=Z1<B.,V^6?4].:YTNY>6WF9U_C_P#C]^S[KGAG7?&W[.WQ<TE-
M/\;^%[PRQZ[ MP;;7M*^QM<>'?&WADQ_N)-*UY,2O; V\MG/<7.FRPS2V<L4
M7]P*P3)$@*3FY@\UIC;K$JQM=+([Q22R0.J2I&S%&4D*DJ!AO:/R_P __P#@
MH1^Q=;?M4?#*/Q#X&^R6/QY^&6G76H?#[4U+(?$NFQQFXOOAOKTZHT[Z=JQS
M=Z)(K+)I>OR0K(8+.\N]VU&IR2Y7\,M/2[_+N[Z:,-M5OO\ =JK=MM>Y_!5J
MGPI\;> -)UG7X?"^G1RZ9-*;F+P]I<-SJ]S,\H\V2;4;A;J\,(;,\DT;RW"1
M<Q6Y#;1Z7X.TOX/_ !"\$1:W:6VL6'B&SN+A-1TKQ!K4NMZ>]ZD<:F%-XM_-
M$]GY,]M=6L.E7EOMDMC'.\2;?LB\U?2K?6CX'\1V9TR]9%T>^TZ^@.EZA'K]
MO)Y7V>[2YAAET[[/<PFR\VYEAN8[BU4S*LUQ*L?$>(/V;+/3;G5/$OA_5+/0
M?M'DMJ5SJRQZ7I6IBTN/*EN[F-E!BU*V\YDDN],@F34X9PUW 9@+I/1C2C%<
MT(Q<=5)-7=O[K>WRZ&<JK;2GH[IPDFU';6Z2[:VV>Q\VI\&=<\,ZEI_BWX:F
M;3[EV5XK6[E2?2M2@G7;+907$BQB>*X63R7L)%AN!DQB.ZN(]X_6#_@GW^WC
MK'[+7B%-%^)EGJVF_ +QYKMVOCCPZFGSW=S\//',B6UFWC+P\TP6X>T:T2T'
MBW1(&$M[H8CU.VLAJ-A%]J^.-$\4>%_AMI+Z'<^)AX\D-RUW#8Z=I,9TNQGE
M\H7,%O=2L]Q-;W*+(EP98]MK?---'$C.[2>=>./%-]XXABM(/"ME96%G+]JM
M+L*B:E;*#+&T*7<H$BVAB>13I91H86B=X(UB14,3I4G%QYN2Z^%ZM2ULXO51
M=[7>MU==1J4WO&ZOI*]KI]T]6_/Y==?[?=1\2^'9;.RUC3;K3]4T[5+6/5K#
M4++48+FPO;&YM(;ZUN[*='6.YMKZUEBN;::%ECE@8HA\N0[OO#]AK]JR&_\
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M3WZ9^F/U[4 5F7'0<=>GKVS_ "^M0OC_ &NG;IWQFK3=,^A!_456;[I_#^=
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M>0 ].F!QP.?_ -=%% %62X(Q@8SD<<=L^OM[TV-RY.>,#IV_S^OO110!="@
M<#C^?K3&7 SGIUS]?\]:** (7.!]>/T-5V;!QBBB@"-FW>V*B<< ^^/S_P#U
L445,FTKKN!"PX)Y^Z1CM_P#KJJ_3\_T!/\L_CBBBLW)OK]V@$5%%%2!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= ),# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^U--)'\2
MY/(('W2000!@YS@XY'//(P%_LA-WW=PZC=D-P<@%B&(Z=",=#7:_8_8?-A<C
M(. ,D<<\9.?7MBE%G[<'(Y!SU([CT'(]">ISD XE=''4J"IS@87/)W'CD$9
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M_!'B:_OKC0]35XL13>*/&,UO>W8:.UGMM9T^RMA'.5KZ-U/69_BO_P %_?\
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M;Z&!)O,DNH0O]=$@R.O&"/S]/\]J_@._X/$OB3<ZG\?_ -C;X/P74DMKX/\
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MG:_^0+1/LTU]]ONO;3YG]'ZKT'H!V[9 Z>PJ49P,DCGID\^Q_$?T],-'/!(
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MH*0#<5P'8,[NXP#'M1MPWXHY7V=_5?ENQ\[^7E;\F_0_1/\ X)(?"N3XN_\
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MXXZ8]>GY=:3CG.<]O_K_ $IP4YXV\9'7DCZ G'I_]?!H(/3Y>.>/PZCWXYX
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MESP!G@9Q]>?U_P ^M1@'N./^^3^GU[FG $$CMU')SGOG/K[?UH <#C_]>/\
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IFVX_'\,T .HHI <Y]O\ $C^E "YSTHHI!R ?4?SH 6BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 0_ SD# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>#@X8'!]#C.#Z X)[4^WGMY^G?Y7%=72NKO975WZ*]WL]DR2BFET!P64'T+
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MX@L3BUU;P[K^G0W^EW*1LJ36\KV\L45U8W$45U974<UI=017$4B1_AU^W/\
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M%1>='V;(XY SU ;'UPP/X^N:/.3W_*@"6BHO.3W_ "H\Y/?\J ):*B\Y/?\
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M0V2A9-*U&'6-'EC1=/B>;^TCR#E0$^XHV-E<AL'H,\%3]TC( X'!('X<7_\
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MK_2;J'3M0-AK<.C3P2QR1Z<]S%<V2A8(UA,31C5_X);?M%_M5>$OVU/VG/\
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MEES(J0/+-,D$$:F2XFD9(T@AC5GFDD9\+&D,0:1Y6*A0I9B,$C^0+X<?L_\
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M_@G)_P %'O#_ ,>/^"=/QA^)?_!0#6?#R^%_@]XY;X"?%GQWKN@7>IZ!X_\
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MP_SQS52:Y*JQ7 (&1N!)Z@%0 06) )[8R*MD>@'3_P#4/IUK.D4O@%!D,!G
M.20<J/F1@2>X8$@ ;ADFD]FWT3U>L?A=FX+WI).VD;MVNEN2[].9:O6,5-WM
MII)QC:[3:<XJ23BG=GY ?\%6_P!IQ/ ?P_B^!GAC55M?%/Q"LA>>,KB*X6"3
M0/ \4A9+>ZF+(+5_$=U"86$CQ$:=!*[!X9R#_*SXV^..AZ,\VF^&($US4XP8
M+B[D)31K)P3AU==LE^R$[4V>5;N00KNH!KK?^"HWCOXW:#^V[\9OAG^T5K<%
MGXB;6H-;\(2Z=!>Z7X+\6?#G58Q)X.U+09+RZN_*2&R0:==:5?ZE=S6.JVEY
M"LVYEB7X.* -M&-C8(02*&QSL^;)5LEB0%8[@2V?ES7]R^&F&P?#O!>6X/**
MV'K2Q])YKFN:4XQE5Q&.Q-"DHPHSBFZ>'PU']Q#VL=(TZ_-%+W3_  I^DK0X
M@\1/&OB/B#Q#P>-P>'R;$UN'>$.%*RG'!Y;D&4XB4,//$U(3<<7C,UJRK9UC
M5A91PT\3C,&G6FL'*$]K7_$VO>*KT:AKNI7%_+N;9 S%+6U#D$0VUNN(K:-%
M*+A5W$1@L[\$XJ*V0J!E>4A1$,X96(*A0 2S.=J*%R<XY/%*!C:-A/ ,HSC>
M&VE ,\%F)V[<YYP1N7 ^NOV0_A OQ&\?+XAUJT-QX0\"F"]OI&CEEM]1UNX4
MSZ!I!94>)XFF@?4;S#,?LMML+1$J:\;Q<\3^'_!_P[XN\3N+*O\ PC\)Y1B<
MUKX=U(0Q&9X[_=LIR?#>UJ0C/%YQFU?#971HTVZLJM2M4TI8&I.IU>"?A#Q'
MXT^)?!/A-P5@Z,<UXKSC"Y5AI0HJ&!RK+X?[1F><XR%"C[.GEV2Y31QN:XJ;
MC&=2G0PU*$_;8R*7WK^RU\((_A=\.;.[U&V,'BSQG%::YKXD ,]C T"?V7H8
M?AECMK=Q<7$0PIO)'=E\T-C[2\$J#<ZHQ.=MM 3C'WM\P[9Z@L..F 17$A2N
M2.69F=F<C+.W+,S<9<DYZ$>H!&:[?P1C[1J@8Y(M8L<X4GS)QD9.>,YYP<X.
M.!N_X]?'?Q#XD\5^(/$#Q$XKQ<L9GW&&;5<WQEG4>'P>'J8F%/!99AHUO@PF
M78*CEV6X.A2C2C0P^"IN%.+G4=3_ +/?#OPUX7\'?"KA/PSX/P<<'P[P;D6
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M"OAA-//]G-^MG[&_[&GP3_8=^#>G_!7X'Z9J\.A#6)?$_B;Q+XDO+'4?&7Q
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MZI?<MON_ ^Q_KJ_R0^BD!!S@YQ2]*8?U]X579593N ^;/)Z@@]"3U"G@@Y&
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MQS;C+"8/$>RKYUQD\-.E@L)*5XT,=0X/P5:I&5#VE2%7B',L7)X>I4HJ</\
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M (8?M>_ 'P%K?B+3?B-/;166C_%CP+X3TU]6O_AY\5Y=,TVXU+4GL]-L9_\
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M5E7BZC@U^A7[)?\ P47_ &3OVV)-3L?V>/BO8^*/$FC:9_;>K^"M3TV\\/\
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M\3=#^(.A:;<6ECK<%DMQ8:WX;U&Y@^TQ6'B'0=2@M-2TN>>,2"VFFADT^_\
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M=6%++ZU+$QS;$RSIX&I7PU'.Z<\OPT:?M:M?"-1P[O\ V)QB1SME8.,J6^0
MY7<Q'7KD*2,$;MR]N/SBU'_@D5_P3JU;5=4UO4OV8O!-YJ6LZMJ6M:G<S76O
MAKO5-8OKC4]1N75-45$>[OKJXG81A$5Y6VA0 !^CL+G<JL#DAMV,D@@/N.&Y
M" _(6QMW<9W$5-LZD8XR"<<\,1@^A;GGL.@[5^4X#.,TRQRJY3F>8Y;]9A25
M6>7XW%X)UZ:M*,:LL)BL-[2";<E&?/&,F[1O='[)F>19-G4*5/.LIRW-EA7-
MT(9G@<)CU0G*+ISE2CB\+B%"<U!1G4@H.JHQE+?W?X__ /@D/^P]^RM^T/\
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MUU/3+F2(DV<DL#6&I*LLVF7M]!$\@X;Q1^W[^R9X'^*OQA^#/C7XT^'O"'Q
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MO%XKO?!/B.'PBZK%+)#=_:1;/K<-E=-&EO%<7&@Q>6]Q%+=1VULLUQ!\"_\
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M(OS#\H?^"V_[%WPK^('[(/C_ /:!\->#M&\(?'/]GNUT;Q[X5\?^#+"W\/\
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MX_\ P_U7XK_ ?XP_"_0[RQT[6OB'\,?&W@G2=0U,3-IUGJ/B;PYJ.C6=W?"
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M)\1C<OQL:V*P]&E3PN(CC,NJXF>$JUJ>#E1J<LG^/?[0G[3/[/7QI_X+-?\
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M\-?LE_LL_L0_LU?$^U\$:!<^/?B7^U!X#\,_"[0K#X+>)O"[7=U;1:!;:/\
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MFED;7,<_X3KULVS/"8OC3$U\SI8F6!X>QN8XNEEF4XS'.51UJV;X;B*K7S3
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MU;]H_P ?3^-_A-X#^(>NZIJFF^%/AZ7UO5HO$?A/1-3E5?!&A?$CQ'XHUA]
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MO7GAK_A+;R."*TAU#Q#I?D7VD7&K);0>5+K%E8V&IWZLIU.ZO6AMVAZO3_\
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MJ6FZ]I]Q/!>V?V;4&LX!JJZ/;0SK=WT##\X4_95_X-X=*AB_:&&I_!:3PQ%
M-;@T6?XN^)[_ $AFLXWF^R#PA)KDGB:ZN/M3Q >';BZGM7NX;>P-E)9"2SF6
M'PM#B3A?AJ6?93Q7765U\UR?)\RX6P&%SN.98>>/I8Z62X^A5=3%97C<+C,3
M.. QN(<H5\'C:DZ<:JH3FWB\7B>%>+N*X\.9[PAAY9QA\GSC.,LXPQN,R">6
MXV.6?V?3SO+:]+V6'SG XK!82%3,,%0C"6%QN#I4%*FL0HP\3_X(P_&1/VK/
M^"AG_!2+XU2V-UI%A\:_"TFL6&FZ@B-J&F>$[[Q=I?AWPA9ZG'&YB_M*R\#Z
M?H,=]&I,9O!.L+",9?O/^".?Q9\-_L8_'C]K3_@GC\?-;TSX:^-(/C)J'B_X
M1OXKN+/0-(\;Z5>+- MGHVI75P-*N-0UC0AHFNZ1:0W^Z[M_MEG9K+>V-S!'
MV?\ P0Y\-:Q\6OC?^W;^W5;^$+KP/\*OC?X]C\'_  1TJ32X-%MKGP;I.NZA
MJ<-IIVFVT=O:VEAX0\,6/@7PZHTZ$Z8M\-2T^SD$FEW2K^N'[6'_  3Z_9._
M;9L[)?VA_A5IGBW6=$LOL&A>,-/NKWP_XOTBRDD266SAUK3)8QJ.GF7>T>FZ
M]::MI]N\TTUO;PSOYM>[QGQ!D>$XFXHX9S"AC*/#^9Y%P?EU:GEM3#8W'Y#G
M'#F4X6IA5)U94\+FLLOJ8FMEN9T54IRKU98AT94ZM%1C\_P)PQQ#BN%>$>*\
MLQF"K\2Y3G_'&8TGF<,5A,NXDR/B?.\9#$P<J%.MBLN6.6$I9EE.)E2J0H?N
M(5H3@^>?P=_P6Z_;%^%WPR_8^^('P)T;Q;I/BGXW_'^UT?P'X/\ AUX6O;?Q
M!XG_ +'U#7M+NM<UR]T?2I+RZM]/N-.LI/#^C-<BWN-9UK6+6TTM+R2VNQ!\
M??\ !0GX&ZY^S9_P0!^$?P5\5Q"V\8>#'_9^B\86"O;.NF>+_$/B^Y\3^)]*
MCGM;B[MKJ+2==UW4=-2]M[AXKV.S^TQ[/.,:_J=^S%_P2"_8(_9+\86/Q'^%
MGP:@N_'VC7 N_#OBSQQJ]UXJO/#5VL31B]T+394M/#NG:E'GS+?6!HTNKV,F
M'L+^T)8-]@_M$?LU_!S]JOX:7OPB^.WA7_A-?A_?:MH^OWFB'6=<T.1]5\/7
MKWND77]I:%?V&HC[+,TC-$+E(IT?$\;IE:^;RWB[(.'*_"& RF&;8G*,DXLI
M\6YYCL9A\-AL;FF-HTG@Z-# 951K5*&%H8++Y3H4HXC&.K7J8FK5K-<E+F^H
MS+@;BCB7#\:YGGM7*,)G6?<&5^#LARK!8G&8G+<GP4\1#,*]?,,SKX>C5Q>,
MQV-DJE>>'P<:-*E0HTZ:E>?+S_[%1_XPZ_9)4GD?LR_ (C: #C_A4WA7/'8
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M+:;HLVF70EU6TTZP^&\?@_4[RXA8(MK?66HC[9IZN[)(8HW?Y P+/AT/VJO
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M)'3 Y_PQ2U,DFE=)ZW>E^EO+7\;"MJWWM?SLK:][+1:;66VA$T4;'E>V,=L
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M5!UJ-*JZ&)IQE&GB*#JPFZ->G&I4C"M2Y*L%.:A-*<N:/RD&,@#H!UZXP?S
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MRH_S^G;_ #ZTVD]_*U];:6ZNUNRMZW#OYV;\[:*_>RVO=K74YKQ+X5\-^+M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPVF^%HOAU-XW\8RQQ_;+C0G\-:?/-XSLFM;0%Y;O1[_3]2@DM(P)1)%Y.SS
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MNROK;57UT('ARI*[0>I.PL03]Y@6?TZ]SC@@\U3GM?.699)$>-X]KQB,;7
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M=PZCIERVGZJEY:"YT[4;>UU&PG,):TO+:WN;<131I(OR5^T'^V=\-/@-XG^
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M^O6N@27TEO=:M8:;,D=VD*LUO--%$1S_ ,'_ -F[P#\/](^&^JZQX*^'5_\
M&#P/\.?"/@O4?BEIOA'2(O%5W>:!X1T[PEJ%]:>*[BQ@\02PWMK8FR@DNWCO
MDTJ4V+RQVX2*/V'P=\3? 'Q)\*Q>-/ /C#P]XP\)7,=PT7B#0-5M+_2@MIS=
MK->)(8K5K8<SI<^4\"Y>5%4 GXH^.W[<O@+1_!^CZE^S]\2_A7\0/%:?'W]G
M_P"&/BK2H=7CUY]-\,?$SXR>%OAYXHU&.PL+^SN)+BRL-9F32]4B>XTVUOW@
MFN1.D9@?.I/"4>;%UI8=VITXQE.5*;LJT:JJ0C*Z<E.I%JI3C*M9J/.HIH^4
MXCQ7 &35O]>,YGD];$+*J?U.K*IE6.EC,-@<YP&9T<7E& JN<,?F-#,\PPTX
M9AEL:N8QIMT5BI0I0HTNZG_97LO$/[2_Q@^*_P 0K'P#XY^&7Q%^#WPY^':?
M#[Q-H46OD:WX+\4Z]XA;5=5T[5[&?1)+(1:G#'I;Q2O=VEU%+<!8@8V3Z;M_
MAUX%C\)P> 8O!7@^/P-:V\%I:^#%\-:,_A2WM+:1)[>VA\/"U_LB&"WN$CN8
MD2V91<JDX(D16'F?QWM/VD;BR\.K^SGKGPCT*^CU*\7Q7-\7-$\3:[:7&G-;
MF+3DT6/PY>V,T5Z;[8;J2Y>2+R,K&J-DGXC_ &8?C!^WK\=Y+GQ5J?B+]F/2
M/ O@[XN^,/AIXST^W\)^.[?Q#J$'P^UEM*\17V@W<GB"YL;1KO;YNGO?JT<2
M'=<*0I594Z6'K*A'#5E/%2Q-7VBP]X2DO9U<1)UG4FX:N$VN5Q2DDHI.R\^6
M8<+\'\14^',-PEQ#B<SXGQN>X]9CAN&J.;87'?6JN"SK/W5SJM6I5(Y=@ZF,
MPU?$X*O.6%PL6XT\/BJL*SC^HVK^&]%\0:1=^'M;TS3-8\/:C92:=J&A:GIE
MGJ.CWVGR1>3)87^FWB3V%U:/& IMYK=HBH5=HP:YWP)\*_A[\,]&FT'X;^"O
M!WP_T2XNFU&XTGP;X8TGPQIUQJ+10V\E_<VNB1VD-Q=M!!!%Y\JM*J6\,:N(
MHUB''>%_VE?@'XT\<7GPW\(_&'X>>(/&]A)>Q7'A;2O$NGWFL>98-LO(;:"*
M79>S6CG%S%927$D0#&155&87_B9^T/\  [X,W>D:?\4OBKX(\ 7VN1/-I5GX
MFUVTTZZN[='"-=K!*YDCM/,/EB[G$5L9 465F5PNZJT+>VYZ#Y&X*LY89\KC
M=\OMKVC]KW/:*[YG*-V[_92S/A2<)9Y/,.&Y4\N]I@'G<L9D4E@&Y1A7P4<W
M=:I]1YI14:F#68X:,O>YZ#C*;EZ#%X>T.SU74_$-KH^BVVO:Y::98:SKEOI5
MG;ZQK%EHINQHMAJ>HP0)>7UGI3:CJ3Z9:7<L]OI\E[>&U2%IYG;BO&/P7^%'
MQ'U+1-<^('PX\ ^.=9\/7#2Z#JOC#P7X>\37^COYB3XTN[UJTNKBQC6XBCN1
M%!(42X19419%4CQ/]IO]K[P+^SEH'PRU74[_ ,/ZI+\4/'_A3POI"77B6STJ
MSC\+ZMJMA;^(?'RWL8NEO="\+Z?JEG?7;VBR1R?:K-3*D,YF7U;QC^T7\#/A
MQX:\/^+/'GQ6\#^&/#GBF-;GPOJ^K:]96MOXALY5$L5YI$8=IK^V:)E=I[>)
MXHU(,DBEAF.?#7JT9/#R=&-&=6%3V$H0]OSUJ=2<:D94XRJZU(U)*[LI1G=1
MOQ5<^X+QM?.<FQ>8</5WD4<KS#.<#F#R:>"P"S>57&Y5C<52QZK8!U,74H_6
M<+BE&595%0J/$5JV(PSJ>A:[X-\-^*O#FH>&/%&A:)XC\/:O"UKJV@Z]I5KK
M&A:A:A@RP7FDZ@;BRN((VCB>&&=7CADB1XA&T:;>>\+_  @^&?@JRTNW\&>
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M^MA\#@J5/#X>OB,11]G7A'"PC!?F#\5_#VA>$OCO_P %!='\+Z+I6@:1KO\
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M:SKHO+R;3+2>*U7Q+;1JO^DQ?9V^C?AI>)!^T3\6/@W\<OV;_@[X.^-/C?\
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M[7H9)WN?$4G@;2I=$\+FZ22:6VB_LG3YY+>-+:%5E1V><RRG<. ?]F'X#O\
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M)VJX2*6U*IKT=ZCD_P 7^!TT/AE_B_06BBBN,W"BBB@ HHHH **** "BBB@
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M[9@MOXC\;W\;:;;W*B273M.74=82-FL@:_IGZ/E3*LCR;COC7-IK#X7+(8#
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M?X_\*W?B>?Q1H$=V^O>'8/#\.JMJSZUH@L;UM6TP6GV_3TL;V2]M8D@D">O
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MK>"WB54@@MX8XXH(D54BA1(U&T#'P#^PX<?&#_@H,02O_&5VW*#YN?AYX3R
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MI3A4G[..$]V7)"%5U%[.^LCR<!XQYYF>)P^6X+)LBJ8_-<ZX%R_*,95S7B;
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MS#\</%>I+N\810QW#67P8^(6MZE=*L?B^T@A@TWX7ZU<E?\ A,8#!X.NI/\
MA+8M$C\29^+?AOA,WR__ (B3P-['&X/,,//,<UP>#Y9PKQ5*<ZV=X*A0C[2F
MXTTUG&#<*==588BO2I2JTL539P1Q=B\%BUP?Q0YX?'86;P^ Q6)=HRC%J$,-
M7FVE*4H7EA*R;A5I<D:DE.*1X1^P[I'VO_@ZO_:>E8972?B+^U[JR_[!NOAO
MX9TQG/< C7".<#+G!R0#_8_^T]^T/X$_9,^ /Q3_ &C?B=%KUQX!^$'A2^\7
M^)X/#&F'6-=GT^Q"JT6GV'FPH[RRO&CRS3Q06Z%KB:1(XV8_R+?\$_K5)_\
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MOAF_DT;QAX)UMK8>7+=:)J<!EL;^-8H]:T&\T?7;:*.VU&)!_'!_P<*?%_\
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M3Z&NJIH-XJNL4VFWGB;Q%X>UF6&=6$EWX?L2N KJW;XCX&/&7B]AN$*67X#
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MW:WN@>._@7IOBF[TJUU&WN((]?\ !OBZUM[35C:PSLPN1I>I7-D7*.5A8*2
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MK6= \7ZEX8LKZ'6)I=*NK/PYXI@TBZUC21J,\%W;Z;/:R32R!TD?\K_V;/\
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MW^F&#Q!X%\8V$3F&:*[TZ[:2RO[9OLFL:7<PW]G(C,5B_&G_ (.M? ^DZO\
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M0/!9ZE, UQ"4)0^B?&']D7X0?%?7/#GBRZ@\5^!/&GA?0AX4TGQE\*?%6H>
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M/]U-_+\5JOO_ ."<CHZCR(!DAC"JMDXQE/E!_P"!;?H< ]:ZB*(%?F!]% X
M XR.^&P3SWSZ5S6D7-FT48C=Y!L4%A:WB(2I!X>6WC4J<<%&8YQ@$=>G5XF&
M7+'@ *(I@5 P22"@.6 P,Y!].*]I[R_Q-_B_/Y7...R6K^7]?<8]X1'JWA?:
M<(/&O@Q6R!P3XGT52<\?+M"CT'+8/?ZU5@1[\DCN,DFOD?59;<7V@%9%5H_%
M/A"8(Y*.1'XET5]R^9M# \(5#;MV-J$8S]:1C]Y(=N,,>>A^ZOZ-R?R/>O.S
M&*YL++JJ=73_ +B:=?._ZG3AY74UV<7]Z_X!-1117GG0%%%% !1110 4444
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MNJQ>!['PIXC:+1_$]KYGQ#AU>#PEX,@T_1/#[VVHZ5>_VG-,L]I/";?]C/\
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M';J^FLOAQH'Q#TJSM]?U#PCH"0:;<ZG8MJ$$=K:Q6=K!Y!\1/V%/V;OV9O\
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M;SH5U#Q-XKT?X*:[KE^T#SS;7N]2O[NY*M+++&68-/(<NWY^?"C]@#]EQO\
M@@QXG_;,U7X>?V]^U?9_"/XB_&SP)^T7JFKZI=?&/X.^)_AM\3O%]Q\/=(^"
MGC=KU=;^&'@[PO-IPF@\+^$KK3M*U2XO-0N-<MM5N;DL/Z5/!G_!/CX,^!_&
M?[/GCRP\3_%+4_$/[-W[)^H?L=^!YM9\1>')[?5?A9J5AX4TR76/%\-EX.T\
MZKX]AM?"&E"'7=-?1M-WR7LEQH5PTZ[)=!_X)_?!;P[^PU=?\$^-/USXCO\
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MFF6T<%@MG%# L=K+!);2Q0V\)@GMY(6AC=&C3\T?V&6LO$__  5[_P""V/Q
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MG_@M;X0^"/B_X<6_P]^&'[4/[/\ \:9/V?\ Q;HFJZKI_P"V?\<_AO\ L_\
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M ++7P\_:$/C/4KOX%:7)IFK1ZIXT\4^';CP]'I5O'-;/IUE%=Q79N#<R/$Z
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M>W6M>.-1N->U*UU_7KB\UQK"VU74M5N[[Y]UW_@D5\*=/\=?$3QI^SO^TO\
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MT86G44H12<VW=;1T:U9^XXE3(7/SG(*E7#="3G*YP,<'T],@5QOC_P ::/\
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M?#SX3:3X@\0ZG<>(=8\-Z@MSINDV_A/P;IXL+344OK7#\-_MI?M)?L:>#?\
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ME<Z]JFJ>&KF.]%K=0]IXW^.'Q#_X);_M%?\ !03X-_#OXE_%OXS_  B^&/\
MP1U\2?\ !1OX7>$_VCOB)XH^,^I>"/CK\/\ X@?$3X8P^&M+\9^);FZ\;/\
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MO),_Q(A^&_BG4)-&NM9U.YFF\4>'GMK37E5VE$GUI\2/V>?B5\.OVE_V5/\
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M?QK=K8?!_P"!_P"W]_P4(\"?%7Q3LEDL/!NF_M&?%CXX^"/#GBS6V@CFDM-
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M:F#QM3 QC%P51?A_^PQX+_X)C^%/V[;_ ,*?\$_O@?HNOWGA;]EK5_'?CO\
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M?5?#>EZ'XKU+Q%XLO+5IH= \.^'KG4]5DL;.]L))XO$_P*_89O?VI_@IJ?\
MP4-T7PTOPE^-O_!-S]FK6_@CX[\<>/?&7P[\):9\0_@QX:BTGXE^$U\0^$_$
MOA:SN-9U+P7KOA/6;&VUJ81W,D,&G:3 =0U-8+KVC]KKX6?ML^)?&W[5'P7@
M_8W\)?M ?$?]H6+QY\,_V;/V[_[$\#Z%'\&/V>OC5HZ^%_$W@[Q_K=CH]OK=
MCJ/PQ\-ZOXFT+2-3FF.M:O:3S1R27.F2"WU/]RM3_9?^"/C/X1_#CX*?%/X;
M^"OB[X(^&GASP;H7AZR^(7AG2O$$-M<>"]#L=#T_6K.'4;>X:PU":TL@LLUH
M\320RRVTWFP2O&WC4LNQ.*JRC+V<E@8QAAOKN&G"G)TL?F-?V&*@Y-XJ,J6-
M<I5</RTVXT.5N<:B7Y=E'"6;\18K&8.IA\+4H\)PP>!RFAQ1P]F%#+95\%Q5
MQ7FM/+,^HU9<N9UZF7YPZ_\ :.0U*^#PU&&4/#U*E?%XNCA_P>^&"_ B3PQ_
MP2U\2?LU_ S4/@%\%/%W_!0+XF:MX \-:OXS\5>.+OQKH%AX2\3>'=/^*45[
MXNNIM>TBW\;0Z*+^R\.W<MQ_9%K'&&D+O)G]%?\ @L+X!\6>)_V-[OXB^!-*
MN=?\1_LV?%SX1_M.P:)99:]U32?@_P"*H->\26UN&29 T6@F]O9GEBE2"VM+
MB=XI0GEM^D%S\-?AU>CP8MYX'\'W2?#B[M[[X>17'AG1I8_ =[:V9TVWN_!R
MO9%?#=Q!I[-8PRZ/]D>*T9K9&$;,IZ^:VAGBEAE DBF1XY8W1)(I(I%*R1R1
M2(8I(Y%9TEBD5XY$=D<,I(KW*67VP^-PU1T.7%T\/!>RHN%&FZ.%IT?X+DWR
MQJTXRIQA-*,$HZ=/U+!<!.EDW$F38K'X51XBP&4815<ORREEU' XG+<EI8'Z
MY0P5%O#TU_:6'PF-P^%HQA3HTL/[*3E6KUIG\Z'A?XN?\$ZOCU\</V=]*^$_
MQ>^-WQ:^+'[1WQ6T[XRVO@3X;Z9X3U!/A3<:'^TO\-/VS]8N_C"=9\/Z+/X'
M\)Z#XX^$UAX9U2RN+^^\53>"[K6H=.LK[7;S0M=MOZ.8%VM*A);A6+?-N8LS
MYXV[< C PS$<@X& O@7PL_9<_9R^"7B?Q/XQ^#WP4^&?PU\6>-I)!XG\1^#/
M".CZ+K&K03W<5_<64EY;6HEM=,FO((KV;2K VNFR7D$-T]J9HHG7Z!CBVECE
MOF55.0,X!8Y! !S\V"3G@#OS6^!I8FA2JK%3PDZM:K[2;P="IAZ;:C&+G)5*
ME64JDW%RFTXQ3E9)J*;];@_(LSR7"XZ6<RR*>8YCCUC,5+A_ 8K!8*<_81H5
M*]3ZYB:N(K8O&U:<\?BIN-.C2K8JKAL/1=&G&JYL9[#Z@\@\]./?\*=28XQU
MXQ_GI2_E[5UGV-]?ZT_K\PHJOO8D],9QT/(R?0\#'4^O>D#G[Q8$#'0>W/(/
M(SMZ <$]^:6JML[OIZ-WWLE=)7;2O?5Z(ERBKW:5M7H]+[+9W?DKO;0?."4P
M.[*,CJ.>J^AXQG/'ZCXO^+W[)]S\4OVN/V4OVHX_B#%H5O\ LQ:)\9]&G\ O
MX1DU63QY_P +;T30M*CNE\6CQ=I4?A1?#IT=KAK=_"?BEM8%R(?M&E&'S9/L
MTN1MY'.>0"."03WP,8'OR>W%?*W[5/[87P:_9"\+>']?^*FH>(+S7?'&IZCX
M=^&?P[\">%M<\=_$GXE^)-+TFXUF_P!(\'>#/#-GJ&M:F-.TZW:[UC45METS
M0K)DO=5NK6V82-T8-8R>(A3P'M'B\3"OA8PHP52I-8JE]7J4W!WLG3DU-Z)1
MYI.4(IS7/BWA51G4QCIQP]%4Z]2=27+3C[&I[:G-WE':<';1OF2CRR;47XA^
MU]^PWXL^.7Q:^#7[4'[/'[0>J_LJ_M7_  ,T/Q-X$\-_$Q_AUHWQH^'?CCX1
M^.;[2-2\:?"CXP?"#4_$7@YO%_AVZO\ 1K?5O#.HZ%XY\):]X1\22/KMEJ-Z
M\<%M'4^%W[%'QBL]'_:B\0_M%?M9>(OCS\:_VHOAR?A;<:QI'@"X^&/[/OP4
M\#:9H'BG1?#6A_!K]G2;XB>-SIDS:CXOU'7_ !UXE\3_ !.\0>*_B!J=O8Q2
MZSX>TFTM=+BZC]AW_@H3\%?V[O"E]>^ 8O%/@;XE^$_"W@/Q/\1_@S\1?#.L
M>%?'/@O3/B/H\NK>#M=AM=8L[)/%7@?Q'#:Z@/#WCKPX]]X;US^S[M;2]\V*
M2)/5_C?^V#\ _P!G7XC_ +/_ ,(OBGX\@T;XE_M/_$6#X9?!GP58:;J&N^(?
M$VO3P++-J=UIVEQ7%QHOA#29GLK#5_%^J1P:%87^K:79W-Y'<ZA AZW_ &W1
MK4\LGAJ\<5@5*5.BL%AI8ZC1PE19BJ=*NJ%2LL#&6'EF"Y:[PT8)U83E%-2Y
M.;*ZM*6-52BZ.*NY5I5JD:%2>+@L)&=6FY0C*O-55ADFI5&W&E*,+*4?SU\+
M_P#!+3X[? UOV8?&/[*W[9/A/X8?&?X(?L5> _V(/B9XL^)G[+1^,GP_^,_@
M+X=PZ3<>&/&6E?#RV^/7P_USX7>,-&\06VK:[;6]E\2_%FCZI%J%OHWB2VUB
M*PCOI+?PO_X)%7/A3X/_ /!0KX3?%C]J3QC\=6_X*(P6&N?$CXA^)?AOX9\*
M>//#OQ+E^'L/@S7O%MFWA77H?!^H>'9-3L-)U?PAX$T[PEX5A\(Z3ID'AJ7Q
M'K[%M;K]G6>1>N>1T49SC'(Z_-WXP0"><#GXS_:1_;T_9T_9:\6>&OA_\1]<
M\9:[\3/%NBWWB?1_A;\)/AOXV^+_ ,1Y/"6ES?9M0\77_@_X?Z/K>L:5X7M9
MRT+ZUJ5M;63RQRI!)*T3A+PV;9[BFJ>$J5<37E*A5Y\/AL++%N."Q,L91D\5
M[!XCV>$Q,_K"E.<:<'4491FI1<<\1@LIP\)SKPHX>CRU*<HU:]>.%_VR'U:K
M3>'C6A2E/$4Z;BK1E4M!N+@TU+X\\0?\$UOVC_$'A']F;QP?VY]-\-_MQ_LH
MQ^)_"/PT_:H\&?LK^']+\ >)/@MXQMM'TKQ%\&OC%^S3K?QA\3:7XWT#4=(T
M*P,?B'1/B7X/U_1O$EI:>*/#MSH]XEQ;W?KW@+]@'Q7XPL/VF[K]NS]H?5_V
MLO$'[4_PB;]G;Q-X5\'^#]3_ &=OV?/AO\ IM-\0Q7_@GX5?!W2?B-\1-2L_
M&.NZSXM\0:UXI^,OC+X@>+?B)?R?\([I/AR^\(:!X>CT>Y^Q?V??VB?A!^U-
M\,M(^+_P.\;:?XX\"ZQ=ZAIB:C:6]W8:AI.MZ'=R:?K?AKQ'HFI0VNK^'?$V
MA7\<MEJ^AZO9V>HV-PA2>W4[:^,?C+_P5J_9/^"/QS^*/[.7B'3/VC/%WQ1^
M"_\ P@O_  LK3/A'^S!\:_BUH_AH?$7P58^/?!RWGB/P)X2UC2&.L>&-0CNH
M3'<XCN;/4[%O]*TZ\CBTA6X@QV(G@Z>'Q%7&8*-2=14,OPD<=@Z,,="O6IJ<
M:$*N#PBS"I"HZ.'K4*,:\VH04:]:%5NGE-&G#$<]*G0Q+I*C*>*K?5\34EAI
MPHNG"=6<*N(^K0E#FE3E.5&GS2;JTJ?+\:_%;_@D#^V-\;_V?/#7[)/Q5_X*
ME7'B+]GGX:MX5?X>:;;?L?\ AG1_BMXCB^&WB/2M4^$EA^T-\2[#XW1V7Q8T
M[P+I&B:=I]Z/!'A#X,7?CK6;.P\2^*[R>6VNM.U/]9OVR?V9M*_;!_9;^,/[
M,>M>*=4\%6?Q5\(0^'[?QIIFE6VKW_AC5],U'3==\/\ B.'1KN[LK76$TW7=
M'TZ\NM(FOK!-0MHYK-;^T:9;F/._9H_;5_9X_:Z\"^+?B#\"O&=QXCT[X?:A
M<Z)X^\-:MX9\0>%/B%X#UBVT^35DTKQ=\/?$=AIWBS0;^_T]/MFCV]_ID/\
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MG0Q=*$%-*,L3R4X5)6YY.G9RBVT_-?VMOV2+K]I_Q1^R1XDM_B'%X _X9?\
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M[JG6]E4="DZ-#VE)58TY3ITXPI1JR4VJ=XR3Y()?A3XB_P""2O[1_C3X,/\
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MHX5QKTY45*.(IU*=:<JE652K"K.-2HJLY574G.I42DYJ46O9PLX]?RE^(W[
M7Q\T#]HWQW^TW^Q/^V#IG[,WB?XWZ%X:TS]H3X<_$[]GC3_VD?A#\2_$7@S2
MQH?A'XG:'X?MOBE\&_%G@#X@Z7HTDMEJ5QIOC;5?#WB2WM].M]1T139O=W'U
MI^R3^SCJW[,WPI3P-XH^-'Q,_:&\?Z]XI\2_$/XE_&+XK:DLVO\ C/QWXRU*
M75]?N]%\,V4A\._#GP58W,XTOP7\.O"<2:%X2\-V-CIJRZA>K<ZM<_4WD*,X
MP,L&]>^>_3UP,#/UIWE#<&W,2"#SC\1Q@8/TZU%?'XW%TU1Q52G4A&-"#D\/
MA5B:E/"0E#"0JXR%"&*J0H1JU:5*%2JXTZ?+%<RA35.J."P^'FZF'INE*;J2
M]VI55*%2K:56HL/[65%2JU(QG.48<TY<TI.\Y\S(N-RX/&U\@8),@/3V4<9]
M0>@PHG&,GC!_^N?ZY/XTT(%.03^/88/ Z=R2<Y)/Z.'7OT R>^,URQVUW;;V
MVN[VV6VU^N_6YU]M+:;>>G9)=+]%TM<6BBBA^7=?G_E<"!R1(#Q@!0>,\DM@
M>HS^O<="/XW/^#@JZLM4_P""N?\ P0S\*I<N^H0_$Z\U.>QCAEA\FTU'XO\
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MV8)R:6T55O.[V225[RT3Y5=MQ3_3O_@HU^UT/V:_VF/V._!VIZ5I_P -=/\
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MOZ5I5^?A1\,_@P_Q0^'=Z;8P7,^N:KXLUSQ4]MI^GS0:786]Y?+]I?\ +?\
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MF1_,$?A2TQ"2BDCYBH)]3UQD_G^=/_G_ "KQ=?Z7ZW^_3\M?9"BBBF 4444
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M.G1A97O>%2K*3U6W+.*C;S36S=X?YX(_0_Y/6B@9QSU[XZ9HKA]=SH"BBB@
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M&-M9:KI]CK,EOKK:7)%:SRV\MO<RHE3]C[]CGXK67[?&I_MH:G^R;\*/V ?
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MERX:@J,)57"A!2]C2A=M?FC^S[^RCXV\)_M2?\%4O'OQ;T7PM>?![]LGXA?
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M9>6SV=WJNF_E;\3V%V;O;\?/LKZZ= HHHIC"BBB@ HHHH **** "C_/Y444
M!Z''7M2+G'/7G/XDTM% "<Y'''?VI:** "BBB@ HHHH **** "BBB@ HHHH
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M35K<CZ?0R$#!R5RO3<,-PPR,D@G)'4G&"3G''S/^U)\(/B]\=O -A\-_A/\
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M^+-.\7:3X8UC6;>.2YT*P\5P6=SX>GU: #[#_: N90UNDH;X&_:L\5_M^_\
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MM_A[TM%%EVZW_+TVMI>[\P_KK_F'^?\ /%%%%, HHHH **** "BBB@ HHHH
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MOP!)+;\V_P VW^/R044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !'7X1?_ #'4?6.&O^@;B3_PX</_ /S(%LQ[X3_P#&?_ "1X]_P]X_X)6_\
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M'4?6.&O^@;B3_P .'#__ ,R!;,>^$_\  ,9_\D>/?\/>/^"5O_21_P#8<_\
M$HO@S_\ -C1_P]X_X)6_])'_ -AS_P 2B^#/_P V->P_\,)_L/?]&:?LI_\
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MCJ/^&$_V'O\ HS3]E/\ \1U^$7_S'4?6.&O^@;B3_P .'#__ ,R!;,>^$_\
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MA/\ 8>_Z,T_93_\ $=?A%_\ ,=1]8X:_Z!N)/_#AP_\ _,@6S'OA/_ ,9_\
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M?A%_\QU'UCAK_H&XD_\ #AP__P#,@6S'OA/_  #&?_)'CW_#WC_@E;_TD?\
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ME;_TD?\ V'/_ !*+X,__ #8U[#_PPG^P]_T9I^RG_P"(Z_"+_P"8ZC_AA/\
M8>_Z,T_93_\ $=?A%_\ ,=1]8X:_Z!N)/_#AP_\ _,@6S'OA/_ ,9_\ )'CW
M_#WC_@E;_P!)'_V'/_$HO@S_ /-C1_P]X_X)6_\ 21_]AS_Q*+X,_P#S8U[#
M_P ,)_L/?]&:?LI_^(Z_"+_YCJ/^&$_V'O\ HS3]E/\ \1U^$7_S'4?6.&O^
M@;B3_P .'#__ ,R!;,>^$_\  ,9_\D>/?\/>/^"5O_21_P#8<_\ $HO@S_\
M-C1_P]X_X)6_])'_ -AS_P 2B^#/_P V->P_\,)_L/?]&:?LI_\ B.OPB_\
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M  #&?_)'CW_#WC_@E;_TD?\ V'/_ !*+X,__ #8T?\/>/^"5O_21_P#8<_\
M$HO@S_\ -C7L/_#"?[#W_1FG[*?_ (CK\(O_ )CJ/^&$_P!A[_HS3]E/_P 1
MU^$7_P QU'UCAK_H&XD_\.'#_P#\R!;,>^$_\ QG_P D>/?\/>/^"5O_ $D?
M_8<_\2B^#/\ \V-'_#WC_@E;_P!)'_V'/_$HO@S_ /-C7L/_  PG^P]_T9I^
MRG_XCK\(O_F.H_X83_8>_P"C-/V4_P#Q'7X1?_,=1]8X:_Z!N)/_  X</_\
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M\/=_^"5QZ?\ !1[]AW_Q*+X-?_-CZ_X>]>P?\,)_L/?]&:?LI_\ B.OPB_\
MF.I/^&$OV'^O_#&O[*8]O^&=?A#[>O@W/)]Z/;\-?] W$G_A?P_V?_4(NM@M
MF/\ -@__  #&?_)'D'_#W?\ X)7]O^"CW[#I_P"[H?@U^/3QB<GVKUSX*?M]
M?L0?M(^-&^'/[/G[7O[-/QO\?)HM_P")'\%_"?XU_#WQ]XI3P_I<]G;:EK;:
M'X8\0:GJ*Z583ZA8PW=\;?[-;RWEJDLB&=,J?V$_V(!C'[&W[*8R0.?V=OA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFL[6-3L-*ABN]2OK+3[-98X'N;ZZ@M+<2SLD5O$9[F6*+S)I7$<,1;?-(51
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M'9.L;''Y9EV.S>A/*GB\P6&A@\<Z=/,*&!I5:6,K?KCG)8DGT&2<9(/7H>Q
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M_P""P'@SPG\<_AGIGPH^(W@'_@G5\8DO+3PGXWD\=_#OQSH&O?M#_ N]\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\0%_8N7X>^,M:\/75OX5\<?\(I\%Y-+\4KX2UJZMTL]>;PWJV_3/$2Z?//\
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MPKE@K;0J[V5@3@@JV0RDC!W8 S@J,U (4EMW4Q>=NBG&V3+^8S8#[Q)+*&#
M.&67=\KMR%;!Y*O%<L3"O]<P%+$8Z6#Q>4?7ZF,S%5*66YGC8XVK1G1=6I#$
MUX/V].EC<57JUU2K3C76)K>SQ-'S<;XJ5<TPV8RS3A;*<PSS,,@XAX3CQ!6S
MSBGZSA.&N)\^PF=8W!RP=3&XRAFF8X6=#&93@,\SC-,3F*RS%U%F*QV8T,-G
M%'YD_9+_ &C;#]K_ /9W\(?&[_A7?B3X6VOC6?QMI%]\/?&<ME=^(M G\&^-
M?$/P^UK3M7FL%BMUG;4- OXIH8P9+1A/:2YFMY#7YW?"'Q9\6_\ @F6?%W[/
M_C_]F_\ : ^-W[-:_$#QEXS_ &>/C'^S+X$;XOWFC^&_'NM7GBFX^%/Q0^&6
M@7,?C?PIJW@S5[R\L-!\4I::MH/B+3KJUC2_BNXI;6W_ &)\!^"?"/PW\)>'
MO /@'PMH7@KP3X.T;3_#OA7PIX9TZVTC0=!T33(EM[+2]*TZT2*WM;*"(!HH
MEB5FDW/+OE:263J)LMDK%(74;6=$D0N,YP'W1[B>3LWLH !"],>?2S7"T,1F
MV&IY5#$9+F->-2.78G%5XXG#<D_:X"IA\RH7K4\3AH.I2G.I3JX>O"K.G5I>
MSC0G#Q*'%^59?B.+<#AN&J&-X)XES&EC:7#>89OFE/&972R?'8O$\.8S!<0Y
M=3EF-+.LKP^.QF$Q&*6 QN"S3"8_$83&9?6I0P=7"_DY\#_!?QQ_:E_:X\.?
MMD_%OX0^,OV>_A3\&_AWX@^'W[-_PM^*$FD6GQ>\4:AX_O;2?QU\6/B/X1T/
M5-8M_A[ VFV%OH7AKPKJMW'XC$(N+G5;*V3R&N>[_P"";OP^\<_#[PE^U9:_
M$+P5XD\"7?BG]NG]I/QIH,7B;1K_ $:YU[PEX@\36$ND>*=)2^MH9=0\.ZO:
MV2R:7K4+3:?J$"M/!<2Q/L'Z6QQ,RD! !L"@2 '.,_,3O9N>IP2<@8.214BP
M2;%VQX(DW\N%4_=R2%)W _,<''[P9X&"-<7Q%B\5@L3@%0P^'P=2GE>'P^&I
MRKS>#PF55\;B</3HU:DU4K3K5L=B*F)J8F52K5JU)58RH.T*;SGQ S'.,IS#
M(5EN7Y?D>)RSA/),KRW!SQ]2GD&4<'YCG>;8##X/$8RKB,1F.+Q^8<19OC\\
MS+-V\=C\7B?;PI81RIX7"?RM^/\ X/\ Q#^+.E?M&^!OVE/V.OVQ?VF_V[M9
M\;_&O3/AAK?B-?$S_L9>"?!.MWFKCX.>.?A7XJ_X6%H_P \.> O#WP_F\.W]
M[I%MI&J?%Z_\8V>I>&M7T=_%#_9+'[<\'_"[XJW2_P#!$R__ .%5?$^QM_A-
MX2CT_P"*T>N>"==TW4_AC<6'[/=OX3DC^(T%S:QMX1EEUNS>Q1=:^SFYNG@6
MWWF1<_MZEL[7+$Q+PJ?+EV08R.CS-&,*S<I$LA.2K<FKPB.%)B^9<@-\N!C;
MPPX/. !P1@'G."?7Q?'6-Q-*-&.787#P3Q=2-&.(QDZ%+Z[D\LFJT<)A9>PP
M>78>GAZCJT,'A:=7DKQ;GB\5&;C'[#,/'#.<=AJ&$CP[D^$H8>OG^)I86CF/
M$%;+L%4XBX#Q/A_CL)D.65)8;+N'LCPN55?KV69%EF%E2HYHW/&9KG$*\ZJ_
M.#]J/XC_ +5_P#^-'@;XR^$/ ?CC]H?]E*Y\&W_@WXR_!GX1>&?#^O?&3P+X
MM.L#4- ^,'A+0)X+7Q!\0M$-J5\/^)/"&CZS]KM(&36HM,VVT\Q^8_A/IOBW
M]JW]O[X;?M=>!/V9OBM^S/\ "/X/_"'XI^!?'/Q&^-?@73_@W\2?VD]9\>6V
MBVOA;P9;?#9Y7\4W_@KX9M97'B&V\8>*X[2*36+EM+TL-)9B)/VTEMGVR%5&
M,$C 52.[8VE.?1MVX$C)[U6^Q/+ $*;PX.6\R3>(R-@!+.69T#L8U,A7."7Q
MN%>7AN(983!U*>'R[#4,;4RS$Y)4S"A6Q5!5,LQ<:D:WUG+*+C@,;C8TJGLH
M8RO:I4IVGB*%3$T,-5C\ME_B LJR+&8# <+912S[%<'9UP/4XDPV89U@?KN1
M9W0KX3%2SGAF@Z'#F=9[]3KSP%'B#,JDJM*FL/C\3E>-S3*\LS/#_P XO[&'
M[7?BG]G*X_;Q\.7'[*_[3GQF\,Z]_P %#?VN=5^'GC7]G3X91?%C3M<\9MXL
ML=/\0?#GQE9Z3JUKJ7P]U&QDA\-:GH?B/Q9#9^'_ !!IGB'4K;3KYI_#%^@[
MS3OV3?CQ\/?V2/V5]#\2?#?7+KXL>+?^"@V@_M,_&/P)X*A?QU;?"F/XD_$G
M6/%.J:1?:KX<M)M,?2/!&BOH]GXD\211Q:#::M_:4R7DUFD5]<_L'\!/V:O
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MM_['DUJ6T%O!=FVAN7C$Z./3AD.28J6=4,'EN.JT<KQ>:QP^5QS.K4Q>.Q.
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MMS(()KFQU/1M:TRXBN]-U?3YY+2ZV31H 86)_-C]K?Q]H_CW]OB?]FO]I?\
M:*\<?LR_ C2?@5X*\>? _3?!GC2X^$=C\?/B!KWB#7=/^(4_B7XMM"T*S_#B
M#2]-LM'\#)<VT<D6J7FM7K222V!3W?\ 9N@NA_P5'_X*6R/;SK;CP7^QK]EE
MDMIX[:1XOA;.6$<C1B.=DV-')L9S@8)R0!A?M*?M&?#?P3\=_B=\&?\ @HA\
M)OAQ9_LK^(M(\$Z]^RK\;?%/@36_&G@G7]17P[Y?Q?\ A]\3-5MK364\&?$&
MPU^!KWP=9VFG6%GXE\(Q_;9KQ[VS:,^1E,*6"X@Q$\NP.*Q"Q'#U+%8;#X2O
M@\3FV7ULSP5&M6K9/#,<)B,/C\;E_)-8>C5HK&3P%7$5()8BBYOYKAC!X3*^
M.\UJ<,</9OCJ6,\,\%G>6Y;D6,RC-^,^'L;Q+D>48['8W@6EQ+EF/PG$>?\
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M"> 0#G)SVSR"#7T;\/=+M-0\:^%+F[MHKAM(U>?4+"65 WV&[.D7]DMS;NQ
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MG4(V2N[?CKCIG:"0=O7KT./8<U^<7_!4_P#;)M_V*OV0/'WQ!T6ZMX_BOXT
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MQG_!4[]JW]C;]JCP1\%OV>->^'>E^'+KX#>'?B+XK7Q9\/K?QC?/XF\4>/\
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M\5>*(_#^FQ6(\3>.=>N/$WBW6$@$S?VCXA\2:@J7>IW[ABEQ>7(60*L:EB%
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M7VK'Q3:/?SB25RUS-:P/(,@H-HS^U?\ P2T_X);^%/V!_!=[XG\8W'AGQ_\
MM->-[=K?QIX_T>":;P_X9T6*YF^Q^"_AM<:QI=CK>G>'YX1;7OB&[NH;:]U[
M5%47<2V=E:0U\6?M/_\ !OUJ?[1O[17QF^/*_M6IX/3XL^-KWQBGAC_A4?\
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MI"3I1Q%\1/DA.K&4\/BITXPG452ARSJ+] #I\$48MHH8D@'F-Y(A58R\KL9
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M7OV9O@#X+_9?^ ?PJ_9_^'\)C\+_  N\(Z7X9M;MXUCO-<U.V5I_$/BG5#&
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M*35*,HTXN7LHR?Y ?LS0Z?)_P6G_ ."G=X! ^K0?L^_L*6#3;HVO8M/E\/\
MC:Z6!F/[Z.&:X9I70[5F=59@Q5,?D-<ZE9>#/V!/V)?C7KK&P^$_[.7_  <=
M_&3XJ_&7Q:$D?0/A=\*8?VT?VS/ ^I>.?$4ELCQZ-X1\/^(/'GAMM8OVC2TT
MVWO_ +9-LA+25_7I;:!H]KJFHZ[:Z5I=MKVK06=OJFM6^FVD.KZG;Z<KII\.
MHZG#"E]?16$<CI90W5Q+%:!V2!(U;!S?^$(\(G0M1\,-X6\,OX:UAM5?5O#;
M>'M*'AW5I=<O)=1UB;4]%-I_9U]+JU_-)>ZI+<VTKW]U+-<W333RR.V>%XAA
M0G3=3#*K"%'(\-5OB:?-R91EN997.$*DJ<I4Y8F.95*M)1BZ=.K0IPJ\])24
M]ZF37HUZ,:\6Z^*Q^(BY07NRQN883,5[NBE2P]3"1ISLU.4*DITTJEDOY^OB
M]^U9^S]^T7_P6,_8.T+X&?%#PK\4XOA=^RS_ ,%!%\6^)/ ^HPZ]X.M]6\;>
M!_A;=V&@:?XHL3+HNK^(-.T[PO+JGB'3-+O+NXT2QUCP_/J2VIU>U1_A+]DC
M]H[Q)\/?V2_^"1?PH\._$/X$?LL:;\4?A=^UWJES^W1\8/A]X<\;WW@0>'OC
M=XVAN_@Y\+=8\37^A>'_  WXP^(%E=3:M<3ZOXBALIM/T"1!I&J7,4<(_K:\
M,_";X8^#HM/A\&_#?P!X1M]';5WTF#PUX,\-Z$FEMKZ6T>O-IW]F:=;"S.N1
M6-E%K!MO*.I1VEO%>&:.WA5'ZK\)_ACKGARR\(:[\-_ .N>$-,G-QIOA/5_!
MOAS4O#>F7+23323Z=H%WITVDV5Q)/<3S/+;6L4CRSRR.2\CD]$<_RZC2PN#A
ME==X'#4(THK$8G"U\1*I3HYU".,G3^K1P4JL:V;QK1PLXRPS=!4YQJ0F[<\L
MJQLY8G$/'4X8JO7G5;HX>M"BHU*V J2P\9JO*NJ<J>"E3E6ARUE[1RARRBC^
M5S]E36K7XL_$7_@N]I7@#X^^._VN;WQA^P_X3TOPI\5_%&B:7H6H_%C4'^"?
MQB\+?VAX&T7P_IFE:1JO@U-?">&O"NN:1875IJ<<$<=OJ6H1K#*W;?!#XM?#
M/XI_!'_@V/A^'?CWPOXQG^&?QF\!?"KXAP:!J]KJ=SX*^)GAG_@F#\5+O7_
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MQBB:* GXG?M:6EK&'6-W@_X8C\9LUM#A@TD*B*&9X5W1EK>*5DW0QLGZV_\
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M?VHR7EQJ;W9,]VDDD2E@QBD5'X&1_/\ :!>RPVZ!=I"!$*3#!X+$98C&!V.
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MK=DD_1W^_P C_/G&<T*U.BKRO6G3UTUYYPC?R5E==$GK<^T- N(S$$8@*%+
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M9=@,RRG&9@I5ZF-IN>-JT\'B?8PEA7&5>:E*M"-23/\ .&E5[;PZ^-I>#16
M8,-BRI8I''EB!P^P.Q. @D60DXY_TXOV:OA[8>'OV3_@1\+=6M$?3]&_9Z^%
MG@;5+*11M>WL_AEH.AZE#(KC&)%6<,3DK(S$K@U\'?\ #A;_ ()D!53_ (45
MXE*+Y>%?XW?&=P?+:-E1E?QR0T1\L)+$<K+$7BD#QNZ-^P-O81V]O#;1!8HH
M88H8XXU(2..&-(HHT4LQ")$@1078@8SDC)];Q+X[RWBRGE-')Z68THX#%8O&
M5I8Q4:*G6G3HTL*Z4*56K*#I4\-0A&;GS1E!S7+=J7U'C_XR\/\ B=0X6PW"
MN'SC!4LDQ^;YCB/[4P6%P7+5Q,*&$R]866%Q^,JUJE+#87#UJ]6NX2^L^U=)
MQ7LTO\Q']JGX/7_[-7[0WQX^"^HV\L0^&7Q$\4:=HL#*?,N?"M[?2ZSX,:#<
M5:59-!OK"SB=1(LT]L3'DG:/[\O^"8O[/O\ PS)^PW^S_P##6ZMA%K__  A]
MKXT\6M&%+R^+/&[/XHUIII%=R[Q2:B(1N9B#&  NT**7QS_X)5?L2_M'_&>3
MX_?%_P"$EWXD^)TP\*BZUFS\?>/O#>FZA_PA=R+G0&U+P[X?\2Z=H>H/ RJE
MXUW82?VE!''!?+-"BH/T'M]/BMK:*TMUC@@MHXHH(88PD<442"..-$W$!$C0
M(J]  ,<5S\<<?0XHR+(LKP\<33K8:E"MF]2M0HTH5<?3P=*A&6']E6JK$4W6
MC4K1JUH4IQ=27N+5G%XP>-=#Q(X,X,X<P>'S'#XK+X8?'<45,7&%"AC,XP^4
MX?+J/U;V.*Q/UC#PKT\1F'M*D,-.53%2BX)\Q_F__P#!2;P@W@'_ (*#_MD^
M&S%Y"#X[^)O$MM&!A1:>/;+2_'5JZ)\N%\OQ(#A.,(YP2WS_ -,/_!#OQ@/$
M/_!*_P"*?AB1]TGPW\=_M >&HHW8,$M-8\,VGCFW"@@C89/$]T\( V,I!4$'
M)^_?CQ_P2+_85_:4^+7B[XX?&#X3ZUXB^)7CHZ(?$^MZ?\4/B7X8M-0?P[H-
MAX;TJ0:)X<\4Z;I%N\.D:99V\KP6B27#1"2=Y'))]I_9R_8-_9O_ &3_  !\
M0?AC\"?".K>$_!7Q0U.?5_&FC:AXW\;>*FO]0N= B\,7$]EJ'B77]2U#1VGT
M:&.VF_LVXM_,D2.Y)\Y-S>IQ)Q_D>><(Y+DZH9HLSRRMP_7G5JTJ,J#GEJHT
ML8X5(8J,IJ=*E[2FYTU*4VH2DFG-^_QYXU\(\7^&'"O"L,+Q!#B'(L5P3BZU
M:ME^!AE\JG#=#!X+&N.)IYC/$8B=6A3Q%3#N5"A&?+1I5.5WFO\ -'M%8^'%
MW*<'2+D9 P!_H\_?Y5P !SWYR#TK^W_5]5_;!TW_ ((D? G_ (8GT!->^*%]
M\#O!FG^()-)OV7XCZ'\/)M-G_P"$LU7X2Z3) ]KXB\?1V8\C3+&6_L]1M[26
M\O?#T=_XB@TNS?VY/^"!W_!,..V%HOP+\4^2('M]I^./QHW&)U9&#./'(9F*
ML07+;L8&[  K]2/A;\)O!OP8^''@SX4?#O3[C1/ WP_\/V7AGPKI,^I:EK$^
MG:/IL9CL[>75M7O;S4[Z2-<9N;RZEN'_ (Y3@&MN./$C)\^IY#+*\%B<14RK
M-Z69XC"9QAZ:P%=4<-"C&G%4\36J.-1TTY4IVI)\DY<_L^2IU^+OCUPIQIA^
M#)9#DF,QM;ACB>&>U\MXHRW#QR;&X>A@<)AZ>$K1PF85L35CB*U"I.I%OEIJ
M=.35;V3IU/\ +BLKBYL;V*\L+K4--US0]4,ZWL%UJ&D^)- \06$[O=&6X+P:
MSI.OV-ZMQ'??:7MM5M[I9TO$AF26*/T;XD_&#XN_&2^T;5/C#\5?B)\5-1\.
MV#Z;X?OOB'XQUKQ;/HFGRF-IK;36U>[G6R$YCC6=X8(Y+SRXUE9F !_T$_VG
M_P#@EE^Q-^UUK=WXN^+WP9TZ/XA7J1K=_$[P#JNK?#SQ[?M%'#'%)KNL>&+V
MTM_%4D$<$45N_BK3M;:WB01PE(VD5_F?X>_\$!_^"<O@36XM<U3X?^/_ (IO
M;RK-;Z/\4_B7KFM^&A(C%A]LT#0E\-:?J\1)S):ZS'J%K< !+B&1"R'Z^AXS
M<+5L/2Q6,RK-:&9TJ<H1I4L-E]=4^>G"-6GAL?4JWITZLH))JC24H)2J48R4
M5#]0P?TK/#>OAJ&9YGPSG^&S["X><*&%IY;D^9RH3G1BJE' Y_4K86M2PM24
M*=&+GA</5GA:=*EBJ?+%PE_.]_P1<_8&\9_M1?M"^$/CUXET*YT_]G#X'^)8
M_$%[XFU*%K>S^(GQ#T5C+H'@WP>TK8UJVT;45&H>+]5M$?3],6*WTTW?]ISI
M"O\ >$5'S_*#DMD#N2#_ %&?:L'PWX2\/>#="TCPMX1T/1/"OAG0+.+3M"\.
M^'=(L-%T+1M.MU @L=*TC38K:PT^SB (CMK2&*)"=P7.2>D"@YZCGGTY';VY
M//7KT-?B?&'%F,XPS9YAB:4<+AZ--8? X*$G..'H*3E.<JCUJ5\14:JUYM).
MI?E2C%7_ )'\5/$O,O%'B3^VL7AEEV P6$AEN298JSQ$\'E].52JY8O%*G2C
MBLPQ=>K+$8S$4J%"BY>SHX>C&EAXRJ?P!?\ !<M2W_!3;X[J!N)\*?!S:@&<
ML? &G < ;L'*HQ4$#!P2 <?JA_P;(8_LW]MC!!!\0? ;!QG(.C?$SD-M&X'G
MD< G!PVX#]AOV@O^"2O[#?[4/Q9\2?&[XT?"S7O$_P 1O%=IHEEK6M:?\4?B
M9X8MKJU\.Z7'HVD1QZ/X<\5Z9I-JT&G11P336MG#)=; UPTA+9]B_9-_8-_9
MF_8DC\?Q?LY^"-3\&1_$Z[\.WOC$:GXU\8^,FU*?PM%JL&B&!_%VM:R^FI:P
MZUJ*&+3VMXY3,&E5S%$5^WSCQ R7,/#[#\+4:69+,*."R;#\U6A26$Y\!757
M$6J+%2G[-I)TG[+5J-XPMI^M\4>-/"6=>"6!\.L)A<\AGV&R?AC 5<17P.%A
MELZV38W#8C$J->&.G6]G[.E/V%1X92J3=IQI\S:^P!CZY!Q]>WU_^O4]-V#.
M?Q_7/_UOI[\TZOQRZ:6EM-?E=?Y;:=M+'\M?U^?^:"BBB@".7[A]R,=?4'MD
M]NPZU^./_!0W_@JCX3_88_:0_8Y^#NO23P>&OB_XJ\6ZC\=M9/P;^/7Q&U;P
MO\*-"\#Z[?Z)>?#I/A=X-UZS\3^,-5\;6>GZ;JGA[18O%OBK1M!)UB]\,6.C
M3OK=M^QD[$1G SDC/08 .<\__7/6OQ)_X*=:UIOA/]MC_@C+XR\3ZQIWAKPA
MH'[5_P ;+77?$NM7]MI.A:5)K'[-_BR#35U35;R2"PT]+V:.XBB:[GACED5H
MP^YP#Z614,-B<TC0Q>'J8FB\'FE2-*G)0?MJ.3YA6H2N^;GM6H1FH\O,Y0BT
MI.*A5\S-ZM>C@95,/65"I[? Q=24'-*%3,<#2J1<8M2]^G5G!M-<L92?1M?:
M?QX_X*&?LF?LT^,/ _PY^*GQ&\63?$SXC^#[GX@^$_A=\+?@C\>OCY\4+CP%
M:SVUC-XVU?X;? 7X:?$CQOX2\*&^NA86^O\ BW0M"TV[U2WU#2K">XU#3-0M
MH-"X_P""@/[(,'[(=M^WJOQPT:[_ &2;K3K#5$^,FD^'O&^N:<EKJ?C>#X9I
M;W?A;1_#5[X\TW5=,\?S_P#")>)]!O\ PM:ZSX3UZTU.R\2V&BOI6JBU_-CX
MI_'WXB>(_P#@H-^UY\+/V?/''[&G["M]\'_@Q^SAX@_:#_:^^.GP\@^)7QC^
M._ACQ/X4\7>+?A]+X(T:?Q[\)?"K?"_X.6MQXAT#5_$?C;Q/XFCCUO6;VST:
MTTX6ESO_ !GU;QA;>,?^#<__ (*W>(?^%CR_%;3=1_X*+_%_4H?B-J&B6W@Y
MO'%IXF_:Y_9^\4-XSF\%6?EZ=X'7XB/XBF\=2>$[&*WL]-/BIXXXY//:XF]K
M!<+X>OA\NQ%2IB:+Q&+X8HXBG3J4ZE:6&S^IB(QJ4)_4:.$P]1THQG1IRQ>/
MKQ>N-CAY2=.EYN)SVO1K8NA2ITJGLL-FU2E4<&J:KY;."C2E3EB?K52+E)QJ
M26&I8>3:C0KS48N?]!GQ9_X+'_LI0?LE_M4_M'_L[?$*_P#BK<?LZ:/::;:W
M.H? _P#:.MOA_P")/B#XR/B#3OABNDZZGPRTZ/QY\-?%?B+PYJ%L_P 3_A[J
M6L?#BQTV)-9U3QOH_A^]T_6+G0\#_P#!8[]BW3OV7O@'^T!\=?C3)\/&^+FA
M2Z/LU#X'_M#:%!K_ ,6/"?AW0-4^(WA7P)X6U'X:S>)]?6UU;6X[#P4NE6^L
M0^/C)#;^!M0\67'F,?>/^"CV@?9?^"=/[8GA7PAI"V]O8?LN_%'2/#_A_0[8
M6EM8:=IO@N\M+/2])TZR$<=M9VFG6\<%O:6J1PQP1"*.(1@1C\J+S7? /Q0^
M*7_!N;J>F:YX;\=:;I_AGQ9>VUYI^JZ;KEK:^*?#/[+OAB-=[6]S<PP:UHEW
M++NMWVWNGWBAO+@EA^595EV2YAETJU2AF$%',,SYL1''X:6(>!PG#F(S'#X:
M7/@)4HSQ&,PRYY\N\JD*2;BK\^8YAF6"QZIPJ8:HIX/+TZ?L*M/#K%8G/:.!
MKXA*,W4DZ&'KM4XJI:=E.<4FI1_3OQ!_P50_8=\-_#'X-?%G4OB[XM;0OVA]
M5\2Z/\$?">E?L_\ [2&O_&WXD7O@IKY/%O\ PCW[.>B?":^^/1L/#;Z=/_;N
MLWGPYL]"T^*:QN+[4H+?4]->[\Q^/?\ P5D_9S\+?\$_OV@/VV_@!X[M?B?'
M\,[?XH?#KPIH>K_#+XVV5WI_[4'A'P[J4_ASX._&_P"'$?@K1OBQ\'7G\21:
M)#XINOB1H/@"Q\.>&]:TWQ+KFN:'X?UG2]<N/,/VO?C)X^B_X*,?"_X!_ 6+
M]E#X!?&Z_P#V-/$WQ'U[]MO]I+P?-XX\967P:OOB_#H>J_ KX)^&[3Q%\/CK
MFI6GBGPYI?Q'\9P>)?'W_"+Z;9-H=S/H4MY-;W1_*GX-^+[_ .)'[)/_  =
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MGF5>%!X;$K&X&OC,1]1E3HPE"G4JU%-PA7Q:GA:=-UI4*D5 VP6-K8O&8/\
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MV-/U+1?B)\8=-L)O"_AZ;P]J3QZ=XMO3/<Z9X0O9)+?Q+?:9)9WHL^W^/_\
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M-5\+6UQ;VUYXF\/Z)XVTC2)O$.B6%S<P6NHW>C->#3IYH5ODM_-C+_F1\5]
MTGP-_P %,-?\/>$+*VTG0/&G[3W[!WQ?\4V&G0_9K%?B=K/A?XR>#M6UDPQ;
M+>/5?%OAK1-.FUB5$6?56T*VN;PS-;!Q]S?\%"]$M;/Q]_P3W^(NB:?:_P#"
MS= _;D\ ^#_#>O1QHFMIX-\??#WXG6OQ(\+Q7*!;BXT'6]#TF#4M7THL;6>X
M\/Z9?S)YFG0N@!]>_$G]HGX1?"3XD_ ?X3^/_%L6@^._VEO&'BOP-\&M%EM+
MN;_A*?$?@SP3K'Q#U^R%U!$]MIZ6?AO0[R9+B^DAAN;Z6STR!I+N]MHGV?A!
M\;/AO\;;'QSJ'PXUXZY!\./BQ\2/@GXUCEM;JRN] ^)7PI\1WGAGQIH-Y;7D
M<<H-M?VRW=A>1AK35='OM.U;3Y);"^M97_$7_@IAK-_=_M&?$'XS6B)J>@_\
M$SO@5^R3^TO<M$9A/H&I>)?VU]'^)/QO2"157R[N;]E7]G/Q1INIK&SD:#XY
M1#D7#H?KOP7XJT7]E3]O3]M[PMK]TNE_##X^_ KPE_P4%\-RE!!H]EXQ^%&E
M6'P _:AV3$^4)I- \.?LU>*[HQE3/>^*M5NY%9VD<@'Z#^!OC!X"^(_BOXG^
M#O!^M/J^M_!OQ98>"_'Z16=U%9:/XHU+0K'Q*NB)?2H+:^O;71M3TZZU".U>
M0V(O;:*;9)+BO5J^ O\ @FOX-U;1/V5O"GQ#\5VLMGX\_:5\3^-/VI_&\4\K
MR3Q:C\<M=G\7>&=,F610\<OAGX;R^!_";PR'S(3H94[""B??M !129ZCT_7C
M.!0#DD8/U(XI-I;_ -?UYV CE) 7 /W@3T/0],'U_H:\I^+/P7^$'QY\)77@
M#XV_"KX>_&#P+=W$%]<^$/B=X/T#QOX9EO+=66WO#HWB2PU'3_M<"NZQW A2
M>-)'59%5V!]4F9@HV\ ,-Q..@Q@@Y]2/Q!_'\TOVY_VL?C!\*/'/P9_9L_9I
M\/\ @/4OCY\?O#OQ9\76OB_XISZTW@#X5_#KX1>&(=5\4^,=0T'P]<:?K7C#
M7;J^U#3M(\-^'['5]+A%[))?ZI=&RMQ:W6^"H8G%XRC0PDU3Q#FY4ZDJLL/"
MC&,5*IB9UXM2A3HTY251IMJ,F[-Z''CL3AL'AZM?%*]&,8>T@J?MW5E*;C1I
M1I[^UE4BG3>W-%/[-U]-?%']DK]EKXYZEX5U?XR_LW_ SXLZIX'L4TGPCJ/Q
M&^%/@KQC=>'-%@+M%HFD3:_H]_)!HD,DKSPZ,"VEPW0%REJMPD<B]O?_  ,^
M"FL>&?&_@_6O@Y\+-7\*?%'Q-+XS^)GA;4/A]X3OO#GQ#\7F?2)_^$K\;:+<
MZ3+IGBKQ*)O#OAZ3^W->M;[4S)H.D2_:=VG6?D?F_P#\$O\ ]IS]L'XM>%?#
M?A#]K3P!I&K?VO\ L[_!?XZ_"[]J'X=Z5K>G> _BEH?Q MM1L/$?@3QQI>KW
M>H)X9^-/@36-,@N-6MM)OYM&\5>'M;T_7=+T_1$BFLVY3]H/_@K-%X3_ &NO
MV>?V7OV>?AO<?$S1O$'[7_@S]ES]I_XZ>(='\2:3\*_A3XO\5:1XFU6+X1?#
M_7)6TBV^(GQL^S>&];UCQ$_AU_$/A+X9V6A/HGC&0^)?$>EV&G][R_.:N,GE
M='$SQDL!"K5C.GF4YX*CAZ+Q.+J5:$GB/94TYX>K)*-*A7J5[0C36(DYKC^O
M9?3PM+'U8*BL3.C1A&I@U'$U:M9T:<*4U[)5)M^VAJISI0IN51RDDC]E;^UM
MM1M9[6]M(KJSO(IK:[M;F&.>WN[6Y1X+FVNH)D>&XM;B)WBGMI$:*>)WC=2C
M,*\4\"_LR?LX_"V+08?AM^S[\%? %OX5\0:]XL\+Q>#/A?X+\-KX9\3^*84L
MO$OB'PTNDZ-:KH6L^(+-(K76=0TO[+<ZA:(EM=221(%KW/<3C P,8Y.>."A.
M>YR,XX.0*_,'XV?M9_M->)_VMO$G[&7[&/@7X,3^-OA9\*/"WQ@^,OQ2_:)O
M_%[>"-$T_P ?:CJ-CX%\&>$?"7@&]TWQ'KNM:RNDW]UJ6OW>K66E:'!Y:"QU
M.X#1#S<%2Q.*]M#"UO94HX:>+Q56KB'A</2H453C]:Q'/6C25.,<3&C!.FVI
M573ES7<7U8RMAL,J<\1!U)RK4</1ITZ$<16JU:KG..'IN--2<G.A*M.;G&*]
MDJB=-QN?:/QG_9R_9]_:(L] T[X]_ [X4_&FQ\+WDVI>&;;XH> O#'C=-"O;
M@QB[GTI?$.FWYL4U".UMXM4A@:.VU&W@A@OX;F%%C'2^&O@Y\(O!8U]O!_PL
M^&WA$>+- \*^$_%:^&O _AC0E\4>&/!&@2>%?!GAG7UTO2[9=8\.^$/#$\WA
MOPQH^H"XT[0=!EDT?2K>TT]C;U\N_L%_M>Z_^UCX$^+MO\1/ 6E_#CXW?LV?
M'?Q[^S7\<_"OAG79O%'@A/B1X!72[F[U;P'XAN[:RO\ 4O"NOZ-K>CZQIR:G
M9P:GIOVR73-062ZM)99/CS6OVM?^"C'Q<_;H_;A_9=_92\/?L7Z;X(_8Z3]F
MA)]>^/>G?&:]\5>*G_:$^#B?$J)TD\">+--TB"WT;6+#6],^:PA86$^E.!<S
M1WKGMC@<QG6Q.7U,7##0RO#O%UEB\SJ4<!AJ4JV&C3G2G*JL.W6E6PU>DJ6'
M4I\U&I[J2DN9XK PAAL9&DZ[Q]7ZK1]C@82Q56O&GB74@XJBZJY:="M2JNI4
M<8\E2FY2;L?I%8?LD_LLZ7\*]=^!NE_LV? G3O@MXFUF]\2>(OA+8_";P/:?
M#C6O$&I1VXOO$&H^#+?1$T&XUJ9;*S5M5:Q-^/L=ILG7[-#Y>9!^R/\  CPU
M\ /B/^SG\'?AC\.?@;\/OB7X0\5^%]2TWX9?#SPEH>F6T_BW0[K0KGQ#<>'X
M-.BTC7-:M(;@2P3:W%>!Y+>W2=I(8Q$?FW]C3]LOXS?&#Q_^U3^S+^TC\-_A
MM\-OVH/V38? .I^)[GX:>*M8\1?!7QOX4^*_AC5_$/@+Q7H.IZ[!:>)M B@;
M1[VQ\5:)KZ&]TV2,3V=S>VDJ7%<%<?MR_';PE>?\$OO#7BO3/V:O%_B']M#X
MM?$KX=_%[Q)\%?%GB'QY\,-'T_P?X6\7^)=)U'X,^+HM1ACU:23^P].LM:N-
M;BU"W@OUU:QAA26W21-U@<[6(JX58JK*I3JPS!TWF%2K1K5(X6MFU#,(2G7G
M0Q3>$R^=:-9MSG.G&#IN?*XP\9EDJ,*\Z452JT_JM_JSC5A[2O2RZ>$FO90J
MT4J^*]C*FVI0@W*,_9Q:E^CGP/\ A'X2^ 7P?^&?P3\"07=OX,^%/@GP[X!\
M,K>R)+=_V/X9TZ'3K)[EXUCC-Q*D'F2B)(XEDD,<2*BA:YD?LM?LU?VU\4?$
M3?L\?!!M<^.6E?V-\:M6?X5>!Y+_ .+^E?:KJ_DTWXF3OHI?QQ9RZA?WU]/!
MXD&HQ7%U<S7$ZR3.7/P-\#/VY_CY\;GBGM;']F3P=:Z'_P %'_C)^R;XIM/'
M?BWQ#X4UGQ/\'_AK:^*UTZX^$=G=ZG<CQC\=]3O],TV\E\.*1I,V@Q:]J$%C
M"+ E/NGX@?M>_LJ_"?X@Z/\ "3XI?M,_ #X;_%/7C8G1OAMX[^,/P_\ "7CO
M54U201:0UAX5U[Q!8:Y.-7D94TLBRQ?R,([,SMC..*P&;X?%U:4_;UL;6]I6
MQ*P3Q&)J5%"I2Q-2I76"IN5E/$4ZGM'"4(2FZD)TJB2>M#&9=5P].5)T:6&H
M*E2H^VY*,*:Y)QI1I2Q,XQ]VEAIQ<5-2=./+/FBW*/K_ (@\ ^!?%^EZ/HGB
MSP5X1\4:-H&K:+K^@Z1XC\-Z/K6EZ)K7AJXANO#>L:18ZC9W%MINJ^'[F"&?
M1=0LHH+O2IX8I;*6!XT*^9?&S]ES]F_]I./1K?\ :!^ GPB^-2^'9FGT%OB?
M\/O#'C2;1FD8/*FE76NZ?>7-C!<-S=6UO*EM=$+]HAEVBNV\<?%;X:?"]+.3
MXE_$GX?_  ZCU*WUJ\T^7QYXQ\/>$H[ZT\-Z3/KWB2ZLI-<U*P%W;>'M$M+G
M6-;N(<PZ9I=M<7]Z]O:QO,F%\&?V@O@5^T/H&H>*?@%\:?A-\;O#.FWS:5J7
MB#X1_$3PI\1-(TW5$RQTW4-1\*:KJUO97S(HE6UNI(9FA(D56C99#PTWCJ,(
MXS#RQM*%.34<506+IPA*3E&=L72C3C1<K2A-K$<DVG&;E.5GUR^JS;P]5X>I
M)\JE0FJ%2>UXN=&4I2::]ZFI4N>*NZ:Y4VO1/#OA[0O"FBZ/X8\,:#HOA?P[
MX>L;72]!\/\ A_2;+1=#T+2K%%@LM-TC2=/@MK#3+"U@C6"VL[."&W@C58XX
ME0!1S]I\+/AAIOAWQ?X,T[X<^!;'PE\0M0\7:IX^\*V?A'0+;PWXXU/QXDX\
M<W_C#1(-/33?$U[XR6ZN%\4W6LV][/X@%Q.NK/=K(X;Y,\&_M4>.?$?_  49
M^.'['E[X>\*P?#SX9?LS?"#XTZ)XEMAJP\97_B7XA>+?&N@:MI6IO+>OHW]C
M65IX=M9M/%K80W@FFG^T7$B>6JY/[2/[7/CWX.?MS?\ !-7]E_P]X;\(ZGX)
M_;/\0_M9Z5\1M?UA-8;Q3X6@^ ?[/=Y\7?"S^#'LM0M=+BFUC7H$T_7VUFQU
M-6TDE-/CM+MOM*;RP.,A6I491E[:O@%F\;5FO:X:.$KYC'$5+2:G.GAJ-:K#
MVDI5*=3WXN-35YPQ.%FN:+YH4L14P+4J<7RU95HX*=*+E&*4)59QBXQ2C*G9
M)231]EWOPR^&U_X>\)^$-1^'O@B_\)^ [KPQ?>"/#-WX3T*Y\/>#;[P4UN/!
MMYX4T::P?3O#]UX2:SM#X9GTJVM)="-M;G3'MA#'LX'XW_LS?LZ_M(VFC:?^
MT!\"?A/\:K+P_,]YH47Q/\ >&O&C:'<3/&\[:1/KNG7=QIHN3%&;R.TFBBNU
MC1;B*8*H'IWCCQ;IO@/P7XP\=:TMRVB^#?"^N^*M52SB:>\DTWP_IMWJ]XEK
M @+27,EM:.D* $M(R@\$U^%_@W]LK_@K%\5OV9XOV_\ X9?!W]D+4_@1K_@Z
M?XQ> OV5I[GXGZM^T3XF^"=M%/JP+?%+1-;;P'%\6M1\/6DNH:?X8L?!^I:.
M]_+;:,T[Z@7CJ\NP>.Q*CBL)BZ>"C2K4L/0Q6)S&>!DL?C83K0PU"NIIO$UZ
M475E*4X1GS1=2=Y*V6+Q.$H_N*^'J5G*E4J5*%'"+$+V&#E",L14BHSY:5.4
ME""5/F5FHK1M_MU;_#+X<6W@%?A/:_#KP';_  K&B/X97X9P>$- C^'Z^&Y(
MMDOA\>#H[!?#O]C2QLT;Z6=/-BZ95H2,YX?X(?LO?LX_LX0Z[:_L_P#P$^$'
MP4C\420R>)6^%WP\\,>"9]?-I)=26*:S=Z#IUG<ZG!8&\NCIMO>336VFK=7"
M6,4"RN#UOP?^(EI\8OAA\./BQIFA^(/#&G?$3P7X>\8VOAWQ9I5[HGB;0H_$
M&EV^I'2-=TC4(+:\T[5M.:=K.\M;JV@FCGC??$G('GW[6_[4/PT_8Q_9R^+/
M[3OQ?GU"'P!\(O"RZ]J=GHUG)?:[XAUC4]3L?#G@WP9X=LXP5NO$?CCQCK.@
M>#_#\5PUO9G6M;LC?75G9)/=0\T?K\ZDL!"IBIU,7B(T:F$IUJW)BL4JCITX
MU::Q#IUZJJ\RIRF\2E*7M>:3G+EWMAHT_K,XTHQH4G5IUY4X*="AR*4G%NE[
M6E%QM[B5*3LH\L8J*EU?AWX%?!;PC\2?%_QG\*?"#X9^&?BY\0-.CTGQY\4?
M#_@;PUHWQ#\8Z;'+:W4=AXJ\6Z;IEMKFNVXNK&PN'AU*]N$>>RLY&W/:0&/X
M#\)?\$S_ (=>*?VCOV[/B=^U#\,O@=\>_AO^TK\4/@E\0OA;X6\;>"=/\97W
M@V7X:?"Z3P/J\^HIXETZYM]-U6]OG\RUGT.4+-IDDMO>,RRRQ-YU'\3?^"W6
MI?#>3X]0?!+]B7PX[Z8OBRR_8UUW4OBMJ'QE7PJUM%J;>%M:^->GZY%X'L_B
MW'8&:R;3++P7<^%HM>1; ZA/;J]U7Z%?!#]IKPC\7?V9_ O[4'B/1]>^ _A'
MQ1X)_P"$S\5Z+\=K4_#76?A7]@FN;#Q-IOC[_A*AH\6BIH&IZ??0-JNH+8V5
M_8QVVKV^VRO8#7J5*.:Y53KU:.88>L\6Z.75)Y;F/UO%T*F&KT\51PBK4W3Q
M-*2G0C["IAXXG#UZ<:E"E4E&]-\5.K@<=*G3GA*U*-*,L;3CC,']7P\J=:G*
MG5Q$X5W[)WA)^UA-4JM"4X5)PBY<Z]-F^#_PIO/AU!\';_X6_#N[^$5IIMAI
M$'PON? _AF;X=0Z3I-W;WVE:7!X+DTUO#D5CI=]:6M[I]JFFB&SNK:"YMTCG
MA1U[K4-,T[5=)U#1=1TO3]1T74=.NM+O])O[.UO-,O\ 2[NW-E<Z;?:?<Q26
M=SI]U:236ES9W,4EO-;.\$L;1.T9\7^$'[4'[./[0FDZ_KWP$^/_ ,$_C7HW
MA78/$^J?"SXH^"_'MCX:\Q)9HSX@N/#.M:FFC*\5O<7"2:E]F66"":2+>BNZ
M_,'[$?\ P4E^"7[<'C3]IGP)X!\2?#NV\2_ GX^_$WX5^&/#>E?%3P;XO\5?
M%7X5_#6R^'-G<?M%>'/#VBWS:BWPK\1>,?'A\.Z)XELK?4O#YN(M+MY-<GU+
M4/LR^9+!8_EQDYX;'?[!.C4QKJT\7!X:ICJL<-1JSEB.2:J5:U-/ZPW&4G:J
MZS2A679]8P49X>$:^$Y\6JM/#JG.C)UZ>#IRKUJ4525G&E"I9TDG&"_=JFG*
M49?1GP?_ &1?V6?V>O$/B+Q9\"?V</@C\'?%'BY9HO$?B/X:?#+PAX-US5;2
MYN(+RXL+K4]!TJSNQI<MY##=MI44L6F_:HTN?L@F425!K?[(/[*WBCXLV?QW
M\3_LT_ CQ%\:;"XM+JU^*^M?"CP5J7CVWN[#!T_44\3W>C3:F=6T_8J:?JC7
M#:A9(J1VUS$JJ!9T/]KK]EGQ+\5]1^ WAS]I3X!Z_P#&_1+R]TW6/@_HWQ?^
M'^J_$[3-1TR5XM4TV\\#V7B"7Q'#JFER121ZAIS:<+ZQ=-MU;0'*C7^,'[3'
M[.W[/2>'G^/WQY^#/P03Q;>2:?X4/Q;^)W@SX=_\))>1%/.AT3_A*M:THZI)
M;^;$+G[&LJ6QEB\XJ)$)UOG+Q"4YYR\7BZ"4(RCFSQF(PS@[N%^7%8O#N&MX
MRK4(+:49SDZL+^S_ &5XO ^PP\T_=> EAZ=5I)2:BW"E4<8NRO3J22YU&<8-
M07XU_LS_ +/?[2.EZ5HO[0'P/^%?QITS0[J6^T2T^)O@7P[XS31;F<H;F?2)
M-<L+R?36NQ&B7BV4T*7:*L5RLT8V5T<?P7^$,?A#PC\/(_A-\-4^'_P_UKPS
MXC\!>!5\">&$\(>"=?\ !FK1Z_X1U[PCX;&F#2/#>M>%]=ACUKP_J>E6=I?:
M-JD4>HZ?/;W:B4:&@_%'X<>+-,U_6_"GQ!\"^*-$\*/<6_BG6?#GB[P_K6F>
M&;JTL$U:[@\0:CI^I3V>BR6NES1:G<KJ-Q;-%82QWCA+=EE/GWP?_:L_9D_:
M$U/7M"^ 7[1/P+^-VM>$AYOB?2OA)\5_ WQ#U3PY;FY%F+K6M.\*Z]JEY8V<
MEW_HD5[<1):R7#B-)68'.26.]A.G+Z]'#8!\TJ:6/>'P,JMX1FXV5/!57SRO
M'DH5+2ES-NI.576^$]I&I%X5U<3I"7-AO:XE4TVU&I&?-B8ODM&,IU5*<.6+
MO!*'J6M_#_P)XC\2>%O&?B3P1X0\0>,/!%OXCM/!OBO6_#.C:MXE\(VGC"PB
MTOQ;:^&-<OK.?4]!M_$^F6\.F^(X=*NK5-:T^&&TU);F"-(Q\_']A;]BYO&'
M@_X@K^R/^S=%XU\ 6EOI_@GQ/;?!;X>VFJ^$[.SN9;ZP@T.>VT"+^SUT^\N9
M[O3# H;3;J>XGL3!+-*S:FO?MJ?L>>$]=L/#'B;]J_\ 9N\/>)-47Q>;'0];
M^-OPXTW4[O\ X5]JE]HOCOR+*\\213F3P?J^EZMI7B2-D$FBZEI6JV6H+;SZ
M9>QP>VZQ\0? _ASP?-\0]>\9>$M"^'MOI5IKUQX[UGQ%I&F>#8=#U!8&L-8E
M\37E[#HB:5?I<VKV6H->BUNEN;=H9'\Z/<)9CA.3EEFF%5:'L:=GCL/3JQ<9
M*T/?PT*D'SU'*G&%2/-5E/D@ZGM*L6P-=336!K^S7M:M_JM648MI.4XM5VI?
MNXISE)-NDHN4_9<E/DOBW\"OA!\??"<O@;XX?"CX>_&'P=+<_;AX9^)?A#0O
M&6CQ7RJ434+6SUVRO([+4(D)CBO+,074:,P295)4Z?PV^$/PQ^#/@K3_ (<?
M"+X:^!_A?X T?[4VG^"OA_X4T3PEX5M6O@3>RQZ#HME9Z>T]^[/)?SR0//=R
MN\EU),[LQ](M+B*]MH;JWEAN+6YC2>UN;>5)H;BVG5)+>>*6,LDD4T3I)&Z,
MR21,KJQ4@U:VC&/R.<\$@\?EZ=?;FLO:UG16&=;$+#*I*M'#.M7]C'$)N]:-
M'VZI1K)Q3YHTXRTC[T;7.CV--U'5<(2J.'(ZUJ;J2A;2#JJCS.#BTK.35GR\
MKC:!\E^#OV&?V-OAYJ'B;5_ G[)7[.'A+5/%VJ:1K?B:\T#X-> -.FUC4_#F
MN:?XI\/75S]GT%0)-%\4Z5IGBC3%@$45CXET^UU^V6/5H5NQ[QX[^'?@?XJ^
M$M7\"_$SP1X5^(?@GQ' +?Q!X/\ ''AW2/%/AG5X ZRK#J>AZY:7NG7JQRHD
MT/GV[M#,J2QLCHK#OB.I]1@^X_QQQGM0!@$#(Y]?8=*=2OBJLHU*N)Q56K"4
M94ZM6O7J5H2BXN,X5IXAU*<H\L+2ISI22A&[E:[(T*,(RC"C2A"7-S4X4J<*
M;4M'&4(P49PLY>Y4C45Y2EHVK>!_"C]FK]GWX%^"]9^'7P:^!/PD^%O@/Q$+
ME?$GA#P%\/?#'A;P]XF6[M'T^Z/B33-)TRVMO$37.G2R:?</K*7KS6+FS<FW
M_=U?\2_L^? [QG\++/X'>*_@O\*_$?P6T[2].T?3/A+KGP_\+:C\-M+TG1X3
M:Z-IVE>#+O2I/#VE6VCVQ$6D)I^GVPTM%4:?]G*KCVP+C([$'Z_R_+TY]:-O
MN>V.>F!CCZ]Z)5L34JNO4Q&)J5W5^L.M.O7E5=914(U957B'5G62ORUI3]K%
M<L8U(QBH J-)1Y%3C&/LW3<5&GR.,I.33A[+E=WNK<CWE"4ESOQKX._ CX._
ML^>#X_ 'P*^$WP]^$'@F._?53X6^&WA#0_!NBS:M,D,%SK%[9Z'9V<=_K%Q;
MVMG%<:I>"XO[B*V@2:X<0QA>$B_8Y_92B^+TG[0,?[,?P)C^.+:A)JO_  ME
M/A5X*B\?G6I)&E?7#XH72/[4&O2.[>9KWGC5I [A[TJQ!^H N#UXYX_E^63W
M]* O)]#SU],'!]<G/X?6J>)Q?/6K+%8M5L2IQQ-58K%>UKQFGS*O4^L\]6[;
M;]I*HI2=[17NDO#4)0ITW1I.G2=Z5-TZ3A2::=X0E0Y%)V3<E&,G)<TG.3YC
M\I]>_P""<?AGXJ?MS?M-?'O]H/P5\'?C1\!_C=\ /@+\,M!^&'C[PK;^+[W3
M?&'PFUWQ5J>I>(=1T_7M.N=(M$GAUZ"/2-0TN9=21HYQ*\2$;_T9^'OPV\!?
M"CP?HGP_^%_@7PE\./ WAJW:T\.>#/ WAW2O"OAC1;4RF>2'3-$T6TLM-LUF
MN7>YN#!;JUQ<223SM),[N>^*DG/.<=0>_H/3//YTN"/?CN>><9&>G;K^%:8G
M&8K%QHTZU:JZ5"CA</1HJI-8>G'"4W1HU(T'4G1]M[-VE5]DI2LG>,O><T,'
M0P[J2ITXJ=:KB*U6JU%U9SQ-15:J=2,(3Y.=)QASVBFX^]%\J^;_ !-^R7^S
M'XS^+&E_';QC^SE\$/%?QHT0Z9-IGQ7\2?"WP7K?Q!LKO01:C0+ZV\6:EI%Q
MK":CH265I!H.IFY.H:)#;QPZ9=6T09#V]I\#_@[9:/X4T"R^$?PSM-#\"^*G
M\>^!]#M_ GA>#1_!?CF2^O\ 5)?&7A+3HM*2T\/>*Y=3U74]1?Q#I,5IJS7^
MI7]XUV;B\G>3UHC(Q_G^M X 'H!64J^)G"G"5?%2A2C&-*$L1B)4Z4(J<8PI
M4Y8ETZ4(QJ5(QA""C"-2:BTIRB5'#T8RE)4:2G-N4YJE24ZEW&4O:35%2FYR
MA"4Y2ES3E"$I*\%(^;?BK^R7^S+\<_$WAKQI\:OV=O@K\6?&'@N6";PGXI^(
MWPU\(^+_ !!H?V64W-K%8:OK6E7E[%;6UUFYM[-I6MH;C$T<*RJ)*]C\&>"?
M!_@'2'T+P/X/\,^"=%FU35=;GT?PGH.E>'-*FUK7M0FU37-9DT[1[6SM'U/6
M=3N;C4=4OFA-S?WL\MU=R2S2-(W7%<YYY(_S_7GT.*%7'U_ST^O>E*M7J4Z5
M"I6KSH4(RC1I5*M:=&DI:.-&E.O.E13^)^SI1UV<8OD*C1I1E*<:=.-6;;G5
MC3IJI4N[^_4C3A.2712DTNJDTI"@$''&,#&/J<_IC\<TU^@/O_G^5/IK?P_[
MP_K2BK67]/1Z_,V7;U7X,81E1[$'_P <K_,F_P""K4YN?^"F7[9CKAMOQPUR
MVP!T-M;V46&SP<&,G'7Z\5_IM<%?Q[^NS'\__K5_F)_\%0Y!)_P4L_;4P06'
M[0OC./!.,&.:&,=!SP._/7G'3ZGA5*685/+#2_\ )I11^]_1Z5^+<U;_ .A!
MR[?S9A03\NBW/F;37>.TD'SY40AL<KO4DDCC&0, XQN8;N],N'*S3 HRQF92
M"1@#&,%>I+'*@8]P<U<TR)Y+20(0""N0>2=K(!M4<[CR,GY>YX4YDOH RE]I
MW QDEN,*R!L\X&[ QZ\ YYK[Y*R2MLE\K)(_L/FBW:VONZV[*'H<M>._DS$!
MAN5\EL\X;)4="05[XP.@Y)%>*Z\I<WJX^:6*<< EL^4X)R0<$'/(.,KS@U[K
M=PEK>3()"ARF,Y'0$DD\+RI&"1D#'K6C^S[^SOXU_:G^..@?!/P-<6&G:GK=
MCK>N:KK>I R6FA^&/#=F+O7M3-LKQR:A>*DUO9:9IT4BO>ZC>VL981+,1G7G
M"G0K5*DN6-*E.HV]E9-._HM3R\YKX; Y?BL?C*D:&"PE&KBL5B)M-8>AAX2J
MU:LJ>\X<GN)1::J26K5T?Z,W[->L1:A_P2M_9VU6-B4U#]C3X+;3GDB[^&OA
M>T93SG.Z3:!DD_-@DYQ^4O\ P42U#^QO^">O[=>I)\DEO^R;\:A&Q.WYKKP9
M?64>"!G/^D ;<\]NH ^@OV<?&GQ;T?\ 9Z^%?[.6GZC9'X=_!GX=>$_A'K%M
M=Z$G_"<:[I_@[1K72-+U+7%8%M%EO3:0W#QV<,,;_9)5A$:&53\W_P#!4G0?
M$UU_P3<_;9T[0M$U;6-;UKX"^)] TO2M+TB_U34[VXU5[.T>VM=,L+>XO;N4
MP23OY5O;S.4C+;"J$5^+8JK&K*M4I-.E*I5<9V;]R<Y.+TL]4[JZTT>J/\U<
M;7PV+SG$8C"SY\/B,QKSHSE[B]E5Q]>O"=I6:O"K%N+>NBNK.3_*W_@ULN3#
M\(?VM=%D^7[+X\^$>K1QD!08[OP?JML9 /[KO&N#Z]<D8K^JS&4;(Z(V\GD%
MRN1^:C+=C^9/\JW_  ;,:>=-M_VO_#;V^NV^M6=E\';C5[/7-'U719K>2TGU
M?3XS%::GIUBR!#,8V"*3@ '<017]7JZ9<.FP12$N&+%0< @;1GTR#SSSQCTI
M975]M@J4U&44I5(^_%P<E&;2DD]6G;5Z).Z2ZCSBFH9EBHJ<*L5*G:<)*<9?
MNXN^FUMFFWWOT.)FN#8W=M=\JMEJFGW)/(PD%Y!,V>0=HV,Y^8'H<YXK]3E(
M&0>&,C[0PQP78C'J",D<\]*_,W5=!N9(I6%L[-RP01,S.V  ,9 ) Y)) 506
MS\O/SZ?CE^U5\&_&WAFQTW6[CXE>"-5N9;?4K7QE"MU_8'V:V_M!X-4URV!N
M;87%JSM9WL0 DGA^S2N\S1H_56TC>]FK+ON^WRU6^IY%&O'#.I&K\,G>,H]+
M)JSVMIIO>ZZG[< Y[$=AGOQFEKF_"GB"/Q1X=T'Q%;PO;0:YI5EJB6LS*\UL
MMW;I+Y#NAVNT+L49U 5MA8 9YZ2H^ZYZD9*48R6TDFO1^MOR04444%!1110
M4444 %%%% !1110 5\J?MS7EU8?L=_M*75E(T5RGP=\;I'(OWE$^C7$$A'(Y
M,<KCJ.O4=:^JZ\2_:5\*?\)S^SS\</" 0N_B'X4^/=,@14\QGN9_#.I"U54_
MB+7(B  YR?EYQ0!\(_M:>(M8T_\ 85^"W[/_ ,/[N2V^(7[5^C_!C]EOP:;5
MT^V:9X>\=>%;!?BGXC@02),L?ASX/:5XVOEOH)(_L.HOIDGGH[Q;NH_8:\*>
M'_#GQZ_X*"6VB:?;V%GX,^-/P(^"7ARTA1=NF> OA-^R/\"X_"^DVY_Y9VEM
M=^(=>U)("WEPWVI7TJJHF*M^>'A+]NG]EC1_VH?V;M9_:5^.7@[X1Z#^S+^Q
M#\-CX&T7QO<75JWB7XO?'7P[I=KXS\2Z/$=/F6[@\)^$O"5KX<-Y&\[6>I:A
MJD)>)G=6]\^&7[='[*W[/_[2G[27Q#^(WQN\#^#/V<?VS_"OPT_:Z_9S^.'B
M"]FTSX8_$*#P5\+]!^#?QI\(Z'XGO+>&PE\<>&F^&WACQ>?",CKXBUC1O&EK
M?:%IVIQ66H1V@!^8?Q^\-V.O:3^U?\,[M WA^.7_ (+%^"5MAN2W&@_$K_@I
M7_P3?^)6LZ?L4!8;=M:^+7BD".)@-EW.ZHA:OVV_X*A:?$GA3]ES7;=1;WGA
M_P#:P^']C8R1QJ)([/Q1X8\7^%M7M( I 2*]T?4KFTE  5K>5HRH'7\._CU8
M_$>Z_9[\9?%#3_!/B#P]XV_:*_9+_P""G/[7'@7PAXJTVXT?7+.S_:+_ ."D
M?[#WCS]G?PKXL@G&_P />,=3^%&G_#2#7?#NJI::QH>M7&J:-<VL=QHE[#;?
MIG^T=^U?\&/VW/%?[.?PC^ 'B^W\:^*?AYXC\:_M)_'WPOID%[-X@^ OA_X)
M^ O&5BWASXMZ:D(D\'>,KWXN7&E?#JW\+ZRL&LSZN-1N+6TDL+"6] !WO_!)
M"RBE/QIUN8&74(? G[(7@Z*618O,M]&\-? JQGL;2)@?,CMO,U2YE6)R2)'8
MJ,GCXC_9O\;ZY^SG^UCJVB_#/]E?X\?M.Q>#(/\ @H-/I'AGX"7_ ,#-.NO
M"?%'_@HI\1I==UG7D^.?QB^#&D):>)O^$"T/1].;PMJ>MZCN\-W/]J6,%BMC
M<'U7]C?]I_X0_L2ZXT'[4'C+3_@[X*_:$_94_9D^,/PH\9^.2^EZ#XL\0_#S
MX<-X(^)_P\T"3R9)M0^(6D7,6D:G:^#8A-XEU;3M1LY]*TZ[\P ^:_L=_&)O
MV?\ X@?"G]J7]IB.;X2_#SXW_$G_ (*)_ 7XA^,_&MM)H/AKX5^/-;_:^\0_
M'7X"Z;X_UF]\JT\-6WCKPWK/C[PY9:MJK6>D)XHTS1M!?46OM=TJ"0 [FRTG
MXI^./VZ/A?\ %WXJ_LR_%3]G#P=\9?\ @I!\!/'_ ,/?!OQMU;X,ZIXSUSQE
M\+_^"7'[87PX\>>+H]-^"OQ8^,'A_3M.TR+P[\,],T^\U37K/4+\V+3PVB?8
M62U_1WX7>']*7_@J)^UCXI6TA&M3?LH_LIZ&;P*//_LN+QG\=KY;9I?O&,73
MF39D@LH)/0#XET3XQ>,?VE?VE_V>?CUIWB?6/%_[,WBG_@I[<^&_V0;E]#MK
M;1;OX4?"W_@FI^T?X-^*?Q/T"]@TVUU6\\(?$C]HJX^(-GX5UW7+NYLM?T'P
MEH?BCPK*?#GC'3OMWWO\,8Y4_P""C_[5DK13B!_V;/V68H;AH)5MI6B\3?'$
MR1QW)40RS)YJ&2-7,D:R(Q7#C(!YS^PV"/V#O'497:L?B?\ :QCAC"A5CB7X
MB?$/$<: !=HR<9^4_-GDU\T?L^?&C]GG]FW]G7]@3XE:WX$^+?Q@_:P^(/[(
MVD_"WX._!CX#>'-:^(GQ3\=> M+NO#_BGQI-8^&)M6T/X=^#O"^@:M=:)<^)
M/BM\5?$O@+P3I$EUI6BZAXRBO=0TK2KSZK_8,T;4M4_8I\6Z%!93KJFK>.?V
MI=.LK.[AELWFNM3^)7CRWLT9;I(72.X>>,I*0$:-A(KE"&K\GOV%_P!L[]F'
MX.?$+X">./B[\4/#/PX\)Z;^P#X<_9,U[QEX]-SX:TCX=?M(_L]?$_Q=XU^+
MOP*\77FJV]FGAKX@W'A/QSX3\2:=X=U%X+KQ5I>DF[\/IJ)T]U !?_92M_&O
MQ'_X*!?!;QM\;?AUIWPL^)VB_MU_\%/OB&?A?9^)](\;M\--2U?]CW]ECPEH
MFBZKXJ\.7$_A;6?&4'P\\=,WC&[\+7FJ^'[?Q+K?B/3M'U75+& :G<?=_P"V
M""?VK_C9&A*M)_P25_:)AW GA)OBEX&A? 4[N48X(R><9!X/PG^Q'\1;OXD_
M\%%8;O5--U30_$L_[7?_  40^*Y\):SI>IZ;XCT7X)_&G]G;]E#4_P!FSQGX
M@TV_MX9]&M/BE\-_#]OKVG6ETD4MIJMOKGAJ]2'7_#6LV5O]:?\ !0?XD^"O
MA)^UI=/\1]>@\)6GQY_X)S?M)?!CX47^J6FH'3?&?Q:L_'G@'Q+'\/-.U&VM
M9K2+Q7J7A\7>IZ-I%W/;SZQ!8WHL/.FMC$0#T70/%_[+O[*'[.?_  3L^(?B
M[PAX_P#&'Q?T']F_P9\*?V9_A'\%/"_B?Q_\5?B#=>)/A+X/O/&VC>"?AIX=
MD@TRXC@TG2;;4_$_COQE-X>\%^!K#&I>*_%_AZRNUN)/BGPOXL^+/CS]HN;Q
M9\9OA$/@/XLUO_@L=^S-J-I\)KSQAX5\=>*/"OA5OV"?%,7A9O'6O^!-5\0>
M!T\=ZMID$&I^)-%\(^)?%.@Z%-.ND6?B763 ]XWN]S\3_A_^S#\7/^"9?QO_
M &@M<TSX:_!W6/V$Y?@G;?%+QK+_ &-X/\$?%*^\*?#KQ59:'XEUF\5+'PO?
M^+M"T;4-/TJ357L$U&]TR72XII+I5MZ^+M9_:F\%+\9_C1^T%X_U"Z\*_"_P
M9_P4[_9&_:<D\0ZCH>OVZ:=^QOXJ_9>\1? OX<_M%:II\FCPZAI_P[\2^.X+
MBPN=7N;.,:#$_P!L\0FQC20@ ]E_9_\ CU\8_%W_  3K\<_!71_^";?[:'QE
MLOCMX9_:_M=3^+'@G6_V,;;X>_$S7OCM\0_C+<ZSXKTL>/OVLO!WQ @\-^(M
M6\5S3)<>*O .C^(X-/D2>YT"Y"+]J^UOV1]*\>^#OVK_ (7>%/B=9W&F?$B3
M_@E+^S)9?%#3;J[L=0O+/X@_#WQMJ&D>(+.\U#3+J]TW4+FQUSQ3KUM->Z?>
MW=E<N7FM;FY@:.5ODSX9?MK>!_V9?V)/CM^R?X.\<V<'[9/P^\6?'?X4_L<?
M#&Q>RN_''QUG_:#\8^,?&?["OQ/^%VDSI?6?BOX<^._#'Q(^'^JZSX]MH]5\
M'>")?#OQ"MO&6I6W_"!^)TM_OS]GWPQXJ@_;?^(@\9>*9/'GBGX+_L,_LF?"
M3QKX[N(K2WG\6?$?Q)XK^+7B;QAK-S;6-K86=K>ZNOA71O$E[;6-C9VMLNO6
MVRTM83!"H!>_X):@Q_L[>-[20!;JQ_:F_:OM[U3]\7#_ !R\6W2F0 8#/;7-
MO)C^XZ>O'YH?MN:/XX\2_MZ^/-+^%_CK3_ACX\N_C=_P3.T'PO\ $35/!&F_
M$K3/"'B-O#W[5VIG4[_P%J>L^'=/\4*=%NI+)+&\UJP>VDOK;5(;EY-/MK63
MZX^'G[3?P/\ ^">?QU_:=^ /[4GQ!\-_ KP5\1OB9XA_:A_9]^)7Q$NF\-_#
M_P >^%OB%IVFO\1O!&B^)[Y(M$;QM\./&&D7MYJGAEKR/6[_ $OQ)9:K8V%Q
M9B:9/FF.XUSXQZW\.?VS9?#6O:'X8_:G_P""I/[..H?":QUWP]J>E>(;GX _
M"#X1?$7X??#GQIJVD7MO#J6C6'CV6TU;QUIUOJEO:W%KIOB*QDND1YXP0#U'
MQ5\._P!I_P" /[9/[$GQ,_;@_:(\,_MG_!WQ5\7M9^"WP='A_P"%#?LT6O[+
M/[3/Q%^%OQ M?!/QBU7X>>%?%WQ!\-_'O_A8NAZ7XL^!>EZSXVU;1-3^"&L?
M$>SU/P+IVHQ>.?&&H:/Y1J?_  4&_P"">'A#]I3_ (*M>#OVG?VN/@I\*O&_
MCGQGX4_9@T[P3XY\0W-EJ]GX!^$_[/NAHM[/9MITD?V2X^)GQA^)WEFU,ZO)
M;/"S/<Q&)?T0_P""F\1M/A=^S7XON#]FT7X>?\%"/V%_%WB756CG>'1/#K?M
M'^#O"^IZM>-;JS6]A;)XEBCOKN3;;6UI/-/=,+=):W?^"7.CZ_:_L0?"#QSX
MKL)=-\8?'RY^(_[4_BR"\M6L]035?VH?BEXQ^/-K::I;NHF@O='T+Q[I>@R0
M2HDMI#I<%JT2&W$:@'YZ?L(?$^Q^,/Q,_P""4WCK3=:L_$EA)_P3_P#C7X0M
MO$>G32W%AXB'PT\6>#?AQ)KUI--'%-)!K,GA1M2C:>-+@K<C[0BS!A7]!L[+
M%$TDCA8X\RN[NJ+&D8+NSN^%5%4.Q9F55  +*N2/Y>/"_P >_@M^Q%_P46US
M2OVB/B#IOPE^'G@#Q]^U^OA/Q3XOM=4MM&O=/^/J_##XN:-IME>6UA=6[7$V
MNIXW:&))6-Q*LH"I+^[K]G/A]^U;^R#_ ,%#O 7QS^$'[/\ \=_"7Q42Y^'.
MM>$O'R^%SJ+3^&](^)>A:YX<L[Z[6]L[ A;B-[XP"%W?-L?FC##(!X-\7/V&
M/BU\&?&?Q&_:;_X)I_%&7X5?%'Q?K.I?$OXJ?LD>.KE=?_8U_:L\7W=O)/K,
M]_X:O&%_^SC\7/B!=Q(U[\<O@OJ.@V^L>)!:Z[\5O!OQ(MVOE;Y/^$'Q7_:Q
M_:\_:C^('[1W["'CO]G?X.^$_CC^P1^P!\2/$^@?M6_ [XF_%GQAHU]K_C']
ML2*R\-6,?PT^.GP@T_PWKWP_UC3/&'A/Q[IVIR>*;74?$6GP-I%U9VUC+<WG
M;_LV_P#!53]F+]G7]CGP9\-/VB_%=SX._:U_9B\%Z)\ ?B)^R/9:3J.L_M%^
M,_C'\.M/M_!VA^&_@_\ #33[3^W_ (EP_&.YLM*UCX6:YX8M+KPSXB\/^)+'
M6)M8M=)M]5O=/Z;_ ()2?"#X@_ 3XG^//A-\5=+M])^)?A3]A#]A"Z^)ECIL
ML-]H>C_$_P >_&+]O_XM?$7PEHNMV+2:1KMAX,\3_$6\\/6VHZ7<3VUS96EE
M?Q+:VNHVD;@'F7QW_9!^-'P9\)? .1/VH8O$O[:7[1G[>'P@\8?%']JKQ!\&
MM$U#PG'KWA[PGXFT#PGX?\%?L]IXMM-!\._#OP3X2\[0/"OAU_&EUJR:C?ZQ
MXOUSQ%K.NZO<2#OHOAQ^T]\!OVY_V5?&O[;'QV\.?ME> /B+JOC7X0_ 'Q+X
M=^%UK^SM9_LT_';7?!VJ>(HM1U+X6:'XK\=>'/BQ<_$[P9X3\4:!IGQ!UCQ!
MI?B7X:O8WFE>']'N+#Q9J]XOV1^W-#/-XT_88,-O<3B']M'X:RS-!#-,L$*Z
M'XF#37!BCD$,*DX,LIBB5B-SY(#<S_P4O\3Z7\._"_[*/Q/UR"Z;P[\,/VS?
MAWX_\0W%I:SW)LM,T7X8?&5'FE^SQ2M;QW5U=6FEI.X6+[5J-O"S$S*C@'YB
M:E^WE_P3AOM<_P""O/P7_:B_; ^"7PD^(7[1_P 9_C)^S-K'@_Q?XBGL==\-
M_#[X?_ SPW^S'I@U*WCTZ5;:VOM9L/%_B2T=93%*WB%@LC7S2Q&?XO2ZA^V?
M_P $Y/\ @D%\>-%\8V5AXL^-O_#-?[.7Q<\4B"YNI/$/PE_;)\":+\$?VJ/"
MVF,1#<1:G>:C"FM>'KN^2#[%XB\+Z3>7=O!/'(D7Z\?\$VO!^L>"/V'?V<8?
M$EO=6WB_Q?X"3XJ^/(+R-HKQ?'OQ?U&_^*7C3[6DT8N/M(\2>*]3CD,H61F#
M&0!BH3\L-*LM8\(> [_X WFGW4</P _X.!O!\/ABSM].O%@L_AM\??C[X=_;
M"\&O9F.V:-]"T;3OVA[CPY#=+(UG8CP_-I\LT)LC%& ?T4Z?IUCI=A8Z9IUG
M!8Z?IEI;:?I]E;1K%;V=E8Q+;6=K;Q( D4%O!&D4,:@*D:JJ\ 5>ZTT-QDG^
M\?3@''Z<?7K3N?\ ]7_U_P#//XTOO_K^MP*LA4$E\G:Z]!T 92">G ! XR<,
M3@C(K^;;_@GI_P $L_\ @H)^S1_P5)_:E_:Y^.O[4.@>//@3\5+GXLS6>GZ9
MXM\9:_XJ^,4/C7QA'K/PPM?&?@?6=&L/#'P^C^$7AL+IUI_8NM:T-!ETJR\(
M>"%/@G4]2NK7^D\H&Y//7:#R,'GD$>IQWX"DY(I-@^;(&.5R N<9[@ #D=<#
M/ICK7?@LUQN78;-,)AGAE3SC!4\OQJKX>E7J/#TZ\:T71JU(2E0J\\$E4I<D
MN5N/->S7!BLNPV+KX"O65;GRW%SQF']E6G2@ZLJ4J<O:0BU[2#C-^Y*\>97:
M:NBNV  3ED  *_,.<<%C@ !6(!]^2O''Y6?\%!O!?[(?[0?CGX4?LY_&;5_B
M7X'_ &E(_ 'QA^-_[+/Q)^%.O^,_AK\0?"%[X*\/QZ-\0&\$?%/PS)!I\&IZ
MEHNHQ6?B'P%X@&JZ9XI\.2SS7NB7L%J)+?\ 5PH" .>,8/ _#&. !V '' ZF
MOEO]JS]C?X"_MD>!M/\ !?QN\&MKDWA74KCQ-\-_&6C>(?%W@;X@?"_QJVF7
M6EP>+/ /Q"^'7B'P=X_\*ZBUK=-9ZM#X?\4Z9:^(M*,NBZY%?:7<3VKQE>(C
MA,QPV*G5Q-"%&;O6PE2"K46U3BJT5*+C.E&*G#$89_[QAYU(WYU%BS##2Q6#
MQ%",,/-U*?PXBDZL)J+J3<':49*;<HSHUHR3I5H1DDXMH_&[_@D;\8?VA_AE
MXX_9Q_8O^*7Q7L_V@?A3\6?^">'A']K/X.ZOJ?@[PWX1^*/[/=IX:\3^%_AW
MJGPF\:7_ (7-C8_$7P)K4NOPW_@3QSK.BZ7XQM-1TO6_#VLW'B"!(=0L_I[_
M (*K0P6_Q)_X)(B"&&!9?^"L'P5ED$$*1)+//\*OC;(\THB0*\\Q8R232$O)
M(SLSLQ&?I3]@_P#X)Y? C]@[P);Z9\.](;Q#\6O$'@WP%X5^,'QU\2:MXT\3
M>/?BD_P]T<Z1H$4^I?$+QGX]UCPOX,TJ*2=O#/PV\/:W:^"O"4%P]IH&E6,*
M1U])?%O]GKX0?'/5?@]K/Q4\*2>)]2^ ?Q:T/XZ?"BX7Q-XL\/KX6^*7AK2=
M<T31?$\T'A?7-%M_$D=CIGB'5K9- \60Z[X8N#<Q7-UHT]W9V$UMZN*S? //
MZF98>GST'2QE.K5H86C@_KM7$83,\)#&O!X=RPU"-2>)IRY8-MPI3Q-54\56
M<3RJ&58QY1# UZJ555,'.C&K6JUWAJ5'%Y?BY898JJO;UK0PM2'M)\MIU(X>
M+>'HP<O5M3U'3]-6"6_U&QTZ*>Y2U@DU&\M[))[R=MD%I#)<RQ+)<2L D=LC
MF21N$0]OY]?&WP&N_P#@H!_P50_:4MH/CC\4_P!D*Y_8L^%GPW^%EMXE_91U
M[1/AK^T=\:;?XOZ9/XRN=7^(7Q#UGP[XMCU#X3>%I;8:;X.\*P^'F2#Q M]J
MK:HMQ'%$G['_ +1W[)?[/?[7>@^!_"_[1/P]C^(FA?#3XC^&/B[X)L3XI\:>
M%CHGQ#\&W!NO#GB%;KP/XD\-WE^=-N&=CI6J3WNB7@;R[_3;F+"5YM^T;_P3
MX_9>_:B\=Z!\6OB+X<\?^&?C'X9T"Z\(:/\ &/X'?&[XS?LZ?%,^#+Z\AOKW
MP9K/CCX&>.O .L^*/"ES-&VW0?%,^LZ?I[W%S/I,%A=SO<5QY/F%'*_;5:=7
M$8?&8G 8C K%TL+@\3' 3JU:$54I4:\:D<5[?#1JT*WM\/6EAW*,J%&3<IT^
M[,L%+'\D9QI5<-0Q5+$3HNO6I/%0A"J^2I5I2IJE*C7E"I3<*M-5%!QJSAHI
M?$O_  1O%Q\*;7]MC]B0W>B>.K#]C/\ :BU3PE8?'C2]&ATWQ/\ &5_B9X7T
M?XJW^I_&S4+6:YL?$WQ_\/WWB2?2/B7XJMS9R:_*FDZG=Z5874TJS?*W@/\
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MXAGF6.SL- \,:IJEW+%:Z?+*GZ'_ !\_8_\ V<_VGO _P_\ AG\;?AI9^+O
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M^ _P]\6Z39>&=7L[:WO=&TSPW>V5GXVT/PY T&GRZSINE7EK8SR-8R3?N/\
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M0\=>.;O2[WX@^)M173]1\8>*;JYGL=&35=)\)Z5/>+:Z9:Z+IJ+%'\+?L'?
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MGD$Y(^Y7^5UVV_K8_K=OW]NKWW[+\8M[[-6W.=O_ "Q"6"$,ZLP5E/W0 V"
M2!\X)''')Z5]K?\ !(QQ!^WEX>5V"B\^$OQ5MPK95]S+X:E[@, 5C)RGS!@
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M"BBBD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOPWE9,Y.U3S!$0#R'^8C"LN'(#9RHZ]FR 7!([]%:PABV. =OS#<W&T$;@0
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M2/&GPGUSXA>()[SQ1XRT>'Q1H(\1>#+GQ'>W.I:'I%Y=:++=ZA!#;3I\Z?M
M_LO^ _'?_!?7]FW4-5\7?&G3KSQ!^QY\1OB]<IX<^,OCOP_96?B'X9_%CP98
M:+HNF66FZK%;Z9X$U>&65O%_@BR2'P[XLN2MSK5E<S!GD_4/]C;]BP?LQ:K\
M:OB?XZ^*GBGX_P#[27[2/B+PYXD^./QG\5:=I/AY=:;P=I,VB>#?"7@KP7H,
M<6A^!O 7@[3;N\M-$T'358O)<SWFHW%S=/YBX_[1'[$OB/XL_M1?L_\ [77P
MM^.GB+X'_%?X*>&M?^&.M+9^"O"'CO0/B-\'/&7B?0/%'B[P1J6G>*K2X_L+
M4M0N=!CM=/\ %&DR1ZEI$=[=36N9Q$R^8LTPZS;'UZ>)A3CC,BQ65XC'^P=*
MEB\PJY7A\)6Q<J-/#JI26+QE"=3VD,-3?OQKRI0=2<(=$LMKRR["49TI5'A<
MWPN/I8=U)3J4,)2S*OB*5!2J5I.=2CAJL8-.K47N<G/)1C)_G)\#/V;Y?^"H
M7C+]K[X]_M%?'_\ :@\-67A#]JCXW_LT_L^?#OX$?'WQ[\"O#_P8\ ?!3Q-!
MX3T_Q#=:%\/]3TVT\3_%#7]?T[6/$FHZYXR_X2#3Y=-U2UTR+25LHD1_MC_@
MDO\ &GXO?&#]D_5-#^/7B>;X@?%W]FW]I#]IK]D;QC\4);.VLY?BO)^S=\9/
M%/PTT/X@SV]EBTEU/7O"^F:*GB"]M<0ZAXDMM8U"*.!;OR(^>\:_\$Z/C3X8
M^*GQG^(/[&/[9OC;]DWP]^TUXRN_B+\=/AY%\,? /Q9T*3XCZQI$&C>)OB;\
M+9_&MM/=?#SQOXGMK/39]9EMVO=$N=4LAJW]E+>$./M']D[]E_X>_L>? +P!
M^SQ\+!KMSX5\"0ZU<3Z_XHU%]8\6^,?%GBWQ#JGC/QWXZ\6:O(#+J/B;QMXS
MU[6O$>LW)VQ+>:A);VD<%G#;VT:S?,,'BL%6IT,52JT*M?+:N6Y7]4C1J9+1
MHX1T<RCB,3]3IQ<L1*/L72I5L=#&1KO%571JQG??+<-B,/B8RJX>K"I3IXN&
M+Q;Q4JE/&3JXEO#N-*56;J655U8572H?5:5)8:TUR,\8_:(\%?'V]\(>,3_P
M3<\0?LE?#;XR^)/B-?7/QJ\8_$WPIJGB>TOO$5IX/ATV.?5K;X=/#<WWQ.L!
M'X3M_-\:3,+/P]#!'+!+"MM;O^!VM:EX1T[_ ()&_!CX8Z#HOB;PMKG@S_@J
MK\$?A9^US8>)=>LM?N=;^,G_  T[IWB'XO\ B.[UC2HK;2=5\'^-O&MYI6M:
M+;1V5O8P:1>6.EW%N\UI([_LY\0?^"?OQGT+XU_&#XS?L:_M@>*?V5F_:/U3
M1/$GQY\ W'PN\"_%[P9K?CS2-#M/"\GQ.\"67C*)IO 7C;5O#EAIECKDMC-<
M:-J]UI5AJ=]IDMU$SOVWA/\ X)D_ 7P]^Q1XR_8BU6\\<^+?"'Q'O=?\6_$/
MXF:WKH_X6MXK^+?B77[;QCJ/QDE\0VL<4>F>.+;QC9:?X@TF2P@ALM.FTZSL
MX;<62/$_1@,SRW+J&'Y\5'&M9CE6-BJ6#K4<RIJEA<7AL=3S2O.?LL?2PL<7
M&.64H59<LJ5.K"=",IQI\6.R_,,;5K1A2>%3P.8X27-7A/"OVE;#U<'+ 1BG
M+"RK/#-XV;C'FIU:E.<:LE&_SS_P6,^W6B?\$QM1T.$'Q#!_P5^_8YL].N;>
M.-;V#2=5M?BAI_B^*WFP9H[2Y\)'4DU*.(A)[.+$V452G(?M<_L1_M!(?^"B
MEI\/?CG\!?AQ^Q]^W]X<T[Q/^U7XB^+6F>*)OB'\!-+T_P"">A? C]I/Q;\+
MY=-C_P"$4\0:=XU_9T^'OAZZT9/&^JZ7;^!?&\6IZR3<:*ZVB?0?PY_X)Y?$
MVZ^,?P8^+7[67[7/CC]JV+]F*XUC4OV=O!>I_#OP'\-?#WASQCJN@#PFGQ.^
M(2^#+2VN/B/\1=*\,SZGI>CZIJDD.F:7)JNH:M::<NJW,ERWTI^V%^S;KO[5
MOP\\)?!>X\8V_A7X1ZS\5?!&M_M&^'CI%Q?ZE\8?@?X1N+SQ-K7P2T[4;;4;
M$>'=+^)OBK3/"&A?$34)4O1JWPL;QIX0BMXI_$::A9\4,PH8+^R,!0QM"M1P
MWUR6-QD\$ZF&Y<5FN&S*FJ%&O2I5)8K"++J4J$W1A2AF.)A&7UC#PQ%2KT3P
M6(K_ -IXN>&K4JM=82.$PT<3*G6E/"X.OA'*I4A4J0IT:M3&2YG&4JCP>&YX
MQHUG0C3_  ]_9Z_:+^.=I\:=?\6_ /\ 9W\(?$/X_P#QP_9FT']H+P_X;^,O
MC>_\ Z?\ O\ @F;\,-<N_AY^R;\)]+O[?2->U<_&7X]WT?B7XS^*[.ZBTS2;
M/4=?CT_QA.;GP-HUO'^U?PY_:Z\/_&']AVW_ &S_  /X=O(]-OO@7XP^+5GX
M-UL@WUAX@\':#K=SK?@_4Y;60I-)IGB7P]J&AS7=NX2ZA@-W %25,>6_M0_L
M)>,OBS\9M,_:+_9[^/NK?LP_&NZ^#>J?LV_$#Q+9> ?"GQ'T7QK\"M5\10^+
M8=$A\.^*$:ST#Q=X2\0I<:CX0\56+>98KJ6I6%U;7=E=21-]/? 3]G+P#^SQ
M^SY\//V:O!UC=ZM\./ '@E? \47B=TU:^\36%U!='Q%?>)6E'D7EWXHU#4=4
MU#6(UB6T>74IH8(8K<)$IF6+RK%X;!8B%.,L:\1@E7H1AB/:QPE*.*6,PV(J
MUIK#SIR;P]/!2PUG"G/&U<0G[64)7@<-F>&KXBA*K*.%]AB53KS]DJ?UFK*"
MPU6A"E3=:#Y%6EBW6YH\ZPU.FVDY+^?'PS^R%\2?BE_P39U'_@H_??MG_M9Z
M;^W/X@^ 'B/]L#0?B+HWQM\667P?\*>(]#\)ZKX]T'X8:9^SW%?P?!^Y^&5O
MH^GV_@[4=.U?PQ?7UT)+G79[YK[;&G*?$SX:^%/VU?V\/^"%WQ\\<>(/C;X0
MUS]M#]CS]J7XN>/-*\!_&OXC>";+PAKG@WX ?LJ^(M,L/AI:Z1K5LO@'2-;N
M_$5\GCFST".S7XA6]MI'_"7#5$TRSCA^^[G_ ()"_%"U^&NN_LC^$_V]?C+X
M5_X)^^)DUG3+_P#9[M?!O@B[^)6E_#_Q'JTVJ:]\'/"W[0MS9/XXT3X:W\%S
M=:%':)'+K.G^&[RXT6SU..U<@_<OBO\ 8C\$:Y^TA^Q#^T#X>U6^\#6/["_P
M[_:$^&/P[^%^@Z9IG_"+:SX9^.W@KX6>!TL;VYGW7FDVG@C2OAAIKZ)#I>W[
M2;F2*Z?R(?+E]7$Y[AZ-6K4H9A'%SJU\\EA*F'P<</5RS*,=D];!8#**KJ8"
ME";CCJF'G5I06)A1CA74IXJ?UBI"7'ALHKSC"&)PSC3AA,NIXJG5JRJ0QN9T
M<QHU:N/@X8N4XJ.'IXB/.G1C/VZ3I<L8V^0_^"XLHA_9#^%VI716WL-)_;G_
M &'+[4[MB!;Z?9M^TEX$MQ=73-GR[=KFYA@,F"JO(FXA<M7T'_P5JNX+7_@F
MC^W7/>31VUM'^S7\40\\SA(U+:)<0Q!F/"EY&5%&<L64 $FOHS]I[]F?X:_M
M=_ KX@?L]_&#3M2O/ WCZPM[6\N=(OFTK7M#U72=1M=9\,^*?#6JPEI-.\0^
M&=<LM/US0[]<_9M1L;>0H0"#^<WBG_@EY^TA\;/"MA\$/VI_^"CGQA^.7[+E
ME=>'GUSX76_PJ^%WP^\:?%C1O#EY;7UKX6^+_P 5O#.F0^(/$^@W\]G:G7H;
M*+39M?$1&I2RF5FKS,IQ.!]CD*Q>/A@Y9)FV+QE2E+#XFM+%8:OB,OQM\).A
M!TWB?;8&5"I1Q#H4HNO2JTYJE"LCOQM#%1JYJZ&%GB/[2P5*C2DZU*E&E7IT
ML3AE#$1DFXT73Q$*T9QE5YN24)*$['Z+?LGI/'^RS^S;;S6[H\?P&^$D4JL,
M&*0^!-"#*ZXW Y.!QD=P!DU^8/Q _9Y_:"C_ &R_VG?VL/\ @F/^T[^SYJ'C
M;Q_<_#/X7_ML?LX?'?2-8\3^#?\ A9GP-\!6VG_#^\T'Q3X*N(?$/PV\<_\
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M^PQ^T3_P<0?M2_"SQ-\8M3^)G[(\7[+MY\'H?%'Q=\?>+/#U_P"+/VC?V1=
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MGA*E3$U(T\+[).GB*V;4<1]:E+%XF4J#K86G&+JT(5*T(1=%4HRG%OP?X9?
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M+Q#\.]#^(^I,_B"ZM=4T75KP3:I TTOZN>./^"=7QGA^*6A_M-? #]L7Q/\
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M3%-\I_[XZY&1GMC_ #_*K%% " 8 Z9 &3COCDTM%% !THHHH **** "BBB@
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MG\OS_P @O_5T245'O'JWY+_A1O'JWY+_ (4<_E^?^07_ *NB2BH]X]6_)?\
M"C>/5OR7_"CG\OS_ ,@O_5T245'O'JWY+_A1O'JWY+_A1S^7Y_Y!?^KHDHJ/
M>/5OR7_"C>/5OR7_  HY_+\_\@O_ %=$E%1[QZM^2_X4;QZM^2_X4<_E^?\
MD%_ZNB2BH]X]6_)?\*-X]6_)?\*.?R_/_(+_ -71)14>\>K?DO\ A1O'JWY+
M_A1S^7Y_Y!?^KHDHJ/>/5OR7_"C>/5OR7_"CG\OS_P @O_5T245'O'JWY+_A
M1O'JWY+_ (4<_E^?^07_ *NB2BH]X]6_)?\ "C>/5OR7_"CG\OS_ ,@O_5T2
M45'O'JWY+_A1O'JWY+_A1S^7Y_Y!?^KHDHJ/>/5OR7_"C>/5OR7_  HY_+\_
M\@O_ %=$E%1[QZM^2_X4;QZM^2_X4<_E^?\ D%_ZNB2BH]X]6_)?\*-X]6_)
M?\*.?R_/_(+_ -71)14>\>K?DO\ A1O'JWY+_A1S^7Y_Y!?^KHDHJ/>/5OR7
M_"C>/5OR7_"CG\OS_P @O_5T245'O'JWY+_A1O'JV/\ @/\ A_7\*.?R?X__
M "(7_JZ)**A+>A8\\#@?F<\CV[TY6W<'/3IQ[=QC'TY^M-2O;1ZNW5V_#_(+
MKT^:_*]R2BD],>IS^&?ZTM4,**** "BBB@ HHHH *CFSY4N#@^6^#SP=IP>,
M'CV(/IS4E-8!E93T92#CK@C!H]+7Z75U?I==5?==5==0_K9/\'9/T;2>S:3;
M/./B?:_$:_\ AMXZL?A#K7A;P[\5KOPAXAMOAMKWCG2M0USP9HOCF?2KE/"^
MJ>*]$TJ[LM4U;P]8ZRUI/JVGV%[;7=U8I+!;W$4LBNOX[)\+_P#@X="J&_:W
M_P""7I8 !B/V:OCR<GIGCXAJ/KA0!Z#%?N88L8()XZ# &?7/U[TGD+V. ,8&
M!QC/.>O.3G)KHPN,J83VD887+<4IM3<\QRRAF$T[)<M&=;$4I4J>E_9J+BI7
MDI-Z'/4H*MRR=7$4FH\MJ5>5*-E)M7ITX2C=I[IWM9/8_#?_ (5=_P '#O\
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MCR!_>/Y"CR!_>/Y"C^U\1_T+>&__ !','_\ -P?4E_T%X[_PJJ?_ "L_#?\
MX5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '#O\ T=M_P2^_\1J^//\ \\6O
MW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__ #<'U)?]!>._\*JG_P K/PW_
M .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\ !P[_ -';?\$OO_$:OCS_ //%
MK]R/(']X_D*/(']X_D*/[7Q'_0MX;_\ $<P?_P W!]27_07CO_"JI_\ *S\-
M_P#A5W_!P[_T=M_P2^_\1J^//_SQ:/\ A5W_  <._P#1VW_!+[_Q&KX\_P#S
MQ:_<CR!_>/Y"CR!_>/Y"C^U\1_T+>&__ !','_\ -P?4E_T%X[_PJJ?_ "L_
M#?\ X5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '#O\ T=M_P2^_\1J^//\
M\\6OW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__ #<'U)?]!>._\*JG_P K
M/PW_ .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\ !P[_ -';?\$OO_$:OCS_
M //%K]R/(']X_D*/(']X_D*/[7Q'_0MX;_\ $<P?_P W!]27_07CO_"JI_\
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ME_T%X[_PJJ?_ "L_#?\ X5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '#O\
MT=M_P2^_\1J^//\ \\6OW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__ #<'
MU)?]!>._\*JG_P K/PW_ .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\ !P[_
M -';?\$OO_$:OCS_ //%K]R/(']X_D*/(']X_D*/[7Q'_0MX;_\ $<P?_P W
M!]27_07CO_"JI_\ *S\-_P#A5W_!P[_T=M_P2^_\1J^//_SQ:/\ A5W_  <.
M_P#1VW_!+[_Q&KX\_P#SQ:_<CR!_>/Y"CR!_>/Y"C^U\1_T+>&__ !','_\
M-P?4E_T%X[_PJJ?_ "L_#?\ X5=_P<._]';?\$OO_$:OCS_\\6C_ (5=_P '
M#O\ T=M_P2^_\1J^//\ \\6OW(\@?WC^0H\@?WC^0H_M?$?]"WAO_P 1S!__
M #<'U)?]!>._\*JG_P K/PW_ .%7?\'#O_1VW_!+[_Q&KX\__/%H_P"%7?\
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M7?\ !P[_ -';?\$OO_$:OCS_ //%K]R/(']X_D*/(']X_D*/[7Q'_0MX;_\
M$<P?_P W!]27_07CO_"JI_\ *S\-_P#A5W_!P[_T=M_P2^_\1J^//_SQ:/\
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M;;6SNK]>5[2C>]I+22M)*S%HHHJAA1110 4444 %%%% !1110 4444 %%%%
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M8+34M*U.T2XMYY;.^M89FM;JUNXE>VN8)I/79)1@\]%Z;".H4=CG!R.>"!G
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MP64T]V)H;+PL?)BL(4>Z=H?(+R6ZHTFV%ALX(KQGX8_#[4OV0OB'!\(M-O\
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MN9Y['*:? U/$?VO"AALMH9%E&;9UGE&O#A'"TZ/$]#%8M?3_ .T=\:[+XA^
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M/A#5;&\O]/\ &/A_Q1X/UG5M'\0^'W2PN[2:2(07L>HV\EC]B,FS?^<)\?\
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MXK?7[S2I-80PZ5):PM9I9QS0,'G-R"LN\>6 Q&<@5^P8_P"#=OQ>P('[4FB
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M3O%G@KQ;8QZMX?U[2IUFM+VUE!#!L$O%<6TWF6]Y:3*L]K=0RP3(CJP'QM\
MV_96_;I_8PL--\)_"_2=/^ ?Q!M-=T.^^&DVD6FC-X8UW3=6N8-8AM%T[;%8
MZQI6OK+J>G:UITD4QG\F[B8"1D/XO>$_$_QM_P""(?Q_E\">.YO$'Q/_ &&/
MBMK$UUX=UV&%[F[T2[,>+B^LXR3:Z1XPTN2Y@77=&5K:R\7V,1U*P"W:3&+X
MVCPOEN;O-<IRN.89;Q5EF.Q4Z.2YMB:-66;X"G-\^%P\X*%".<X;E2E1C4]E
MB%.E*E+WFE^MXWQ*XAX2EPSQ/Q)6R/B'PMXCRC+(XOB_AG+\=0I\+YUC4E0S
M''8>53$5L3POF\W34<5[&.)RJM&K#%+EBG+^D[XR?&;X;? +X>:]\3OBMXJL
M/"/@OP[&K:CJ]\Q9VN)SMMK"R@3,U]J%XY6*TM+9))Y7;A" 6'R1IW_!3S]D
M>[^#&H?M 7OC/Q!H7PLM_%$/@[3-?U_PIK6FOXK\2/:M=OI_A&PGMOM.MBUB
M1_MMS9QM;6TB%))=QQ7X\:5I'QB_X+:_M$'Q!K8U[X>?L(_![7W73+%/-LY_
M&%Y:NDD=NL99(=2\2:RL+M?W\8GM_"^FS"VC<WTN:^F/^"R_[*'BO7?V8/@1
MH/[._P ,;W5_"'P7\53PW?@3P5ISW$VE>&KO3([:VO8-)M0+F\@$EH\&I30)
M+>,UY]H.]V=CZ&&X3R'"9AD?#^?9G7I9]F>+C6S?V.)PE/!Y%A)X:K7H9;5G
M7_=U,TJNG3I5X2JTZ.$G6Y'*511YO%S3Q5X_SGA_C?C[@C(L-6X)R'+:^'X6
MGC\JQV+SCC?-:>,HX7%9WA,-A94L30X<RYO$8K#PCAJF+S6.%:I\F&E49]$+
M_P %P/\ @GF!AOBCKY920V[P7KJD,"<J5-N0".A')/>FO_P7!_X)Y*K2?\+3
MUX"/*M_Q1FN\@]06-MP<#&<@#[S8 K\Y_#G[7_PJT7PWX?T>_P#^"-OC2[O-
M*T/2M.O+R/X>02175S9V,-O<7,<EUX6>ZDCGEC>57N7:<AQYSE\DMU[_ (*!
M?LP^"8;34OB9_P $E]<\!^%KN_AT^XU[Q!X)T73K-9)&/[F&74/#MG;3W?EK
M*\-FT\3W)1HXV!KZ!\$9+*7)2X8XHJMR<(1I<5<+2<VG-15.,:_M9N7(G"GR
M.<N;D<6SX7_B-G%].C'$XOQ-\.,)3C2IU<3]9\+O$VA#"J4*+JJO7GEU*G2C
MAYU7&=24Z=)<CE)QA\7[]WG[5'PHL]/^%&KK>ZM>Z1\8M)T[7?!U]9Z7=O -
M&U2W@GL+_5CA6T^&9)X@HG'WG"GJ*^E$D)P=V1P.G5&!(/))ZGD>AY':O"_A
MQ'\(OB_\./A1\0_"?AK2;SP?JG@[0]8\!K+ID5M_97AZ^L[:\T_3X[1<1VR:
M>4BA:T56CAN+;@85<^\A, D+DA>G&.<@G'7CTQZ&OQW&1PL9JE2PV(PM>C4K
M1Q%/$U%4J1DJ]6,:<G&T5.E"$:57ENG5C)VC=(_KC):F98BE]:QN89?F&#QF
M#RK$8&KEN'J8>C>KE^$K8BO!U92E4P^-KU:F+PK;;IX6O2I3M4C-*R"<>IQS
M]<9Z_P!::0Q&#CK_ (\^O?&/;TI5X4<8Z<#MD\=SZ^M.KC:3Z?T_Z_$]RW?3
MT[^7]=NPP*0.N#@="3R,]<]?\:249C<8'*L,9QD%<=<C'..XZ#UIYX!YQQU/
MKVJO(_RGYEY4^QQM!(R>,\COCU I;:*[=KZ67I;SNDEOJTM= ;2W=O-]%NVW
MH]$G)O>R;6IDO FW8Q 4A49&^Y*%!4"16)215))$;*ZAB6(]'QPPE G*I$7"
MX.U$RQ8QQ@8"%<Y"JJJ5(P,8 _.G]O/XI_'FV7X:_ 7]E?6UT3X[_$:V^)/Q
M&AUA+"SU6'1/ WP?\'7FMBUU"TN618H_B%\0;[P5X"T^60QI<-JFH)&_[IQ7
MU7\"_CYX1^-_[/W@#]H+1)1!X5\:> K?QM/&KB\DT698+@^)-$N)(E4R:AX8
MUBQU;1+Z (DT5Y936\D:2HR#V:V0XVADF5YY*6'JX7-L54PU"E2G*IC*4DZT
M<'B<30E?EHYJL)CEEU65'FK_ %'$1E)<^'57XO"<9Y)C.+L_X4C#&4,PX>RO
M"X_$XW%4(T\LQ-*]'$9GAL%C_9-UL1D#QN45<ZH5<2J>$EFF$J>QJ3IXET/;
M4CC4 NA^Z5^;:[MAB,%L L% & P.5ZD;:D)@B )P$+ +MVA!EB-J@ #N#D_>
MY'7KX._[2GPA;X$:;^TJ?$5TOP?U/PEI'CBS\1#2KYKB;P[K;0C3;MM)6+[>
MCW'FIOMVB$L6_#J"*Y?XO_M7_"#X/3>'=(\07/B[Q)XE\6:$/%>C^#_AYX&\
M0^/O%<WA(&/?XFN]&\/VMQ+IVBPO(L1NK]X7DFS#;0S2J5'-2R?-\545"AEF
M/KXB>)Q6$=)4)IRQ."Y9XZB^>O2H4ZV#A4I3KJ=;#JC&K3<YT^>,)=V*XKX8
MP&'GCL5GV38>C]2R[,?K,L3AXRJ8+.9U8Y9B::I82M7JPS.M0JK".CA\2\;*
ME6=&A+V-2=/Z=67<I8Y(W-Y9\S "AUVE".!N8C@Y8;0 <*"!=FY1YCE@%0N6
M\R0F0>8-SM\Q&Y=HX*D*H?(&!^;'[1?_  4 \#>!_A1\!?B3\(=3_P"$UT+X
MO_&7X>^%7UNT\(>)=9MM.\#R>,[#2OB;;O:6UAYVE>/[&Q-SI&D>%=7CAUV?
M6#<16.FW-W9NH]D^)/[<7P ^%B^";?Q1JGC3_A(/B/\ #G3/B7X&\#Z3\//%
MFK>.O$GAS4[J"UM[:Q\*6MB-7A\16[7$EQJFAW\%I?:38Z=J5YJ"VT.FW93T
MO]3^)O9X&I'),;.IF57-</A,-3H59XGVN35J>'S6C6PGUB-;#?5:DX2JNNJ,
M%",JOUBE2A*<O#CXH\!RKYSAI\4951CD.'X;QN88FOCH4\NC1XKPV*Q.03PV
M8/#U*.+6/CA:L:5.C[>I5KSCA%AZE6480^O;J-=L97[JR>8,,% ;:2&!)!#C
M=]X;>XR,<2KL;#DNS $$EBQ4L & +9W YPQ8D<^G ^0_'G[:GP2\$'P58W,_
MC[Q%XI\;>#-*^(NF>!O!GPW\5>*O'6E>!-6AC:W\2>+O"^GV*WWA+3S-(+%H
M]=^QZ@=02XM8;.:6WE5/+_B)^TTGBK6?V*/$_P #?'BW?PY^,7QWOO"7B5[6
MS:.;5M(LO#&MRWWAO6;'4;:+4M%U#3]:LO*U"RN(+6_M+F'RYE5"-V6%X4SW
M$U*$JN65\'A\5#&RHX[&T:M+!_[!@,WS&K!U:>(JR4L53R7&T<(UAZ5*MB*=
MZ=?$4:->M"\?XC\'8!XY4L\P>98[!RRF.*R[+L90Q..IT\WS/(,FP^(G0J86
MA"5/#U>*,JGBDL9B:V#P^)I+$X7"3Q%'#5/T.#QLA"L!NW'Y3@DE@I"MGA@&
MZ8^G -1H(BK*K,H.#*S.03\G8LV[=\V=V6*GG.XY'Q/X=_:(^'GPY\-?M >.
M/B5\=)?$_AGP;^T'XE\#1?;?#-Q8WOA+6Y)M.L=%^#7A;2]/MY-4\;:NMY="
M'1FTRVNKK59;B39B*WEDC]!^#'[5_P (_C7XAU[P3X>E\6^'?'_AO0[7Q;J?
M@#XC^"==\ >+_P#A#[W4'T:V\6:?H^OP1G5?#W]KJ-.FU+3IKB.ROFBL[U;:
M>6-&QK\.9WAX8K$+ 8RM@<'*$<1F,,)C,/AE.KAL'B>6<J]6C5;HQS'!>WJ+
M"5:5"5;"U*E>G]9P7M>[!\<<,8O$Y;@*F<Y;ALUS6-:>!RBOFN75<=5IT<5F
MN&4HO!QQ.$FZW]A9I.A2J8ZC4KTL%C(X?"5ZF"QL</\ 2!@03[^K(=B$MEP%
M7#J&)W;><;59!@Y I\\4)A9'VK&3A@0&CS@$,T;,58C^ ,& QE0#BO@U/^"E
M7[)U_P#8;_3_ !1XOU+PO-=I8ZWX]T_X;>,;OP#X+OY+Q[!;#QMXMBT\Z7X>
MO/-59+FW>2>6PM)[2\U%;6WO+>23Z>^+7A#Q1\3_  -'I?P^^+6N_";4KJZT
M[5K;QOX-L]#UV]NM,\LR"TMTUB*[TZ:TU.&6*1;I%8F-4DB?!S6.*R',\NKX
M.GG&"Q.24,94M3Q6983'4H1A1;]I-4L/4JXJ<\.IJ<Z$:>'Q,?:TZ\<.N:,I
M/ \79!GF"S:MPMF.7\75\'AX8BOEN29KE=:MB98IU%AHRJXJGAL#&&-5*K3P
M^+Q4L5A*DL/5PTL5S494H]1XX\'>&/B-X*\4?#OQE%=ZEX3\:Z'>^'/$.GVN
MIZAI4]WHNJQ?9M0L%U/2[JTU*UBO;662WG>TN8)/L\LL8<!V8=586&GZ196U
MCIL,5AI^GPVEC96=NB);VEG900VUK:VT,8"111P10I$BA1&D:;0 %-?CI\(O
M!'[4GQ.^*_[3GPYO?VXOBOH]G\!_'?A_P?HVIV7A#P%/>:W;:WX.TGQ)+>ZE
M%/I9@2ZM9]0>WC6V1(I(D21UST]W\;^/?C+^T+^T7\2?V<_@M\0[SX-?#_X
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MT3XG:YH^B?$+]GWXI_$#3_@[K7@V^T:?Q5IUMXA^'!L_&^O76LVUGJ7A75/
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MI&%3'T:M"O4E@L?A(2EXU#PFXHEAH0S/-.$\97R[)> LAR6GA\MXQRVG2P_
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M\./%XJ\.6EFUI++I&AZI<B>^N(FBDT]XHQYBC]-? /P@^&7PKMKG3OA?\.?
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ME6L[0FSN+ -9VA%G,(O,LSY"8LY3$[1F6V \A_+=H]R$1.Z ,=N'&. 1P/O
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M%@98W-\7P[A<TX1P[P&"XBXLIX&>;Y[B8\.*G6S2K6Q+Q.!S##0P\*U7#O\
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MRX8D(VHN/9RGAGABAQ!0C+#YOCJ&59KE>7YCA\7B\!&&.Q69<$8[B:C6A&&
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M^ 2?Q/?WJ)HV)/(YQVX&,<X]20<\XYZ=*FHHMYO[VM_1K[OUU*<4]TGZI/\
M-/\ K3;0C*$D$$< C!YZY[XSQV^@]\FPX(R.A''U!].O7]*DHHLEW^^7Y<R5
MO3_.YRK7SO?2.M[7O[NNW6]^M[))NT< ]NOUP!^7K]!3/+(Z,?O9]>.W;MZ#
M\ZEHI_-_>_OW"R_X=)VVVO%VV7]620C(/;IS]#FEHHH_084444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 44'Z9Z?SZ_AUHH ***0G&/K_D_AWZ8&3VH 6C_ ":/3C_ZW!Y_I^-&
M1ZB@ HI 1^I ]#QG@]^.OH01SBEH **** "BBB@ HHHH **** "BBB@ HHHR
M/44 %%%% !1129X/'(SQD=NGL,^_3/- "T444 %%%% !29Y]NF??.,8I?I5.
MXN&AR0J%$&^5G;8D<8+%I7<G:BQA"S$@CC.5'S"9244V^BOU;LW&-[)-NSG&
M^CWV?0OJEWO;Y*4MVTEI%ZMI;*^J+9QCV/'YG%-=1M/LIYR0>![=\#CWJK;7
M0N$21&BECD&Z.:%Q+%*I!*/%(I*,A((W*S $<GD&K,A8(VW@[3@^AXQ^IP>1
MP"0PZT<R=_)M6UWBVM$U%]';1-Z:*Z3E.+2>U[?%9:.S5]6K)/5W:5F[Z.WS
M[\1OV9?V?_BUXFTKQC\3/@_X#\:^)](BAALM=U_P_97]]]EM29+:UN)FC+7]
MG:R%Y;>UOVG@MWR\0#?*.^TSX9?#S1_"6H>"-)\$^%K#P9J=UXGO-5\+6FBV
M$?A_4+WQAK6H^(_%MQ=:4L(LYY?$'B#4M1U?56D@<WFHWMU=2J96<U\,?\%-
M_P!O"Y_8=_9VU[Q+X"\+Z=\3?VD_&GA_X@K^SM\(KNZD2W\5ZO\ #GP/J_Q$
M^(?C[Q0EM+:7%M\+?@C\/]%U;XD?$:_?4-&BO+/3=+\#V'B#2_%/C7PV9N6^
M,W_!0K5?V<?^"4OA3_@H%XU\"Z7\0?&=_P#L^?LV^.KKP'X>U-_ WAK7OBA^
MT,_PT\*Z+8#6M9?Q')X+\!Q>//B/93:EJ%V_B*\\.^%(+NYV:O<V82Z]VG3S
MW%8+*)+&8NK@L3F$,LR>A+,:KI?7:2]I3>'P\\7RX:G3O.-*O"-&G3J0KPHU
M8RH58Q^>C@N&J&/S6K2R?**6.JX*OB<ZQ4,HPGUC%87&?NJ\,776"YL2\7:+
MQ.&KU9K$TYTZF*A44XS/M3X4_LR_ 3X+ZIJ.L?"GX2>!_ 6JZE$UM>:CX>T&
M"SOWLF<2-IT-TRO-9Z891O\ L-HUO:,5!,/"UZ=JW@+P9K?B;PYXRU?PIH&I
M>*?!_P#:">%?$M_I=I<ZSX=CU>-8=471M1EC:YL$OXE6.X6WD7S5'S==M?D_
MH_[4G[>O[-7[0W[+OPK_ &X--_9'^(G@S]K_ ,7:U\+/"WB?]EG1OBSX"\0_
M![XNZ7X4N_%FGZ-K6@?%?Q7XS_X6Q\.=6LM)OK-_&^F7'P^UG0KQHKB^\*75
MN]O:R?JAX_\ B?X"^%GA]/%OQ-\:^$O 'AEM8T7P^FN^,-9L_#^C-K?B/4H=
M(T'2QJ6IS6]H-0U?5+FWL-/MC+ON;J:.&,%W"G/'O-7BL/B<1CJV98C,:%2.
M%QV'Q^*S"6-H0J5,!5HT<0Y_6*L%6IUL'.BJ<%4<9P=*I"?OUEF#X?P^!J8'
M!93EV68/ XF%:ME_]E9=E^'PF-BJ>-I8FIA*-!X2C72E2Q=/$\TZE.T:D:]&
M=.T--/ OA%?%MYX\'AG1%\9WOAVV\(7OBHZ;;?VY=>%;&_N]4L_#UQJ'EF>7
M1X+^_O+R*Q<F&.>[N)E3=,]>1>#/V4_V<_AWXWF^(W@OX*_#WPUXTEEO+A?$
M6E^';"TOK&;4 5U"33"D?E:3+?(Q%W+8);O,/,$C,),UY_HG_!0C]AOQ+I'Q
M5U_0/VN_V<=4T'X'+;/\7]8L_B_X+N-,^'<%YJ$FD:=<^*KS^UD@TNVU#689
M=(TZYE:2WO\ 5T;2K5YKT^4O26?[2OPT^-/[-OQ ^./[+WQQ^!'CS0-/\%>/
MKKPM\6+GQ;:>(/@QX<\8^&/#UY?Q3?$C5_#=Z;K3/#OAR\2RU'QM9B6SUC3]
M!%U-Y<3O%+6<7GF&C.FYYQ@*-=8? UE46982A4IS498;#5U*,(RH>SQ+G1I6
ME^ZE6]C2<7.E5=; <.8^I0Q,\!D.95\%5Q.:86K+#Y5BL1A\5*SQ>,PLU"<X
M8N<L-#VV(4N:I5IT74J^TA3K4>H^*?[-7P!^,VI:9K7Q3^$_@?QSJNBPFTL-
M7UW1[>YU*"U$F6TYKT(D\VFLZCS;*>26TWC:T18,!Z[H>A:-X<TO3M#\/Z7I
MVCZ-I-O%8:1I.E6<&GZ?IEC;(L4%I96=HD,%K! BH$BCC4 +D@Y)K\O='_;#
M^-ME^TI_P3N^!6KZO\!O'6B?M*_L8_%SXW_%GQ_\+;'Q%JGA+Q%\1OASX5^%
M.IZ9K_P.\0W?B4+'\)?$6H>,-:U'1H];TS6=4U/PU/H;QZG921S&;D/V6_VT
M?V@_C]\"OV,_BIXA\;?LK> -9^,/[1GQ:^'GQ0\-^+K;Q7X:U3X@>"O _B?X
M@^'M&\,_L]:4?%.J-/\ %5X?#>DZIJ,>N7^I:=<Z?;ZS<P65MNMX8.NM@,\K
M8##TZ^,J5LNPT82PF'EF&.K86@L0\SIQEA\'/VL*4'#*L8K4\/3<(.*E&E3J
MS4.?#+AS"YCC\QPF5X#"9IC*GL\RQU#*LOPN-Q=2$LOJM8W'PITJN(FZF88.
M3E4Q-13J)2<JU2E3F_UA\.> _!/A73M:TKPSX4\/Z%I?B+5-8UK7-/TO2K:T
MM-7UC7Y))]<U+4[=(8XKR\U>2223499XW:Z+L9&<$UY)\//V4OV<_A/XINO'
M'PX^"WP^\&>*[B&[@&N:+X>L;6_LK>^\HWEKI4JQEM*M;QHD-Q%IXM8YGCCW
MQDC-<5\1OV]_V+O@[\5-.^!GQ3_:J^ /P\^,.K3:=!8_#GQC\4/"NB>+%N=:
M*+HUG>Z7?:C#/IMQJWVBV73(-1-M<7XN86MK>7S(C-W_ ,6?VI/V=?@(;A?C
M;\</A3\)FMO!.N?$J6/X@>-M#\+,/ 'AO7O"_A36?%\*ZO=P-<^']-\3^./!
M_ARXOXE> ZYXHT/2H7DOM2L[>7BI5<]A&<(?VY3_ +8I*<H06:4_[5H>SC'G
MG#XL;25&I&,YRC5@J<U";="24NBMEW#.(JX:O7P'#]>>15F\'6K87*:D\GJR
MK.3CAJDJ+CE\YXF/M(J"IMXJ$:D4L3%58^JZ1X,\*Z)KGB;Q-HOAO1]*\1>-
M)-*E\6:UI]C!!J?B-M"M'L-'.M7:K'+J!TNQE>UL&G:0V]O(T4>T,X)XB\#^
M$O%-UX=O/$7AO1=?O/"6NP^)?"]SJNGV][+X?\006UQ:1:SI+S*S6.HQ6]S<
M6\=W !*D4\B+D.:X3X(_M!?!7]H_P5#\2?V?_BI\._C)\/YM2N]&7Q?\./%&
MF>+-%BU>QCAEO='NKO2KJ=++5K6*[M)KC3KGR+R."[MKB2%8;B)WY+X__MA_
MLP?LKVFA7W[27Q]^$7P-M_$\LT7AH?$OQMHGABYUY[7/VMM)LM2NX;R_CM%(
M^TS6L$L,&=TKQX(KF4,P>*5"G2S"680C['V"IXR>.A[.FZ#H^QC%XN"I4$Z7
ML^2,*>']S2@XJ7HNGE:P;;CE_P#9TY.K)RA@W@JM2=?ZW*K?D^K3G4QC>(E4
M:E*6,4JK;Q"E-^S_ /""^$AXM?Q__P (SHO_  FYT!/"C>*SI]N->?PVE\^H
MQZ"=4V&Y.EK?S27JVA;RA<.TF S%ACVWPL^'=KI7CG0[3P+X6AT?XE:GK&N>
M/]*BT:Q2P\9:UK]M%9ZYJGB:U,1@U6_U:UM[>WO[BZCEDNHX8DD9A&H6SX?^
M*'@'Q=X$T[XH>%?'/@WQ%\,M7T'_ (2K3/B'HOB/2]2\&7OA=+1[V;Q!;>);
M2ZET:328;2.2>;4/MJ6L$*3222IY+ ^%? O]N;]CO]IOQ3X@\$?L\?M-_ _X
MT^,_"UD^JZ_X7^&_Q&\-^*=?L-)CNK:PEU<Z7I=[)=3:3;W=W:VEYJUK#<6%
MI=75O!--'<7$2-5-YDX5:D%C^3"1I0Q$X0QZAA(X2JZF'A7:2CAXX:NI5,/&
MK[)T*MYT84I2YWE.AE#E3A5P^5REBIXFI2C5I8!RQ%3'T?JV-JT;PYJ\\;AX
MQP^,J4U.6*HJ%+$2KTXQA'IO!W[)_P"S=X!CM4\(?!'X;:$=/U[2?$]E-8^&
M-/2ZL_$&@W=Y>Z#JEE>NCW-K<:-->7<FF>2\:6!N)1;*BN4KU:R\!>#-.U/Q
M;K6G^%= L]6\=M9R>,]2ATZTCO/%4MA:/I]F=>F$1.J"VL)I;.(72R".V9H=
MNQL52\)_%/X>^.]4\>:)X+\<>%O%.K?"[Q*O@WXC:7H&MV&IZCX$\6G0],\2
M+X;\56MI/--H>KOX>UK2-973KY(KDZ?J5I=A1#,CMYO-^UE^S/;^&_#_ (RN
M?V@?@U:^$_%6K^+?#_AKQ->?$/PU:Z#KFM^ EO6\;Z7IFK76HQZ?>7WA1-.U
M!O$%M%.9-,^R7)NO+$#BM*F)SG&59JM6SC&XB;A2FIU<?B:VO)BZ<7&4JU>2
MG*G#%0CROWZ4:T*49TO;1Y\+E?#>74*:P>6Y#E^&@Y5J4<-@LKPM&+=*>$JU
M$XX>C1?-0KSPE6JY3DJ%>6&E6E3K2H3=X$_94_9T^%GB^Z\=?#SX,_#[PAXM
MO/M:/XAT7P]86U_;0WSJ]]%I[I'_ ,2R.]=0UTNG+;"0#$N5#UZUKG@CP?XH
MU/PKK.O^&M$US5? .O2^)O!>H:E86]Y=^%/$MQHVI^'[C6]%GGC,FG:K+H&M
MZII#7<!64Z?J=W;D^7-+&_CGP"_:W_9D_:G3Q#-^SE\??A)\<(?"-]!8^*9/
MA?XXT+Q=-X=N;C<UH-6ATFYN);&&^6&4VMU-&MO<>41:7$K .ORM^P/^W5<?
M&/\ X)O?"S]MO]J[Q5\(_A.-:TGQWJWQ)\5+=?\ "OOA5X:M/#GQ4\6^ ]*N
M3<>,/$>LG1X;FUT;1XI5O_$5V]YK%U,MDJ&[M+%=\3_;F(<\9BJ^:5<9A9X/
M+I+&5<?4S&+S*EC7AL/2IUIU,:Z5>E2Q,90I.TEB(ITZRQ;<L,!@^&LNHQR_
M+LMR7!8+%/$Y@J67X'+Z&6U)X"KA)5L5B'A<+2P/UC#UI83V=6JG.,L-3="=
M%X6*A^A&@> O!WA9?$B^&O"VA:&GC'Q!J?BKQ8NE:?:V8\0^)-:@AM]7UK6%
MA11?ZIJ4%K;P7MW.6EN(H8DD<B-:P+/X+?":R\/>$O"-I\./!MKX6\ ZRGB/
MP7H,.@V":5X5UY+V[U!-6T*Q6#RM-U 7NH7UV+BW5)?M%U/('+.[-Q/P _:K
M_9Q_:FT#6?$O[-OQQ^%OQQT/P[?Q:9XBU'X:>,-%\41>']1N(I)[6SUV'3+J
M:ZTB:\MXIKBR.H16RWD,$DD#,@=EY3X=?MT_L<?%GXLZQ\"/A?\ M1_ 7Q]\
M9M#EU2'4_AGX4^)OA36O&$,^ARO%KT$.D:?J$MY?SZ*\3QZO;V"W,NFM'(+U
M8=C8YE'-XU<1[F:QJX9T\1C&J690J8=JE]7I5L5)*,Z,HX>I[*E4K\JCAJCA
M"I[!SBNQ4<DE2P\70RJ5&O&I0PL'3RR5.K"IB/K5>E1I^S=.<:F+I1Q-:E2B
MU/%1A7J4U74)GIOQ9_9\^"WQMATN'XK_  Q\(^/O[#EDFT>;Q!I5M<WNEF9U
MDN$L;\A;VW@N&53<6\4RP3G E!/30A^#/PJMO!WAOX>P_#?P9!X'\&ZSX;\1
M>$O"2:#IT.@>&M<\':K;:YX6UC2=-B@%M;:IH&L6=IJVFWT:)=07UO%=K*9U
M5JM_%KXQ?"SX%>"-5^)/QF^(7@OX6?#[01$VM>-/'_B+2_"OAO3GNI/*MXI]
M6UBYM;,75U*?*L[-))+J\FQ#;QNYQ7E7PU_;*_91^,OPH\<_'#X7?M%_!;QU
M\'OACI^M:E\2OB3X9^(/AO4O"'PYTWPYX>;Q9XBO_'.M+>QVOA>UT7PPK>(=
M0FUPV$=GHZOJ,Y2TC>6JCBLXG@\/"GBLV>782NXX>$*V8O 8;%S:I\M%0J3P
MU'$-XF47&BHU(JO42E"56<:N4LIX>>88O%5,JR-9IF.'MC<5+!95_:>/PD/9
MVCC)U,+]:Q6&3PM&RQ$Y4Y_5Z*FJGL*/L?;?%W@SPIX_\.:UX-\:^']'\4>%
M/$%G+I^O>'=>L8M0TG5[*7'FVU[:72R0319VD,R Q2)&RNL@4URGASX)?!_P
MA'9Q>&?AMX/T<VO@R;X>6S6.BVD4J>!+N]DU"Y\*^?L:1]!N+^>:[FL&<P/,
M\DS!G<U_-_9?\%N/'Y_9L_:T_;8N/VD_V%=0\->$?$_QM^&'[,7[%=MX3UNS
M^,0\4Z=\3O%G@S]F?Q;\6_BC/\?9[K7X/B3X*^''C3XJ:SX(\(?"#P[)J7@R
M%]2\+>*;--)U.*T_7OX$_M5:#\.?V4[']HS]L3]N?]CKXC>"O$>K_:=!^/?P
MG\.Q_ [X)&T>VM-.G\':6_BCXU?%YO&.O:5XJLO$-DNM6.O:;=ZC!;P6\WA/
M2;VSNXV[ZV5<09;0]A-8VA2GC)82G@:-3,7SY@L-AI5:,,+"$83FJ*PT'.E"
M3J^RIQBZJP]Z/-"KPWF.+^MO#93C,5#!PJRQ]7#99.K#+_K.)E2<L4XU:L*4
M<37Q-14ZE1*G4Q5>:5.>(JJM]LZ#\)OAIX6O_#>J>&_ 'A/0M0\(^&9?!GA:
M_P!+T:RL[GP_X2GN5O)O#FDR0QJUCI$MU&L\EA P@:55=AN%>*>(OAIJ7P'\
M'>)[S]D+X"?"9O'?C7Q9:ZEKNCZKXC?X8>%[F>:TU"-_%FJ7VC>&]?GU*?3+
MJ2T4Z%;V-G)J-M=WI@U*SGC59O3_ (-?'WX.?M#>!K3XE? CXI_#SXN_#^^G
MNK.W\8?#OQ7I/BKPZ+RS?;>V$^H:1-<16E]9X<WEG=B&XM2,3Q1DY'D'PO\
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M?!86EA<.J6-QT<)1R_#+$XREA)U:JA@^(J6(Q%3#RQ/.IX6>?TGEU%XMJ=/
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M=Z'X@\,ZII&L6,>LZ-++I&M6D=[]CU2PD:"[@E*1/'6U#]C/]E_4[O7;^_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****  _E]?4\#]:^:/BA#YGC+)X<:'I8.%RN?M&I\<@C&1@=<9X!)&/I?_/Y
M=*\ ^(]L9/%8D&/FTBR0DYQ\D]^5&>0.&8DX(_O \9"Z;M--^?Y:'F\$ PIV
M C&[G=A<D  L 1@CIS][AB N*UX8NG3!X)&YLC<I).0., 9)P7("J@&"9H;(
M@# P0,@[6^4@Y+%3R>W&">A<$!:T8K5L+\Q)/(PI '& QRH&Y<X/"X4*4VG
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MZE$!EWC90V5!QGH<''R\X)7'/)!X YSFU^!< -&!SP!QW(P,\Y/4@X &<'-
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M_P!)\01/\%;'X=Z%X8TKQ!$O@]-%U+6-5U:YUKQ%-KT5]%/-\BQ:?KG[=OP
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MY/YT;1V YQGCT_\ K<4ZBG_7Z_F'_#_/;\M!FS!/(Y/H.F2=OTY^O I=HSG
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M<U^.?[?G_!15_P!GN2\^#_P6@L/%/Q[N+4OKVHWL/VWPW\'K2YMEN+:75K3
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M:_XW@@6/Q_J'@'5]$;Q9EKFXBM=3DEU"7Z0?]@C]GVVD_8]@\+Z%JG@+P_\
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M6M[:M62YKO91OHI.QYZ9R<=Q[>WZT=?48/<>G]#ZU")HB?E8')YP"V2&VXP
M>=W!(Y!Z@8.'F0*"3D =20<=0.N.._7';UH<E=6?KY7TUT:7E=Q\F]AV=[+K
M=+O=;KU756;75+K)3<G P<D]\?TXZ?TI V22,[<<':W/(SVZC& .O?&*:'5Q
M\I) YW*" 3CL>A))Z YSUQW'))V;UN]'>_HEJWW=KVZI M==;;WZ6=[/?;YZ
MWZ[$M Z#M40<$?>S@C((((YQR.H(P>O4\&G"1#T;/('0]3@ =.<DC\QVI\RL
MG?2U^9/2UD^;O;7SMU"]M'O>UO-]/5^8_P!N^/3_ "/PJ*2780,=>_XJ,G\Z
M>3ST/'?!QSP1TP?7//3%5WD\Q]L8#[02<#)0D+MSQ@'AC@G)QQ4\VBLVVMUI
M=WNNO2^NE^WD)]KV_56;:75Z>CT^8X3E@,1D'/()&%!!()YSS[ ^G6GF0CG&
M!@]<<$#@#U))[\>]?)'PO_:MT3XG_M8?M8?LH6?A#5](UW]E+PO^SIXGUSQC
M=ZC97&D>,$_:'\/^.=>T>UTG3H8Q?:?)X9C\#W%KJ<E[++'?2:A!);>6L4F>
MZT']HCX=>)_VB/B'^S!HU[J]Q\4OA5\.? GQ2\:6TNDS0Z%IWAGXE:KXBTGP
MDEOJ\C".^U2\G\*:W/-:P1%;2UAB>68O.$7H>&Q,93A*E5<H8:ECII1C>C@Z
MT85*-67+S6A4IU(/FE9+GCJF[+GCBJ,DFJT+/$SP47)M.IBJ;<:E-+36$HRM
M&+DY<LK72/>1.2,E2/E+'IP.G'J<_GT'2I4?<H)&"3C'^>G?/T-?(_[&O[5>
MC?MD_!^_^,'A[P=K/@BPL?B?\6OA;)H6MZA9:I>O?_"CQWK'@:_U47-A'# M
MKK%WHTU]:VS)Y]M;S)%,S2*37UI%,C$HI#,HPP7EEQV(]L@'L,@G&145:-?"
MU*N'Q,)PQ&'E[.M&7*N6<.7FORR:N^>.B;6CY;NZ-*-:G7ITZ]&:J4:T%.G.
M*DN:,KM-76W*MVHNZ=[/:Q0.@SU[U#YR+@,=I(R >^=QX/0\ G )(&<]#3PZ
MGD'@[0#ZEAD<8R#]:B+O?KO^?J[=M;/2UD]%KV[.]O.RO=:Z]]+[WO;4?111
M5#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@!#TXY/;OSG@GV'4^W2N#U58AKI#, \EA:K&6]%DNF/S ]R^25
M.X8^4FN]KSCQ,H75^ 1BQM@I!P1MEFQSGC!QUSZXH_KM^/3UZ;V=K-IVW[-?
M?I_7YIV:_ S_ (*6?LO>*?BK\;=6U[P+XBUA/$B>&?#%]9>#+O7+^/PUXOB%
MC<1S:;96<MS_ &=I/B$3(3IUYY M+]F&GZB4:6.[@_,[X.?\%1OAI^S'X(;X
M8W_P8^#_ (]\6^%M4FATWQ+!:7VD^)K1H[A)+C1_&P\(:1)_PE]UIEY;&WM9
M[G7=/NQ#%)#?SWDDLLDG]!7[5&D:]<_%'PEK&C3L^H0^'(773EBD:341INIR
M.!9RJ0'U.)%+PV4B_P"F0I(L!:>-4K^';XX^'+3PY^T-\=-!AM-+MUTGXL^/
M+=4ELH]1N7:3Q!>2*L=EJ+WL44H,^Z1%MBJF6/:G 5?Z%\-,UIY[D57A/-\-
ME^9Y?@'2QV$]O+%X#&8%J$X5:7UK+,=EV(Q=!<UJ="I4J6A.JJDGS<]+_/[Z
M2O"E7@7C?+/%_A#-L\X;XDSEX_A_-5EM/*\RR[.Z=?"8>O0QE3*>(<OXDPV&
MS"BZ"PRQF5Y12G5<*==J&(A.>(_4+QI_P74^-=[+-8_#W0?"G@"4"4I#H'@/
M1=/U!O/,1:2TU7QU<>.=?*R&  W5FZ2ET&9EN$58_D/XC?\ !0+]L3XKAY_%
M?Q'\5KIUQEMGB'Q/JTUHD3$28C@U74--T6*#N(X+&.!0/DB5>GF/@;]E']IG
MXUI:P> OV?OC;\1M(R9[2^T/X=:[:>%[2;:5$C>(YM#TWPSI\QVN4NA>6F("
M8V=U!GD^Q/AQ_P $3/VB/%6I:>OQ!T3X*?".>]$SV6F_%'XP1^,?$%^((C+.
MT'P_\"/\0+R9[6,?:)T:>P2&)0;@VT3!Z^[6+X1X;YG1EP9E?LG>,Z6"RZ&-
MC**?+*4W5XAS:<E9\U6&,C4YM73YVI+\!ED?BWXC^S>,H>+_ !1&NY_N\5CN
M('D]525I?5Z$L9X?\.4X>]I&>5U%#F<:.'KTD[_G!JGQ-^(WCZ];2K/XCZE=
MCS!%K6N:-*LNF:)!P9;6T-I':Z=JFNR+F*TLK74)Q;%A<WDD:1JDG;^'M T+
M0O&7PNUFVDU&[?0/B3\+M?%_JVH22SG^SO&WA[4)9K@0^=+-<,T)EEEN-2G'
MFJ24 "QC]P_%'_!&GP)\,/@=\3O&WB_X^>*_$'BCP#\,_%_BS0-!^&W@'PYX
M&\!C5?#6CW&K6]IJ?_"1WGC'7=3TBZ^S21RVVF1>#YL.9HI(64QO_-UX^^*E
MUH_A:/6P/(6SL=&U7SV+)&K:?]EO D$TQBC9@T.SD-(0&8M(0S5VX/B?*N)<
M#G%?"9I6S2IA*=;!UJ]:A7HX:#>%JU*:P6'Q"A[*GHHNKR4ZU:W/4CK9>)GG
MACQOX<<2<&83,.'<OX;>:8_!YGA,/AL=E.:9K56$S3!T:TLZK9?3]RM%QDZ.
M#]I7EAH2DZ<JLIU:K_T(_P!KG-M\,M5L#D-J'CCPS8_-C)6TU2?Q!* 0Q[Z*
M6(P!A 0?E(/$_ Z4:1\-O!NH+)##);KKE^)KDQI;Q>;XCUK]Y(92(EC6#:SR
M2%$4;2S#BH/VM?$SZGIOA/1T.Z+4_%EWK#/E6#1:=X6U:-FWJ%3"R^(( 7PJ
MLRQLF HSRC:/I^M_ CP[X;;^W)1J6D::CQ^$W\/3ZW:-<7\NJ-<SV.OZWHVF
MS6EK),$U"SGG$LL+O$MM+(<1?QC6A"-*,9*T?A;2=FG*L[):O6_6VGJS_9.4
M_:6GI>I3I5))6MS55"K*ZV34IR32LKK1(^E;?XB2:A&\FG:OI&HPPS-;RS::
M]CJ4<=Q$BM);RS6#W$$=S&KH98&E$\8>,R1+O3,X\9ZL[*B7%J[,<*!:9)<X
MP,+$2.A;@':BLY 523\X?#+PKI&D^%;O0P?&6DO)K!U>^N=5U:W^'VHW-_<V
MZ*9=.B\ >*;Z"*SAC18;BW_M:]9IP6G$Q$;+TWBSP7I/BOP1XP\!WFM:W:Z7
MXW\+ZMX3U75+3Q]K=YX@MK'6[*>PGNM,U#7[G7K>WOXH[IV\V6SN(KM0UIJ.
MGWFGGR*X_JV'LK0AY>Z^NW?=->OD)5)J[2>EUJTM%ULM6>L:AX]N["V-U<3Q
M,A1&A6WM%E>[$JDP_9 (U-PLICE $)=T,862)688^./B=^WMHW@2P^*ATKX=
M_$7QMKWPEF\/1>(='T_PGK>DZ7=)XAD1%U#2/%"^%]<M]:TG2$);7KWP_IVM
MC1IFAAOXK8RM)'Q^@?L@^#_!/[-GB#]F[0_''Q'OO#VN^(->\4:CXCTSQA9?
M#SQI;W7B.TBTV_L?!EY\,['P?IW@#28H;:"YL;'PI;V,ZZE<:OXBO)+S5?$&
MJK6/K7@7XA?$VZ\4_"7Q/X<\7>"OAOH5CX$O/!'Q9\!_%C5?#?Q!\7ZII+>9
M?:=JAT33]#OO"UOI)TRW-W>:?K=];:_:W]Q:%;6%)M/$O"X=N\J-.<>ZB[OL
ME=?=V:^9E*M7<K1TT7GKU?7_ (:^YZMX^\5Q_$CX"^%_B#;:%KOAR/Q5)X=\
M3#P_XGLI+'6])&JR7)-KJ-E+%!(C_*)+=Y+>UFN;.:WN9+6V:4PQ_6W[*/\
MQ,?A/\,&89$+II<L;#Y?^);KILFC?)!(#9#H5SM)7H,CP;XEV!MOA#?Z?-.;
MN?2X]$W22S">>=K:YBMVEFE^]-(P!::9MSR.))'')8]]^R5XHDM="T[PZF67
M2_%FHR6[$*R>7J6IC4H2,@@QK)/N<*"S!?E.XJ:[*?*J$H1M:,U&-)MQ;@XR
MC-02BW.?++6/NMQ3?-LC>F^6<7.44D_>ES6O'6_+&SE*<?<E!QBU3DO:3M%(
M_B:^*'B;QCHWQP^.\VD?$+5[%Y/C5\59F746>Y@=CXYU_P"64:C#J>FSK&P
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MDGB!XM<%5,--*EEF)SKB7$X>$5_#IQX?XWRW,L&Z$O>A)0QCPLHMQYI))O\
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MDY^SKRIKFKSC!3FXQ:ES+\DO^"AT'[/GQ$_:V^&7PZ^*?AC]L3]MSQ5H_P
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MW@S]IWX#> KGXP>&-3B@F3^Q/"<'CSX07_Q(BG>W>UBO_P#A6:MJ1+6UCO\
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M1KPE^SU\0?VW_P!JCXI?L$?#OQ#X8\0^#/V*_%=A\$[?PY<6O@K7[;Q+X/\
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MN>&&\57=U80Z]:6=Q'>PZEJ]S';W6O1V>JZU>,Z37!_<?X1_L8K\/OVAM/\
MVK?&WQM^)GQF^.,W[)G@W]DSQIX@\6:'\+O"NC^-=)\(_%'Q;\5HOB+>>%_A
MWX*\+Z9H7C74=9\87FCWEGX=.G^"XM#M=.6T\/)J27>HW6+K'_!.OX$>+M;_
M &Y+SXAW'BWXA>&_V^[#X?Z7\7_ FN7NDV&A^'++X=^#;WP?I!\ 7WA_1](\
M2:7>31W0UJ34=6UK6KZTUJUM+G3)[2")K5L<)Q#A(UJ*S&I4QF!PN3Y)AX89
M4(U/:XK"9Y1QN;58PE2@XSQ5",Y^UK^_B(Q6&:O55-<U?(,5R3GA*=.AC:V8
MYK5GB%4Y?98;%9=7H9;3YE-N4*%25.#ITKQA5JNI%M4U,_"3P9\ OCU\'_&'
M[-WQ"_8X_P""?7_!1'X3_&[PW\6?AC_PO+XM?%S]HOX,^.O!7Q[^#_B'4K6P
M^-K?&32+G]I7QHOB"^O=+OKKQ=X:O=*\."^T36[*WDTI((HHK07/VR/@;K_@
M#XP_ME?%?]O/]GC]O/X@>&-=^)/B+XA?LS_\% _V'/B9J'B[4OV2O@K!HFE?
M\(9:P_!;1?'&@^)_AQJ'P-DM-2U_QKXCB^'GC;PWXLAAO=5U:#5])LKF23]4
MO '_  2S\0V7B?X11?M!_MW?M3_M9_!3]F_Q3X?\:? #X$?%33?@EX<T#1_$
M_A&QFM/!>O?&3QK\,?AEX-\>_M :OX&+0WW@^3QKK%AIMCJUM#JNJZ=K&H*E
MRD7Q!_X)5:QKGB7X^Z9\'/VZOVJ?V:?@!^UCXE\=>-OVBOV?/AII?P*U_3-9
M\8?$[2H]+^)&N?!WXE?%'X5^.OB-\#'\?R&XU?Q99>%M8U*V.JZGJ=_X0C\*
M74MJ]EWRXGP-7%<]7%T6_JU2E/%4L)G,<4Z-7-88ITZ.8U7+%TL13P;E[&A7
MR^ME-YO*)UY4>;$T<UD.(AAXPA2J3Y:].O"A7JY<Z$*\,$\-&=3!TU3P\Z4\
M0^6I6IXO^T(SBL=&FJ\?95/?_P!HKXL?#_\ X=T^-?B\_P"UYK'PL^&_B#]F
MS1?$FG?MH>'_  [::IXGMO#?C'PIHSZ1\7_"GA?2-"MH+[Q?XRM=6L[[PSHG
MA[PY:W9\0Z[:6OAW1K>]CL[,?@7\.(M"^!_[5G_!.#QE^RS^R#^WC^R3X$^*
MGQ\TWX-?%'XH?M7^/;*PG_:1\*^,/ NLWLEAXV^#FJ_%WQ_XWOO%&I7VFP^+
M+7QIXC\+>%)]&N+62U$-D]XFFVG]$?QD_8,_9V^,G[%5_P#L!ZKX8U7PG^SF
MOPN\&?"CPMHW@;7)K/Q'\/O#_P ,_P"P9OAKJ7A/Q!XBC\1S2>)/ VI>&?#^
MMZ1JOBBV\21ZEJVCVUSXDM]9$][!?_+4/_!*_P 2>.OB9\!?C7^TO^WM^U=^
MT3\5?V:/B5H?Q#^#EYJ^B_L^_#+X=^'$TII[?4],U#X7?"WX0^'O#WBK6O&V
MD3)I7C#QWXHN-8\56\,#I\/;_P  V%_J.G7OG9)F^58'#XVA7J8I1Q.)SB$J
M-2%3DJX.ME>(PN7VP^$PBHUZ\L1.C/%5,;C8X7#0A&> PDZLIU*??FN79ABZ
MV#J48T5+"PRRK&I3E34U5P^+I5,9&5?$575I4W1C-4UAZ7MJTI26+Q3BE&I\
M=_#+]CSP%^V)_P %0/\ @HWKOQZ\5?%CQ)X(^ 'Q;_9KU'X6_"[1?BY\0?!G
M@G0O'X^'VC>+7\<W6B>$?$&CP:K>$:?IND&QU(76ER6"7D$^GS"\N"VG\"?V
M8OAK_P %/_CC_P % _BO^V+J?CGX@VGP-_;.^*_[(?P'^&OAGXL^/_ 7A'X,
M?#KX+6GAK2[?7M'TCP%XIT.2#XH>,]>N[_Q?J/B^]8ZQ:07FEPZ,;.V26:]_
M8+X/_LK^$_@O\;/VH?CKH7B?QAK7B/\ :J\5^ O%OC#0=>E\//X>\+7G@'P?
M!X+TVS\'KI>B:=JZV=]86ZWFHC7=4UFY>])^QSVMOB ?+OQ1_P""<?BJ;XT?
M$GXV?LE?MH?'[]B'6OV@-4T/6_VCO!GPN\*? [XE?#7XH>)=&TM?#US\3=$\
M)?&_X=>.(?A=\;-=\-6NAZ!KOQ#\'7D%EKUAX8\/WFO>$-5URRGU6ZSJ9^ZU
M>JJ.95,M2RG)\#E6*CA9J.!KX6&%GFD8TL+A*F)PWUYT*E.KC.2<L1.,8UYQ
MI8B3-/['A##P]K@J&,4\QQN)QM!U8*>)A5G5>#G)UL1&BY4754HTW)4HQUI1
M=2*3_&C]G3XZ?&+Q#XW_ ."?7P,\>?$?Q]X[N/V0?^"ZW[=/["-G\4/$NO2R
M^*_C5\*?@/\ LV_'V_\ ASK7Q)N[%;*S\2ZWIFA:WHGA'6YI+-[>ZUWP6U[=
M!M6$ER_ZM?$CQ#K"_P#!:G]GOP[;Z_JD6AW/[ 'Q^U6[\/0ZG=)I4^H6_P 1
M_ =M9ZK=:4LRV<E]!&T\-M?21--$CRQ)(JN:['Q!_P $G_@@/V5_@A^S-\+?
MB%\:_A#XD_9K^,-G^TO\&OVE])\2Z)XP^.]M^T]'-XTOO$GQU^)^H>.O#VN^
M#_C'K/Q1U+XA^.'^+?A;QCX4?PAXJTCQ9J6A:-H_AG3[/PO'X?M_L_\ _!,V
M3X6?M-6'[9OQ@_:V_:*_:A_:4?X3:_\ !OQ)XH^)&G_!GP?X$O/!FK7VF7VD
MZ=X2^&/PO^&WA'0/ %GX;GL=1OK6'1KFYO->U3Q!J^H^+=1UR8:5'I=U<WR6
MO5K8J-5I1P.=82CAWEW)5Q&)Q^+PF)H8J2I1=&BI>SQ=:I2J\M;"2KT\%3IN
MG'VJJ6 Q].&%P\81DH8S+L17K1Q,%"GA\-#%0J4+3ESU'&G5P]&+A*:G[%SE
M-2DXQ_#_ ."W[%/@CXF_\$I/V@/VTO'OQ&^.NM_M,> K?]K7QY\$OBC#\:?B
M1I5[\#O^%1_$CQ_JW@70? &BZ?XEM] L]-MKW23)KAN]-O&UZ*ZF@U S0PVB
M0_6G@*#4/^"H'[6?PF^"W[4WB/Q-JGP+^#G_  3F_9P_:2U3X.>'_%>N>"-#
M^-/QW_:#FOH]2^(?CI?"U_H^I>*=&\ :9X;;3-"\/W-Z=!TW6]=O=2DM)KR:
M/R_UB^'?[ GP\^''[%'CW]AW2O'_ ,1]2^'WQ"\/?&WP[J?CC57\(#Q_IMK\
M;]8\3:MKMQILEEX6L_"YNM#F\3W<&A"]\-W,/DVUO_:D=^XF,GC7Q&_X)>Z5
M<I^SOXV_9W_:7^-O[+W[2O[-7P+L?V<?"'[0W@S1_A=XVNOB!\&[1=.F/@+X
MX_"WQ_X/U7X;?$/0(]7TYO%&D16NC^&+[PWXIN7U;1=2M-L-NG57XFPV+K9C
M.IBZD*M3%9O')L7+"<RR[#X[+<#AL).E3I8?GH4'B<-5I.-"A*MAI5I8J#OS
MR?+_ &+6I2PRI4J3PRP^$CF&$=5?[;4I8W%5JT:DYUDI3]A4A-RG)0J1IQI2
M?+I'Y?\ ^"8WP1TW]G7_ (*<_P#!7GX1^&_&/C#Q?X-\->"/^"=ESX!3QWXM
MU7QQXF\!^#-<\#?'S5-)^%LOB379KS6[S0O!$\][:>#TUF\O=2LO!EUX?L+F
M_OYK26\EQ/V??V2_@;9?\%U/VS?%]IX?\11^(?!7P-_9X^-6B7K?$+QY+;P_
M$3XK>*OC%#XUU"ZTR3Q%)INH:3>0V-JNF>&=0M9_#^AA9&T?3+-YI)3^@?[%
MG_!/3PM^QU\4OVE?C='\=?CU\?\ XN_M;#X5ZC\;_&WQTU/P-?WNM^,/A9%X
M]MK+Q#X?L? O@CP5I?A32[W2_':>']+\#:/:1^"O!GA/PGX2\-^#-)T?3K&?
M[9T7B#]B>>3]MS3OVW?AW^T#\5_A9KNM_#KP;\*_C;\)-!\/_"/Q%\./C?X+
M^'6M>*-=\%V6NW7C;X?:]XY\&:EIVH>,-:CU+6_ 'BO0]5U73H]+LEGL4LY_
MMW'B<_IU,PSG$PQ]>HLQX:R_*)XJ5">'>*QF'P.74*KJT(TXRC3JUL+BE&7)
M:2C"I-+ZPY+2ADDH87*Z3PM"E]1SW$9C#"PJQJ+#4*M;&3I4Z=55>64H4Z])
MWYK+FT3<%$_GN_98_8%^$GQ=_P""='[8'[2_CCQ5\9F^,W@CXJ?M[>+/@EXG
M\,?%WQ]X.MO@7??#7XD_$+7?#-Q\./#_ (=UW3M!L-1NM<TX:GXCU.^TZ^N_
M$!G:TO9#:Q1(.O\ CK^TA\;/VK=._P""4/P)\:_#SX^?'WP)\:_V+[_]K#]I
M/X1_LU^./"?PM\=?M!Z_I&F^$?#7A[2/$WBCQ-XY^&8B^'/A/Q'JMQXS\6:!
MH'B^PO?$&LZAX=M]0M+O2X986_>SX.?L*?#WX+_LL?%3]E#P_P"./B'K'@WX
MM:E^T#J6M>+-=D\)GQEI$O[0VK>(]8\2Q:.VF>%].\/[/#\_B6ZB\.'4=!U
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MSQ6VI.!G>OG,.&!(^=)]*LBSNVFZ9/*S%Y9)=/LVD=\L':4R0,[2,<$N[%B
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M.?<#TX4LV\8/\3K@ Y/R'&3@XYWGCC# 9SC'\T7Q2_:J_:]\,?L=?M=?L?\
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MQ9#:7\!+@KE?D^,GB*#=M.&96F^&><9R,;6Q]T,P&6^3O#_@K]N6W\5://\
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MLO7 <_Y_G14 FC![ 'GT(4<;R#@!2,8'!R2N"^Y0OGIN(PQZ#(VE<\D\ALC
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MJGS\N_+[1\E]KZ;NR]"!!Y%%-3[JXYX!R>O/-.IFGKOU"BBB@ HHHH ****
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MB_:HTGQ%^U7\-M7UC5_AGXP^&OAC3?!^KQ?L\_#G3O[&U6U\=>)-"N9]1O\
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MDEO&OW7_ ,%'/VD/C+\#O _P"^&O[.\GA?3OC]^V'^TYX#_95^&OC+QIIO\
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MX%TOQ-+&U[J7AB^UW7K'P=#JFI1Z7J+7-C/XBM[F*-HAZU^U)XF_:G^!VE_
MSX;_ !<_X*?_  V_9E^&7A[X>WMS\0?VL]=^'7P?/[0W[1GQ976;I+/POX9^
M#>N0:MX$\%>&='\.E+[7]7T+P_K]QJ-]':V=DFG_ &EVC[;]GK_@GK\:?ACK
MO_!(W5_%7B+X>-!^P#^S-\4_@7\2K/0)-9E7Q'?>)/AGX4^'7A'4/!C74:'[
M%'#X7CO=6&I;)4\\I "4%2_M-?L;?M*P?MTVW[;?P \)_LX_'BZU_P"!&@_
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M_"CP7I,\OGR6G@[P)X:T[PKH5G/.%1IYDT?3;5;BX9%DGE\R=B&F:OQB\/\
M[&__  4F_9C\,?%K]DK]DKQ/^S/JO[*WQ1\6?%SQ-\-OBM\6+[QK9?%K]FG1
M_C+?ZEKOB;P59^!]#M)O#_Q'L_#NNZSK5QX(U&74M'DM8+VW764NC;LM>/E>
M+P,L7F=>@LNP5:6895/+EF=.A4P]'*,/CFL=1C*MAZT'C52P^"JU:D:4,17B
ML9*E4C6JSB>IF&'QD</A*-26-Q5-8',:>*G@YRA7JYA6P?\ LM1JG6I<M"4Z
MU>$(J;H4INA&<)TH19\<^!?VY?%G[)/_  2)_P""4_PZ\%^-_!_P-^(G[5L5
MU\.[CX[^._#=UXR\'_L^>$O#;^)O%7Q,\??\(G;%1XN\2:9;FUT/P/X?OYX-
M+U+7=2MIM5G73[6Y>O;/V2?VY_'FI?M:>$_V0-$_X*&6G[=G@[]ICX.?&VZ\
M"?&V3X">'? OQ-_9C^./PN\.:?X@L5\4Z7X4T'P[\//&'@#QKX:U/7]>\%0Z
MQI^G:E;^(/ 5YX>O;[5+>]%T?<H_^"7?QC\/?L1_L!>!?!'Q)\!:9^V+_P $
M\=:B\8_#'QMKNG:IK'PH\:ZCJ$.N:#X^\%^,[ $:LGAKXC>$=7-G>:I;(^IZ
M'J\%MJ5FK&'!^IOV;? 7_!0'Q7\=+/XP_M6:K\$?@I\-O!W@/7O"7AG]FW]G
M>\O/&6E^._%_B2^LI;[XI?$[X@^)?#^E:HK>'--TTZ7X%\)^'XK6VLQJVMWN
MM75]<30Q1^GF>-R:MA,YK4OJ.(Q.(Q7$U6<ZU3#0KXC%XC,*M3**]"G/+:V.
MKTG1E3G26%Q6$PM_;PQ]*SBY>?@<+FU&MEM&?UBC1HX7(Z4*=.CB94X4:."C
M#&TIS_M".&IRC7C.-:57#UJRA[!T)SDFU^ G[/?BG]K#]E#]B[_@H!\:M"_:
MB;QK=P_\%@O$/P/U+P]X@^!WPOL+75?B+KW_  43^"?P_P#B_P#'2YN$AU0?
MVK\5_"%]KNGKX%%F=!\ 7&O_ &SPC?07.AZ5=I^IOB7Q'_P4 _:>_P""AW[:
M/[,GP@_;!@_9@^!'P#\)?LW>*K/Q)X<^#'PY^)'Q-A\2_$;P_P",)I?"6A/X
MXMY-"MO#&O2:5+KOB/6-;T_Q!JT,NBV.B:#'I,&IWFHPUM=_X)??&_5_V-_V
MI_V>8O&?P\C\7_'#_@J=J_[;_AK59)-8;0],^&5_^V-\.?VA+;P]K#K;BY/B
MY?"?@^]TV5+9&L#K,]N@F^S,TM??7P-_9C\:?#/]MO\ ;<_:5UO6?#]YX,_:
M4T']F[2O!FDZ=]L.O:1+\'?#_C?2O$,FNB5?LHBU"X\26<NFFT9BT4<OG!6*
M@SFV;9;7_MC&499;7QU:ECU@ZGU"BX.=^&:6#E3PKHT\/3JQHX;,5"IR+FA&
MM*:YJB1U8#+<51IY?AI+%T*%.6'>(IT\55T3CFDZT'7=25>5)U*U"4H*:Y9M
M<ME=O\=/%O\ P5<_:.^%W['.A^$/B#\1OA;H?[3FH?MV?$/]@_5/VH=>\$7D
M?PZ\/>%OAG,=3\7_ +1VJ?#71[FZM9O&-IX,FL)=(\ 6FH#PWJ'C"[ABN+^'
M2K:XCDZ?]E3_ (*)>(? '[7OPP^!>L_\% --_P""BOP5^-_PX^-VMZOXRN/@
M=HGPL^)W[/\ \0?@IX#;XG":^G\":+H7@W6_AE\0_!VC>,+31[;5M.7Q!I/B
MC1[.U_MG4+.Y8U[3K'_!*OXS77PV\=ZKX5^)W@'PE^T7X+_X*(_$7]NG]FGQ
M;=:/J/B'P;#:^+TM]-O?AI\2M)F:.=M(\;>%WOM \2W6FQ376ER?8-0TQM\$
MB2?3_P "/A=_P4!^)WQET_Q]^U]-\ /@S\&?"?@'QKX-7]F_]GF\U+QK8_&?
MQ-XWM+/2KKQQ\3_'7BC0=*U#3-!\-Z0NIV?A#P=X>2*=;O5;O4-<U.["PVJZ
MXG%<,_4L4Z-' 585*V9RQ%*E4PF%KRJ8F.7RP$\#2K9?7QL:5&^)="E@\9A\
M/3K0Q-/%0M.G-\T,-GJQM!2Q&)A&$<''#SE3KXA*E2558I8NK#%T<'*=62BJ
MM2OA*U>5-T98=IQF?F'?ZU_P4X_;!_X)S?%7_@H5IW[4OAKP)X;^-_[/7QF^
M*_@']@BX^!W@SQ#\*A^SSJ7AGQD_@OP/K'QADOM)^*US\8O&'PYCTW7Y_B);
MWVG>$[/Q/J$-BOP^M=(CN)%_:C_@FPT(_P""=W[!KP.\EL?V-_V:FMY'&&:)
MO@]X0\DL,Y/[HKGN?O$ L17Y7:/^PK_P5(^$O[,'C3_@F=\&/B%^S3-^RI-X
M)^(GPM^$_P"U-XTO_' _:!^'/P-\87?B%=,^&FH?#G3[0^%]>\;>%/#>KKX*
M\._$.WU;3]+M=-BMM4DT(7NF6\<_[3_LD?"37?@-^RS^S9\#?$]UI=_XB^#7
MP'^$GPLUZ]T4SG1[O5_ ?@30_#%_<:2UR%N6TR2ZTR5K+SU$WV<Q^8-V:\S/
M\31J97/"X;$9/.G_ *Q5L9@,-E]&G2Q%+*WE%/#8>6*E3P]*;E%VH<N+K5\7
M&NL4ZDI1G&I+MRO#U5F/UFI0S"+_ +'AAL15QU3VD98M9C.M4A2:JRI7E#]Y
MS8:G2P\H.FX1BTXQ^BTP0N>#CCD]  #_ )__ %U)35&%4>@ _P ?UIU?)+9>
M73RZ+Y'U#_K\_P"O,****8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R>IP7TM^9(+
M226,VT 9U\L#?F9C'EY$^Z"/X" 2,G)%=910!QRV=Z0NZUGP 1M_<G@$C!/F
MKC(')"],$8S2FRNC_P N,P^C1#_VI7844 <E]EO>UG,N01D-%QGOCS.W4?CZ
MFHVL+UL9MYVP<](N!@],R]^AYZ<]0*[&B@#AI[/4D3$-G.[9(',2[2<$$CS>
M0OL>_7(IJ6VI''F:=<@J "?]'(8YR=H\W/<YS@YSU'-=W10!Q!M+Y<L+*<D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
